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A B S T R A C T
Equilibrium d ia ly s is , u lt ra f i l t r a t io n  and frontal analysis gel 
chromatography have been shown to produce comparable results fo r the 
binding, to bovine serum albumin, of a number of drugs with markedly 
d iffe re n t degrees of binding and physico-chemical properties. The 
binding of sodium s a licy la te  to ra t serum has been studied by in vivo 
dialysis  and the results shown to be in good agreement with those 
obtained by in v itro  u l t r a f i l t r a t io n .
The binding of a series of a lip h a tic  carbamates to bovine serum 
albumin has been used to study the importance of hydrophobic bonding in 
small molecule-protein in teractions. Binding was found to be d ire c tly  
correlated with the lip o p h ilic  character of the carbamates and associated 
with negative free energy and positive entropy changes. A model is proposed 
to account fo r the fluorescence observations on the binding of the carbamates 
to albumin.
Warfarin has been shown to be a fluorescent probe and th is  property 
used to investigate the nature of its  in teraction with d iffe re n t species 
and preparations of albumin. The binding s ite  of warfarin on albumin was 
shown to be located in a hydrophobic region of the protein and its  binding 
suggested to involve the amino acid residues;lysine, tyrosine and h is tid in e . 
Differences in the a f f in i ty  and nature of the binding sites were apparent 
fo r the in teraction of warfarin with ra t, human and bovine (c ry s ta llin e  and 
fraction  V) albumins. Binding was found to occur through one primary 
binding s ite  fo r a ll species, except perhaps for bovine albumin (frac tio n  V). 
Approximately eight secondary sites were apparent fo r a ll  albumins. Good
agreement was found for the fluorescence of warfarin between ra t and human 
albumins and serums. The potential of the fluorescent probe technique to 
evaluate drug displacement from protein binding sites was demonstrated.
/
l-Anilino-8-naphthalenesulphonate and the novel fluorescent probes 
warfarin (R+ and S- isomers) and benzidine, together with difference spectra, 
have been used to investigate the nature of the hepatic Microsomal cytochrome 
P-450 binding sites(type I ,  type I I  and Reverse type I ) .  The type I and 
Reverse type I sites were found to be closely associated and appear to be 
in a hydrophobic environment, whereas the type I I  was hydrophilic in nature. 
The binding of R(+) warfarin presents and in teresting species difference  
being type I in the hamster, but Reverse type I in the ra t. The binding of 
these fluorescent probes to albumin and microsomal protein has been compared 
and the binding sites found to be located in s im ila rly  hydrophilic or 
hydrophobic environments.
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VThe Road goes ever on and on 
Down from the door where i t  began. 
Now fa r ahead the Road has gone,
And I must fo llow , i f  I can, 
Pursuing i t  with weary fe e t,
U ntil i t  joins some larger way, 
Where many paths and errands meet. 
And wither then? I cannot say.
J.R.R. Tolkien.
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General Introduction to Protein-Drug Interactions
The effects a drug produces in a biological system are 
ultim ately  consequences of physico-chemical interactions between the drug 
and 'receptor1 molecules. This concept was f i r s t  proposed by Ehrlich  
(1909) 'corpora non agunt nisi f ix a ta '.  The capacity of a drug to enter 
into specific  combinations with constituents of the liv in g  organism, 
especially proteins, poses fo r pharmacology one of its  most fundamental 
tasks - to elucidate the nature of drug action in terms of specific  
molecular in teractions. I t  is lik e ly  that the in ten s ity  of the 
pharmacological response e lic ite d  by many drugs depends on the extent 
of receptor occupation. This is largely  related to th e ir  a f f in i ty  
towards the receptors and to the concentration of drug reaching the 
environment of the receptors, i .e .  the receptor compartment. I t  is not 
usually possible to measure this concentration d ire c tly , but i t  is  
anticipated to be related to drug blood leve ls , which are measurable, 
based on the assumption that an apparent d is trib u tio n  equilibrium  is  
established between drug in the plasma and the receptor compartments.
The factors modifying the drug concentration at the receptor s ite  are 
shown in Fig. I ,  1.
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In 1938, Bennhold suggested that the plasma proteins were a 
transport mechanism fo r the regulated d istrib u tio n  of natura lly  
occurring and medicinal substances, though this may be something of an 
overstatement, plasma proteins do in terac t with a d ivers ity  of ions 
and small molecules, including drugs. Goldstein's (1949) excellent 
and farsighted review emphasised the importance of the binding of 
drugs to plasma proteins. His review contained a summary of the known 
plasma protein-drug interactions and also set forth  the concept of a 
rational approach to the problem of drug-plasma protein in teractions.
He further suggested that such interactions could serve as useful 
models fo r the general phenomenon of drug-receptor in teractions. With 
the increased awareness of the significance of protein-binding a large 
number of studies have appeared since Goldstein's review. Meyer and 
Guttman (1968) recently summarised, in a s im ilar tabular manner to that 
of Goldstein, the experimental observations on the protein binding of 
drugs, dyes, hormones, vitamins and other small molecules made since 
1949, together with a discussion of recent developments in th is  f ie ld .
A number of general a rtic le s  and reviews on this subject have also 
appeared:- Scatchard (1949); Brodie and Hogben (1957); Thorpe (1964); 
Brodie (1965); Desgrez and DeTraverse (1966); Goldstein e t a l .(1968);
Prescott (1969); Kreiglstein (1969); S e ttle  et aj_. (1971);
Cohen (1971); Davison (1971); Benny and Hamlin (1971); Thorp (1972); 
Hasselblatt (1972); Hamlin and Shah (1972); Westphal and Knoefel (1972) 
Shah and Herd (1973). The present introduction to the subject is 
concerned mainly with the protein binding of drugs.
The in teraction of a drug (D^ ) with the unoccupied binding 
sites of a protein (P) may normally be considered as a reversible  
reaction obeying the law of mass action (equation 1 ).
k
Pp+ P % DP   (1)t   ^ r.
where DP is the protein-drug complex and ki and k2 are the rate  constants 
of the forward and reverse reactions.
At equilibrium
5 , - t  .  K -  £
"DP Kl
where is the concentration of unbound drug, P the molar concentration 
of protein and DP the molar concentrations of the drug-protein complex.
K is the equilibrium  or dissociation constant.
This is the simplest form of the equation and assumes a single  
binding protein with a sole binding s ite . In the case of several binding 
sites or proteins a succession of such eq u ilib ria  w ill  be required to 
describe the overall in teraction (Thorp, 1964). V k is termed the 
association constant and is a measure of the so-called a f f in i ty  o f the 
protein fo r the drug. Because of the use of concentrations rather than 
a c tiv ity  coeffic ients the constant is more accurately termed the 
'apparent association constant' (k ) .
At equilibrium , fo r any given concentration o f free  drug, the 
molar concentration of bound drug depends on:- the protein concentration 
(P); the association constant (k) and the number of binding sites per 
protein molecule (n ). The relationship between these values and the 
fraction  of drug bound is expressed in equation 2, (Goldstein, 1949).
I t  can be seen that the fraction  bound (3) depends d ire c tly  on P9 n, k 
and inversely with the drug concentration D^ . Goldstein (1949) has stated 
that reports on the percentage or fraction  o f drug bound should always 
specify the to ta l or 'unbound' drug concentration; k and n can be affected  
by pH, temperature, ionic strength and d ie le c tr ic  constant of the solution  
(Goldstein, 1949; Meyer and Guttman, 1968; Thorp; 1964; Agren, et a l , 
1970; Cohen, 1971). Graphical methods of determining n and k are discussed 
in Chapter Two.
The Plasma Proteins
The plasma contains large quantities of proteins which are able 
to bind a considerable number and variety  of ions and small molecules 
(F ig . I ,  2 ). This is perhaps not surprising fo r Bennhold (1966) has 
calculated that 5 l i t re s  of blood contains plasma proteins having a minimum 
surface area of 130,000 sq. miles. Several detailed tre a tis e  of the 
composition, structure and function of the plasma proteins have appeared 
(Schultze and Heremans, 1966; Putnam, 1960; Neurath, 1965; Turner and 
Hulme, 1971; Marks, 1972). As well as several accounts of p a rtic u la r  
plasma proteins, e .g . lipoproteins, immunoglobulins, e tc .,  (Dettlebach and 
Ritzmann, 1968; Tria and Scanu, 1969; Haaf, 1969; Scanu, 1972; Jonas, 
1972; Mateau, et al_, 1972; Scanu and Wisdom, 1972).
Albumin, which is the principal plasma protein ( -  50% of the 
to ta l)  makes the predominant contribution to the plasma protein binding 
of most drugs, and many endogenous materials such as fa t ty  acids and 
b iliru b in  (Goldstein, e t al_, 1969). The albumin molecule is  a single
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Fig. I 9 2 Examples of Interactions with Plasma Proteins
(Goldstein e t a l . ,  1968)
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polypeptide chain with a molecular weight of about 6990009 depending on 
the species. Its  high concentration in plasma and re la t iv e ly  low molecular 
weight make i t  the major determinant of intravascular co llo id  osmotic 
pressure (oncotic pressure). Albumin has an is o -e le c tr ic  point a t about 
pH 5, when i t  carries about 100 each of positive and negative charges.
At plasma pH (7 .4 ) i t  has a net negative charge of 18 (White, e t al_, 1968), 
but i t  can nevertheless in terac t strongly at this pH with anions as well as 
cations, indeed acidic drugs are generally more avidly bound. The 
circu lating  mass of intravascular albumin to ta ls  approximately 140 g, fo r  
a 75 kg man, of which about ten per cent or more is displaced per hour, 
mainly into the in te rs tia l f lu id , from which i t  is returned to the blood 
via the lymphatic system. Despite the fa c t that the delivery of newly 
synthesised albumin appears to by-pass the lymph under normal conditions 
(Rothschild, e t al_, 1972). The protein concentration of the thoracic  
duct lymph is almost h a lf that of plasma. The extravascular albumin mass 
(approx. 60-70% of the to ta l)  is in a state of very active exchange with 
the plasma pool. The h a l f - l i f e  in the body of albumin is about 10-25 days, 
and approximately 13 g of albumin is normally synthesised and catabolised 
per day. The l iv e r  appears to be the only s ite  of synthesis (M ille r  and 
Bale, 1954; Rothschild, e t al_, 1972), but catabolism takes place a t  
several s ite s , notably the l iv e r ,  kidneys and gastrointestinal tra c t  
(Schultz and Heremans, 1966; Turner and Hulme, 1971). A curious anomaly 
of albumin synthesis in which two e lectrophoretica lly  d is tin c t albumins 
are present in the plasma, occurs as an uncommon and to ta lly  asymptomatic 
inborn error of metabolism, or biological varian t.
I t  is now generally accepted that in most normal healthy adultis 
albumin concentration in plasma is between 3.5 and 4.5 g/100 ml (Marks, 
1972). Like a ll  other plasma proteins,albumin shows a 10-20 per cent
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change in concentration with posture; the higher levels being found 
w ithin 10-30 minutes of assuming the standing position. Serum albumin 
levels are also known to be affected by strenuous exercise (Poortmans, 1971). 
Serum albumin is lower during infancy and s e n ility  than during childhood 
and adult l i f e .  Small fluctuations occur in the serum albumin concentration 
during the menstrual cycle, with maximum levels occurring during midcycle 
and serum albumin levels also f a l l  progressively during pregnancy, (Marks, 
1972; Stimson, 1972). No cause of hyperalbuminaemia is known apart from 
the general increase in plasma proteins that occurs as a resu lt of 
dehydration or venistasis during blood co llection . Diseases causing 
hypoalbuminaemia on the other hand, are common and include:- nephrosis, 
h e p a titis , c irrhos is , carcinomas, gastrointestinal diseases, 
hypergammaglobulinemia, m alnutrition (e .g . Kwashiorkor), heart disease, 
hypothyroidism. In addition, stress, in ju ry , alcohol, carbon tetrach loride  
and acclim atisation to heat are known to decrease albumin production 
(Rothschild, e t al_, 1972). Analbuminaemia is a rare fa m ilia l disorder in 
which there is a congenital defect in albumin synthesis.
The a and $ globulins also form an important group of binding 
proteins (Westphal, 1961; Sandberg, e t al_, 1966; Seal and Doe, 1966), 
several have a high a f f in i ty ,  but re la tiv e ly  low capacity, fo r a number of 
endogenous substances and chemically related synthetic compounds. The 
physiological importance of these high a f f in i ty  binding globulins is not 
c lear, but they may act as transporters and regulators o f biological 
a c tiv ity  (Salvatore, 1966; K e lle r, e t al_, 1969). Westphal (1971), has 
reviewed the extensive lite ra tu re  on the in teraction of corticosteroids  
with plasma proteins, p a rticu la rly  the corticosteroid binding globulins.
The metal-binding globulins, tran sferrin  and ceruloplasmin, in te rac t strongly
and sp ec ifica lly  with iron and copper, respectively, and are essential to
the transport of these ions. Binding globulins have also been 
id en tifie d  fo r other endogenous compounds including testosterone (Rosner 
and Deakins, 1968; Clark e ta l_ . 1971; Lea and S t0 a ?1972), oestradiol 
(C lark 9 e t al_.9 1971), progesterone (Ryan and Westphal, 1972); thyroxine 
(Rail e t al_. 1964; Salvatore e t aK  1966), vitamin B] 2  (R etie f 
et a]_. 1967; Hippe and Ol.esen, 1971), vitamin A (Kanai e t al_., 1968) 
and vitamin D (Morgan e t al_., 1958). A review of the binding of vitamins 
to plasma proteins has been presented by Raoul (1966). Thyroxine displays 
a high a f f in ity  in teraction with prealbumin (Tritsch , 1972), which appears 
to be greater than with thyroxine-binding globulin (Davis and Gregerman,
1971).
The plasma y-globumins have not so fa r  been found to in terac t 
s ig n ifican tly  with drugs (Goldstein et al_., 1968), except where they 
occur as specific  antibodies to them. The production of antibodies to 
protein hormones such as insulin  and gonadotrophins is well known as a 
cause of lessening therapeutic e ffic iency in cases where these drugs have 
been used fo r a long time. With growing recognition that many chemically 
simpler drugs are capable of behaving as haptens or antigens, the 
p o ss ib ility  that some patients can develop c ircu la ting  antibodies capable 
of binding a drug avidly and extensively must be considered.
The overwhelming mass of plasma lip id s  are transported bound to oer-fein 
proteins known co lle c tive ly  as lipoproteins. Free fa tty  acids, a t low 
concentrations, are transported p re fe re n tia lly  by serum albumin, but a t 
higher fa tty  acid levels binding to a and 3 lipoproteins may also occur 
(M o ra ^ t£ l_ ., 1955; Polonovski, 1966). The formation of a b iliru b in -  
lipoprotein complex has also been reported to occur a t high plasma b iliru b in  
levels (Cooke and Roberts, 1969). However, the p referen tia l association 
of b iliru b in  is with albumin (Lathe et al_., 1966) as is the binding of
endogenous prostaglandins (Raz, 1972a). The drug tetrahydrocannabinol and. 
its  metabolites are reported to bind to lipoproteins (Wahlqvist et a l . ,  
1970; Wi dman _et .a] . ,  1973). The in teraction of both exogenous and 
endogenous compounds with erythrocytes has been reported and include 
promazine and chlorpromazine (Jelnchen et a l . ,  1971), steroid (Brinkman 
and van der Molen, 1972), b iliru b in  (B ra tlid , 1972), sa lic y la te  and 
phenobarbital (McArthur et .a l. ,  1971), although usually the amount bound 
is small, the significance of erythrocyte binding should not be overlooked. 
For the majority of drugs and exogenous compounds, albumin would appear to 
be the primary binding plasma protein , although interaction with globulins, 
usually a t high drug concentrations has been shown for some drugs e .g . 
p e n ic illin s , tetracyclines and chlorpromazine, methadone (Olsen, 1973) 
sulphonyl ureas (Judis, 1972).
Nature of Drug-Albumin Interactions
Serum albumins can p o ten tia lly  in terac t with anions, cations and 
neutral compounds, although the binding of acidic compounds to albumin has 
been extensively studied (Goldstein, 1949; Meyer and Guttman, 1968), the 
binding of neutral (Steinhardt and Reynolds, 1969), and basic compounds 
(Borga, jet a l . ,  1969; Franksson and Anggard, 1970), has not. At one time 
binding to plasma protein was attributed  to simple e le c tro s ta tic  a ttrac tio n  
between the ionic form of the drug and a charged group on albumin. However, 
additional forces must be invoked to explain the observed re lationship  
between degree of binding and chemical structure. In a series of 
barbiturates, for example, a l l  of which have the same pKfl (7 .6 ) ,  barbitone 
is hardly bound, but as the chain length is extended the binding increases 
to 55% with pentobarbitone (Brodie, 1966). I t  seems lik e ly  that ionic  
bonds, hydrogen bonds, London-van der Waal forces or hydrophobic bonds are 
also concerned in these in teractions, (Goldstein, £ t . a ] . ,  1968;
Korolkovas, 1970; Nemethy and Lai ken, 1970).
The concept of hydrophobic bonding has arisen largely  from the 
early  work of Frank and Wen (1957). However, despite a number of other 
fundamental studies on the thermodynamic properties of hydrocarbons in 
aqueous solutions (Nemethy and Scheraga, 1962 a , b, c, & 1963; Crothers and 
Ratner, 1968; Hermann, 1971; Tanford, 1972) differences of opinion ex is t as 
to the nature of these interactions (K lo tz, 1958; Pauling, 1961; Hildebrand, 
1968; Nemethy, e±_aJ., 1968; Holtzer and Emerson, 1969). Hydrophobic 
bonding has been broadly defined as the tendency o f non-polar groupings, 
p a rtic u la rly  hydrocarbons, to aggregate together in  aqueous solution. The 
structure of water in close proximity to hydrophobic groups is  believed to 
play a s ig n ifican t ro le in th is  bonding since such adherance processes are 
accompanied by entropy effects (Nagwekar and Kostenbauder, 1970).THeresulting 
e n tro p y   ^ gain has been suggested to be the driving force fo r the formation 
of hydrophobic bonding and has been ascribed to the disruption of the 
quasi-crysta lline  water structure ( 1ice-berg1) ,  around the non-polar groups 
in aqueous solution (Kauzmann, 1959; Schachman, 1963; Molyneux and Frank, 
1969). However, i t  should be emphasised (Frank and Evans, 1945) that the 
structure of the icebergs need not be the same as that in ordinary ice nor.
the same for a l l  icebergs.
Hydrophobic bonding could explain the increasing positive entropies 
observed for the binding of the anions;octyl, decyl, and dodecyl sulphates 
(Karush and Sonenberg, 1949). More recently a number o f studies have 
further implemented the important role of hydrophobic bonding in drug-
protein in teractions. Hansch has studied the binding of a wide varie ty  of
compounds with bovine serum albumin (Hansch, e t al_., 1965; Helmer, e t a l . ,  
1968; Hansch, 1969, 1971). An excellent correlation was found between 
log P, it (Hansch-Fujita constant, 1964 , see Chapter Two), and the molar
concentration of a compound necessary fo r a one to one complex of the 
compound with the protein . In an extensive study by Scholtan (1968), using 
a variety  of drugs, including sulphonamides, p e n ic illin s * cardenolides and 
steroid hormones, i t  was shown that the a f f in i ty  of binding increased i f  
the hydrophobic character of the drug was increased by the introduction o f  
non-polar substituents such as;alkyl groups, halogen atoms and aromatic 
rings. Correlations between binding and lip o p h ilic  character have also 
been obtained fo r a number of other compounds e.g. p e n ic illin s  (Bird and 
Marshall, 1967), p-hydroxybenzoic acid esters (Patel e t aj_., 1968), a 
homologous series of fa tty  acids (Teresi and Luck, 1952; Goodman, 1958); 
sulphates, sulphonates and alcohols(Ray et c fL , 1966; Reynolds et a l . ,  1967), 
hydrocarbons (Wildnauer and Canady, 1966; Mohammadzadeh, 1969 a , b ), 
aromatic compounds and alkanes (Wetlaufer and Lovrien, 1964; Sachyun, 1966). 
Wishnia and Pinder (1964), in a detailed account of hydrophobic interactions  
of the alkanes with BSA have suggested th a t possible models fo r the binding 
of hydrocarbons to proteins could be:
a) penetration into the in te r io r  o f the protein
b) penetration into surface clusters
c) binding on the protein surface with the formation of a more 
favourable ice-cage
or d) binding with completion of a p a r t ia lly  formed c la thrate  cage
Correlations have also been found between p a rtitio n  c o e ffic ie n t and the 
in teraction of basic compounds with BSA?for phenothiazines 
(K rieg lste in  e t al_., 1972 a , b; Nambu and Nagai, 1972), but not fo r the 
binding o f eight tr ic y c lic  antidepressants (Jorgensen, e t a K , 1973).
Hansch (1971), has concluded from calculations of the free  energy 
of binding for a wide variety  of drugs e .g . sulphonamides, te tracyc lin es ,
p e n ic illin s , cardenolides, steroid bisquanylhydrazones, acridines, steroid  
hormones, that s te ric  effects and specific  hydrogen bonding (not accounted 
fo r in the partition ing  reference model) are not generally important in the 
binding of drugs to albumin.
Attempts to use the water s o lu b ility  (Vandenbelt, 1954; Sahyun, 1966), 
of the small molecule as an extrathermodynamic reference do not generally  
appear to give as good a correlation as p a rtitio n  co e ffic ien ts . This is  
perhaps surprising in view of the finding of Saracco and Marchetti (1958) 
and la te r  Hansch (1968) that a lin ear correlation between logs .of V p (parti tion  
co effic ien t) and V s  (aqueous s o lu b ility ) existed for a number of compounds.
The studies with neutral compounds are lim ited , and therefore 
i t  has generally not proved possible to confidently single out hydrophobic 
bonding as the prime determinant of drug-albumin in teractions , thus 
calculation of the free energy of hydrophobic bond formation is  complicated 
by the fac t that other interactions may be simultaneously operative.
Studies of the s o lu b ility  of hydrocarbons in aqueous solution have suggested 
AG values of 0.7 (Nemethy and Scheraga, 1962 c) or 0.85 K cal/mole (Davis 
e t a]_., 1972) for one H^C....ChL> in teraction . Whether these values are in 
any way appropriate to drug-protein interactions fo r the assessment of the 
thermodynamic contribution for hydrophobic bonding is unknown. The 
determination of the thermodynamic contribution from various chemical 
groupings would appear to be a necessary prerequisite to a fu l le r  
understanding of the importance of hydrophobic forces in small molecule- 
protein in teractions.
The sulphonamide drugs have frequently been used as a model to 
evaluate the contribution of these various binding p o s s ib ilit ie s  to serum 
albumin, however, clear differences of opinion ex is t in the in terp re ta tio n  
of the resu lts . Thus F u jita  (1972), has recently confirmed his support fo r
the importance of hydrophobic bonding, rather than e lec tro s ta tic  interactions  
for the binding of sulphonamides to serum proteins. Jardetzky and 
Wade-Jardetzky (1965), using NMR methods, have concluded that a hydrophobic 
part of the sulphonamide structure, probably the p-aminobenzene moiety, 
does partic ipate  in the binding. Agren, e t al_., (1971), however, while 
agreeing that there is  some correlation between p artitio n  co e ffic ien t and 
binding, found a much better correlation between the binding and 
e lec tro s ta tic  charge, as calculated using the extended Htlckel method. These 
studies thus c learly  i l lu s tra te  the problem of in terp reta tion  of data when 
more than one binding force is involved. Dearden and Tomlinson (1970), in a 
study of the protein binding of a series of p-substituted acetaniTides to 
BSA have shown good correlation between the thermodynamics of th e ir  binding 
and Hammett's substituent constant (a ) , a reasonable agreement with tt was 
also found. Such studies are capable of providing valuable information on 
the nature of the in teraction and of the s tru c tu re -ac tiv ity  relationships in  
certain  series of drugs. Binding studies over changes in pH, ionic strength 
and temperature could be used to fu rther c la r ify  the nature of such 
in teractions.
C learly , i t  is  un likely that a common mechanism of in teraction  exists  
fo r a ll  drugs since binding is obviously dependent upon the individual 
physioo-chemical properties of the drugs. For ionic drugs, i t  may be that 
once d is trib u tive  and d iffu s ive  processes have brought the drug molecules 
into the v ic in ity  of a receptor surface then i t  is l ik e ly  that the f i r s t  
forces to be involved are the comparatively strong ionic bonds. These could 
bring the drug molecule nearer to the receptor surface, the complex formed 
then, being stabilised by secondary binding forces such as hydrophobic bonds, 
hydrogen bonds or London-van der Waal forces.
Brodie's statement (1966), ' i t  is  doubtful i f  the binding of a single  
drug to plasma protein is  fu l ly  understood,1 is  s t i l l  la rge ly  tru e , but
certain  molecular features can be recognised as l ik e ly  to enhance protein  
binding, namely substituents which:-
a) cause an increase in hydrophobicity e .g . aromatic ring or methylene 
group substitution.
b) produce an increase in the degree of e le c tro ly tic a l dissociation of
an ionizable drug at the pH of the plasma. Binding a f f in it ie s  have
also been shown to increase in the order S0£" >  SO2 >  COO = OH
4 3
(Reynolds, e t al_., 1968).
Other factors lik e ly  to e ffec t the degree of binding include, protein  
concentration, drug concentration, temperature, pH, ionic strength and 
physiological parameters such as: disease, age, etc.
Nature of Binding Sites in Albumin
I t  is generally assumed that some binding sites on the protein
<*nd io n ic  £> *~ k < 2£
contain complementary hydrophobic areasA, whereas others may consist of only 
hydrophobic areas. Table 1,1 lis ts  the charged amino acids of bovine serum 
albumin which are the potential binding sites of charged drug molecules. 
Table I ,  1
Ionized Groups Present on the Albumin Molecule: a t pH 7 .4a
Residue Group
Number of 
groups per 
molecule
pKa
Number 
ionized a 
pH 7.4
C-terminal a-carboxyl
Acidic groups 
1 3.75 1
Aspartic 3-carboxyl 99 3.97 99
Glutamic
Tyrosine
y-carboxyl
Phenolic 19 10.35 0
H istidine Imidazole
Basic groups 
16 6.9 6
N-terminal a-ami no 1 7.75 0.8
Lysine e-ami no 57 9.8 57
Arginine Guanidine 22 >12 22
a A fter Tanford et a l . 1955
In view of the large number of charged amino acids concerned, i t  is perhaps 
rather surprising that fo r a large number of drugs the highest a f f in i ty  
(primary) binding sites number less than ten (Jonas and Weber, 1971), and 
fo r many no more than two (Thorp, 1964). Many compounds also bind to lower 
a f f in i ty  (secondary) binding s ite s . Thorp (1972), has suggested that there 
are p o ten tia lly  three separate primary binding sites fo r organic acids on 
human albumin. One or more of these sites may become uncovered through 
local changes in the conformation of the albumin molecule, s p e c ific a lly  
by the structural features of the compound. Such a s ite  may become 
essentia lly  ' unaccessible1 to related compounds with even minor structural 
changes.
Thorp (1964) considered that the N-terminal amino acid group (aspartic  
acid fo r bovine and human albumin) acts as a binding s ite  fo r fa t ty  acids, 
coenzymes such as pyridoxal phosphate and hormones such as: thyroxine and 
steroid sulphates or glucuronides, while Whitehouse e t al_., (1967) have 
suggested that the e-amino group of lysine is a binding s ite  fo r a number 
of triterpenoid  acids. Swaney and K lotz, (1970) have investigated the 
properties of the tryptophan residue of human serum albumin (HSA), which 
e a rlie r  workers (Reynolds e t a K , 1967; Herskovits and Sorenson, 1968) had 
suggested might be a potential binding s ite . Following chymotrypsin 
hydrolysis and tryp tic  digestion they were able to determine the primary 
structure adjoining the lone tryptophan in HSA as:-
Lys Ala Trp Ala Val Ala Arg
They suggested that the highly apolar character of the region and the 
presence of the two basic residues, arginine and lysine make i t  especially  
suitable for the binding of anions, p articu la rly  those which contain both 
apolar and electronegative regions. The same reasoning would also apply to 
the neighbourhood of the 'reac tive ' tyrosine (Sanger, I9 6 0 ):-
Arg Tyr Thr Lys in HSA and Arg Tyr Thr Arg in BSA.
However, the finding that the in teraction of anions, such as dodecylsulphate, 
with HSA perturbs the absorption of tryptophan (Herskovits and Laskowski, 
1962; Steinhardt et a1_. 1971 ) s may support the hypothesis th a t tryptophan 
is in close proximity to the binding s ite . Furthermore the findings of 
Ryan (1968) and Ryan and Gibbs (1970), that the binding of testosterone, 
progesterone and cortiso l, led to the perturbation of the lone tryptophan 
(while androstelanone did no t), is  compatible with binding a t the 
tryptophan s ite , insofar as e ither lysine or arginine would be a good proton 
donor fo r hydrogen bonding. I t  is suggested that in the case of BSA, which 
has two tryptophans, only one is  embedded in the protein structure  
(Ivkova, e t a K , 1971). In i t ia l  studies (Sugae and Jirgensons, 1964), would 
suggest that both the tryptophans lack these positive charges, a t least on 
the C-terminal side, although they may be found on the N-terminal side. 
Whether or not both tryptophan residues bind anions with equal av id ity  is 
d if f ic u lt  to ascertain, but i t  appears unlikely since the determined 
numbers of primary binding s ite  fo r anions is often between one and two.
L it t le  information is available on potential binding s ites  fo r basic 
compounds, in e ither BSA or HSA, although single primary binding s ites  on 
BSA for several phenothiazines has been reported (K rieg ls te in , e t a l . ,  
1972a). Promazine can apparently be displaced by acidic as well as basic 
drugs (Franz, e t al_., 1969), paradoxically however, highly bound drugs were 
e ith er not e ffec tive  or less e ffec tive  as displacing agents, than lesser 
bound drugs. Furthermore, several drugs appeared to cause an increase in  
the binding of phenothiazines to albumin. Borga, et al_. (1969), reported 
that the binding of t r ic y c lic  antidepressant desmethylimipramine (DMI) was 
not s ig n ific a n tly  affected by the presence of several highly bound anionic 
drugs, e .g . phenylbutazone, c lo fib ra te , s a lic y la te , or by several basic
compounds. A possible explanation fo r this may be that DMI binds to a 
large number of s ite s .
Unfortunately re la tiv e ly  l i t t l e  is known about the te r t ia ry  and 
quaternary structure of the albumin molecule. I t  has been established that 
at pH 4 albumin undergoes a conformational tran s ition  which results in an 
increased viscosity and greater electrophoretic m obility (normal to fa s t,  
hence N-F tra n s itio n ). A model to account fo r such conformational 
transitions was proposed by Foster (1960), based on an orig inal model by 
Harrington, e t al_., (1956). Optical rotatory (Sogami and Foster, 1968) and 
viscosity studies (Tanford, e t aj_., 1955) revealed th a t three albumin 
tran s ition  forms could be distinguished a t low pH. Based on Foster's model 
(1960), of four compact fragments held together in pairs by hydrophobic 
bonds and linked by short randomly coiled polypeptide chains-* these can be 
considered to arise through an increase of the distance between the units 
from pH 4.5 to 3 .9 , a more or less stable s ituation between 3.9 and 3.6 
and a p artia l unfolding a t lower pH's (acid-expanded form). Bradshaw and 
Peters (1967, 1969), have sequenced the f i r s t  24 amino acid residues of the 
N-terminal end of human, ra t and bovine albumin, and shown a high degree of 
s im ila r ity  between the albumins. Recently King and Spencer (1970), using 
cyanogen bromide cleavage of bovine plasma albumin in 75% formic acid , 
obtained two fragments which could be fu rther reduced to fragments of 88, 
98, 211, 148 and 34 amino acid residues. The single sulphydryl group of 
albumin was found to be located in the 88 amino acid residue peptide which 
occupies the N-terminal position of the molecule. These workers also found 
that defatted bovine albumin subjected to lim ited  try p tic  hydrolysis gave a 
fragment of molecular weight of about 40,000, the fragment being derived 
from the C-terminal two-thirds of the albumin molecule. Comparison o f th is  
try p tic  fragment and defatted albumin showed that they both had the same 
primary binding s ite  for octanoate and L-tryptophan. The results of th e ir
study are summarised in the schematic structure of bovine plasma albumin 
(F ig. I ,  3 ). More recently Meloun and Kusnir (1972), sequenced the 37 
residues, at the C-terminal end of human plasma albumin and Kusnir (1973) the 
36 residues between the f i r s t  and second methionine residues. Studies with 
such 'fragmented' albumins, despite th e ir  incompleteness, and also 
chemically 'modified' albumins (Means and Feeney, 1971) are lik & ly .to  play 
an important role in characterising binding sites fo r drugs and other small 
molecules.
Trypsi n
(397)
Met.Pro.
Asp.
- i S ' - s k
(545)
Met.Glu
HS -
I s ~S ) 5 -
-  -(S'-S k
Ala (579)
Met.Ala Pepsi n
(88 )
Fig. I ,  3
Schematic Structure of Bovine Plasma Albumin.
(King and Spencer, 1970).
Figures in parenthesis are amino acid number.
- I t  is possibly a misleading concept to consider a specific  number and 
class of binding s ite s , because the act of binding to one s ite  may e ith e r  
'create ' or 'destroy' other s ite s . This concept of conformational 
adaptab ility  was f i r s t  proposed by Karush (1950a). The idea that a bound 
molecule may induce adjacent or remote conformational changes in the protein  
structure which may fa c i l i ta te  fu rther binding, is s im ilar to that of 
induced f i t  and a ll osteric  transitions in enzyme-substrate interactions  
(Koshland, 1958; Monod, et al_., 1963). The binding of some small molecules 
to albumin have been shown to cause changes in a number of properties of the 
protein e .g . s ta b ili ty  to heat denaturation (Boyer, et al_., 1946), increases 
in viscosity (Franz, et al_., 1969). A number o f ligands, especially  long 
chain detergents have been shown to a ffec t the u ltra v io le t difference  
spectrum of albumin, often such conformational changes are so marked as to 
cause unfolding o f the protein structure (Reynolds, et al_., 1967,
Steinhardt and Reynolds, 1969). As a resu lt of producing such
conformational changes a second drug may in terfe re  with the f i r s t  in a
'non-competitive' manner, thus phenylbutazone interacts with bromsulphthalein 
(Rudman, et al_., 1971), and ethacrynic acid with warfarin by non-competitive 
in h ib itio n  (Sellers and Koch-Weser, 1970a). A ltern ative ly  two drugs may 
compete d ire c tly  fo r the same binding s ite  on the albumin molecule, fo r  
example phenylbutazone competitively in h ib its  the binding of w arfarin , 
(O 'R eilly  and Kowitz, 1967). F ina lly  the binding of the f i r s t  drug to 
albumin may also induce conformational changes which increase the capacity 
of albumin to bind a second class of drug molecule, thus the d iu re tic  
chlorthiazide increases the capacity of plasma albumin to bind the ganglionic 
blocking agent pempidine (D ollery, et al_., 1961). Consideration of the
c lin ic a l implications of such drug competition are presented la te r .
I t  is c lear from the above considerations that suitable data can 
provide information on both the a f f in ity  of binding and the number of
binding s ite s . Such data analysis inev itab ly  employs the theory of 
m ultiple e q u ilib ria  (K lo tz, 1953; Rosenburg and K lotz, I960, Steinhardt and 
Reynolds, 1969) in which i t  is assumed that a ll drug molecules are bound to 
the protein with equal a f f in i ty  (or can be grouped into d is tin c t classes 
within each of which the association constants are equal). Furthermore, 
the internal degrees of freedom of the bound drugs are neglected and 
therefore i t  must be assumed that a ll drugs in a given class bind in an 
identical manner. One frequently used method of data p lo ttin g  involving  
such considerations is that due to Scatchard (1949) (see also Chapter Two)
r/D^ = nk - rk 
where r = number of moles drug/bound/mole albumin
Deviations from lin e a r ity  of such plots are usually taken as in d icative  of 
binding to more than one class of binding s ite . In terpreta tion  of such 
curvature can be complicated i f  in teraction between binding s ites occur, 
in teraction may resu lt from s te ric  or charge repulsion phenomena or from a 
conformational change in the protein decreasing the a f f in i ty  fo r the 
remaining sites (negative cooperativity) (Gutfreund, 1972). Laiken and 
Nemethy (1970a) have suggested that while the assumptions of the theory of 
m ultiple e q u ilib ria  may be reasonable for small ions and other compounds with 
a rig id  molecular structure they may not be fo r a 'c h a in -lik e ' molecule.
They suggest that such compounds, (f le x ib le  ligands), are composed o f several 
functional groups, not a ll o f which have to be in contact with the protein  
simultaneously. The binding of such ligands is best considered as occurring 
through in teraction with several s ite s , where each s ite  is  defined as an
area on the protein surface which serves as a point of attachment fo r a 
single functional group,or segment, of the ligand. Although the m ajority of 
drugs would be unlikely to qualify  as 'f le x ib le  ligands', i t  is  apparent that 
a number of detailed binding studies have been performed on compounds that 
would probably qu alify  (e .g . long chain anions, hydrocarbons), such a model 
may be of considerable value in in terpreting  such binding phenomena.
Pharmacological and C lin ica l Consequences of Plasma Protein Binding
( i )  Absorption
A high degree of plasma protein binding may enhance the 
absorption of a drug by rendering the concentration gradient 
favourable fo r absorption. Brodie (1966) has suggested that this  
is p articu la rly  important with a drug poorly soluble in water, 
since binding w ill a ffec t the equilibrium between drug already 
absorbed and drug remaining in the gut, both dissolved and 
undissolved. I t  may be that drugs with poor s o lu b ility  
characteristics, such as dicoumarol, would not be well absorbed 
unless they were avidly bound to plasma proteins. However, few 
examples are at present apparent to substantiate the role of 
plasma protein binding in influencing in tes tin a l absorption.
Kakemi et al_. (1969)' have demonstrated a correlation between 
in tes tin a l absorption rate and protein binding fo r a series of 
barb ituric  acid derivatives dn the r a t , but concluded that binding to 
the mucosal surface is of more significance in a ffecting  absorption 
ra te , fo r these compounds, than plasma protein binding. Recently, 
however, Dearden and Tomlinson (1971) have suggested that protein  
binding may be important in determining the rate of buccal 
absorption for a series of p-substituted acetanilides.
( i i ) D istribution and pharmacological a c t iv ity
Most drugs d is trib u te  through the body water and tissues by 
passive d istrib u tio n  down a concentration gradient. I t  is 
generally considered that only the unbound plasma concentration of 
the drug is available for transport to the extravascular receptor 
sites (Goldstein, 1949; Brodie, 1966). Experimental observations
lend support to this concept, p a rticu la rly  with respect to the 
reduced potency of drugs such as sulphonamides (Davis, 1943;
Anton, 1960; KrUger-Thiemer et a]_., 1965), p en ic illin s  (Rolinson 
and Sutherland, 1965; Kunin, 1967), barbiturates (Goldbaum and 
Smith, 1954) and prostaglandin E^  (Raz, 1972b), when bound to 
albumin.
Providing they do not bind p re fe re n tia lly  or irre ve rs ib ly  to 
tissue s ite s , highly protein-bound drugs are l ik e ly  to be located 
mainly in the plasma compartment, a t least a t doses where the high 
a f f in i ty  binding sites are unsaturated (Brodie and Hogben, 1957; 
Martin, 1965a,b). Under these circumstances the protein bound drug 
can serve as a reservoir which replenishes (by dissociation) some 
of the drug that is lost by metabolism and excretion. In th is  way 
the concentration of unbound drug can be maintained a t a thera­
peutica lly  useful concentration fo r a period of time, over a range 
of to ta l plasma concentration. Furthermore, plasma protein binding 
can reduce the unbound concentration of toxic drugs below that 
required to e l ic i t  a toxic response, thus rendering the drug safe 
fo r therapeutic use. In the steady-state the concentration of unbound 
drug in the tissues, and tissue compartments of the ex tra c e llu la r  
f lu id , such as the synovial f lu id , equals that in the plasma 
(Howell et a l . ,  1972).
Martin (1965a), has discussed a theoretical model describing
the binding of four hypothetical drugs ranging from weakly bound
to highly bound from which i t  can be calculated that only fo r
4 idrugs with association constants (k) greater than 10 M"1 w ill  
binding have any appreciable e ffe c t on d is trib u tio n . At low plasma
c  1
levels a drug with a high association constant (k^JO M ) w ill  
be almost completely bound to plasma proteins. When the 
concentration of the drug increases however, the available plasma 
protein binding sites become fewer,as saturation approaches,with 
the resu lt that more of the drug diffuses into the tissues and 
the fraction of drug remaining within the vasculature is reduced.
For such drugs there is a f a ir ly  narrow range over which small 
changes in the plasma level can exert a profound change on the 
distrib u tio n  of the drug w ithin the body. M artin 's model is  
highly s im p lified , but il lu s tra te s  that the therapeutic dose range 
may be c r it ic a l ly  narrow fo r highly bound drugs which undergo large 
dose-dependent changes in d is trib u tio n . Levy and Nagashima (1969) 
have demonstrated that the d is trib u tio n  and elim ination of the highly 
bound drug dicoumarol is affected by its  plasma protein binding, but 
they emphasise that such effects are lik e ly  to be less pronounced 
fo r drugs not so extensively bound. Curry et j i l . (1970) has 
reported that the plasma concentration of chlorpromazine fluctuates  
a fte r intravenous doses in dogs and in man. Since chlorpromazine 
is a highly protein bound drug (Curry, 1970a), the suggestion has 
been made that movement of the drug between tissue and plasma 
stores could resu lt in small changes in protein binding by plasma 
and tissues (Curry, 1970b). Although tissue binding has not yet 
been intensively in ve s tig a te d ,it seems lik e ly  that some highly 
bound drugs have even higher a f f in it ie s  fo r certain  tissue proteins 
which may or may not be receptor proteins. The cardiac glycosides, 
fo r example, have been found in v itro  to have a higher a f f in i ty  
for cardiac actin and myosin than for bovine serum albumin 
(Genazzani and Santamaria, 1969), such that in vivo th e ir  concen­
tra tio n  in the heart is about twenty to th ir ty  times that in plasma.
Competition between endogenous and exogenous compounds for plasma 
protein binding sites can be summarised as:-
(1) mutual competition between endogenous substances,
(2) displacement of endogenous substances by drugs,
(3) in teraction between two drugs
Although competitioi may occur between endogenous compounds 
such as steroid hormones (K eller et al_., 1966), the importance 
of this phenomenon remains to be ascertained. However, a number 
of examples of displacement of endogenous compounds by drugs are 
known. Odell (1959), has shown the toxic e ffects  that can be 
produced by displacement of b iliru b in  by sulphonamides. This e ffec t 
is of particu lar significance in premature infants with low plasma 
albumin concentration, or in individuals with an impaired capacity 
to metabolise b iliru b in . The view that the antirheumatic a c t iv ity  
of certain drugs, e .g . s a lic y la te , phenylbutazone, indomethacin, 
prednisolone, chloroquine, may be mediated through th e ir  a b i l i ty  to 
displace endogenously plasma protein bound tryptophan and other 
small peptides has been proposed (McArthur e t a l . ,  1971;Smith et 
a l . ,  1971). I t  has also been suggested (Brodie, 1965), that some 
anti-inflammatory drugs may act by displacing steroids from plasma 
binding s ites .
Numerous drugs have been shown in v itro  and in animal 
experiments to compete fo r plasma protein binding sites (Meyer and 
Guttman, 1968), the many potential drug-drug interactions have been 
extensively reviewed (Hussar, 1969; Hartshorn, 1970; Koch-Weser 
and S e llers , 1970a,b; Sher, 1971; Swidler, 1971; Baker and Neuhaus, 
1972). The data re la tin g  to human subjects is lim ited  and largely  
anecdotal. Important examples where displacement may manifest
i t s e l f  in a c lin ic a lly  undesirable side e ffe c t include, 
displacement of the anticoagulant drug warfarin by highly bound 
drugs such as phenylbutazone, chlorophenoxyisobutyric acid, indo- 
methacin, s a lic y la te , fa t ty  acids and various sulphonamides, and 
these in turn may compete with one another fo r binding to plasma 
proteins (Solomon and Schrogie, 1967; Solomon et al_., 1968).
The displacement of warfarin by phenylbutazone results in an 
increased anticoagulant e ffec t which may give rise  to spontaneous 
haemorrhage, yet also results in a more rapid excretion of the drug.
A possible explanation is that phenylbutazone may displace warfarin  
not only in the plasma, but also from non-specific tissue binding s ite s , 
p a rtic u la rly  in the l iv e r . The oral hypoglycaemic drug, tolbutamide, 
which is normally quite extensively bound to plasma proteins may be 
competitively displaced by the administration of bishydroxycoumarin, 
with the consequent resu lt of a sudden hypoglycaemic c r is is . The 
converse situation also applies, fo r i f  tolbutamide and bishydroxy­
coumarin are given simultaneously, the concentration of the unbound 
anticoagulant is also elevated. Displacement phenomena may be of 
p articu lar practical importance in the case of those drugs which 
are frequently self-prescribed and not regarded as drugs by patients. 
Drug displacement may however be of potential c lin ic a l value 
(Mroszczak et cfL, 1969), thus highly albumin bound pharmacologically 
re la tiv e ly  in e rt excipients (such as sodium trich lo roaceta te ) which 
lower the dose of a drug necessary to produce a given pharmacological 
response, could be included in a pharmaceutical preparation of a 
drug (e .g . warfarin plus sodium tric h lo ro ace ta te ). Such a 
preparation could give stable blood levels fo r warfarin even when 
other highly bound drugs (known to displace w arfarin) were con­
currently administered.
From a c lin ic a l standpoint i t  is important to distinguish  
between potential and actual drug interactions since competitive 
phenomena, which are read ily  demonstrable in v it r o , may not be 
of s u ffic ie n t magnitude to have a c lin ic a l e ffe c t or may be 
obscured by other factors in vivo. I t  is unfortunately d i f f ic u l t  
to predict the displacement of one drug by another merely from a 
knowledge of binding data and plasma concentrations. A drug with 
a higher association constant (k) does not necessarily displace a 
drug of lower a f f in i ty ,  unless both share common binding s ite s .
I t  is apparent that u n til such mechanisms are better understood 
great caution must be exercised when administering novel 
combinations of drugs known to be protein bound. Reports that 
hospitalised patients in America (Seidl et al_., 1965) received an 
average of 13 d iffe re n t drugs, emphasises th is  need fo r  caution. 
Appropriate in v itro  screening tests must be sought since i t  is 
un rea lis tic  to tes t a ll combinations in the fa r  more complex jn  
vivo experiments.
Metabolism
I t  is generally believed that only unbound drug is availab le  
fo r metabolism and f i l t r a t io n  at the glomerulus. The lim ited  
number of studies on the kinetics of binding have been discussed 
by Meyer and Guttman (1968), and there is general agreement that 
in most systems rates of association and dissociation are very 
rapid. From these considerations i t  would seem un like ly  that 
protein binding is normally the lim itin g  factor in determining the 
rate of metabolism and excretion of most drugs.
A theoretical consideration of the e ffe c t of protein binding on 
metabolism has recently been made by G ille tte  (1971). He suggests
that i f  the a c tiv ity  of the drug-metabolising enzyme in liv e r  
is so high that v ir tu a lly  a ll  the drug is cleared from the blood 
as i t  passes through the l iv e r  ( i . e .  extraction ra tio  nearly one) 
then an increase in binding of the drug by plasma proteins could 
accelerate its  metabolism, by increasing the rate a t which i t  is 
carried to the l iv e r . A lte rn a tive ly , i f  very l i t t l e  of the drug is  
metabolised as i t  passes through the liv e r  ( i . e .  extraction ra tio  
nearly zero) an increase in the binding of the drug in the blood 
may e ith er decrease its  metabolism or have l i t t l e  e ffe c t. The 
effects of protein binding on h a lf-liv e s  of drugs which are e n tire ly  
metabolised have not been elucidated, largely  because variations in 
drug clearance (extraction ra tio ) tend to obscure the effects  of 
drug binding. Investigation of the e ffe c t o f protein binding on the 
metabolism of drugs is complicated because changes in chemical 
structure, which can a ffec t the extent of protein binding, may also 
a ffec t the nature and rate of metabolism.
Newbould and K ilp atrick  (1960), found that addition of plasma 
to the f lu id  perfusing a rabbit l iv e r  preparation, reduced the rate  
of acetylation of two 'long-acting' sulphonamides, and that the 
rate of metabolism was dependent on the concentration of unbound 
drug. Later Anton and Boyle (1964), and Wiseman and Nelson (1964), 
also reported a correlation between rate  of metabolism of a 
sulphonamide and the extent of protein binding. Raz (1972c) has 
shown that both the rate of metabolism of prostaglandins and Ag) 
and the nature of the metabolites formed, are affected by plasma
protein binding. The higher a f f in i ty  of d ig itox in  (k = 103 |\H )  
fo r serum albumin compared to digoxin (k = 103 M"1) has been held 
responsible fo r the higher plasma concentration, lower urinary  
excretion rate and longer plasma h a l f - l i f e  of the former drug 
in man (Lukas and DeMartino, 1969). The presence of warfarin  
in the plasma and the absence of unchanged drug in urine has been 
suggested to resu lt from its  binding to albumin and its  non-polar 
character (O 'R e illy , 1969). On the other hand, hydroxylated 
metabolites of w arfarin , which are more weakly protein bound are 
v ir tu a lly  absent from plasma, but present in urine. However, highly 
protein bound drugs such as sulphobromophthalein (k = 10? ) are
rapidly metabolised (Brodie and Hogben, 1957).
Elimination
Considering the importance of this subject remarkably few experi­
mental studies have been made. Kakemi et al_. (1962) found an
approximate inverse correlation between the binding of a series of
salicylates and th e ir  rate of excretion. However, such a correlation  
is lik e ly  to hold fo r only a few drugs, fo r which the renal 
excretion is predominantly determined by the rate of glomerular 
f i l t r a t io n .  Several authors have considered the elim ination of 
drugs possessing high binding a f f in it ie s  for plasma proteins from 
a theoretical point of view, but without complete agreement 
(M artin, 1965b; Kruger-Thiemer, 1968; Keen, 1971).
Rieder (1963), in a study of a number of sulphonamides, was unable
to observe a correlation between binding and rate of disappearance 
from plasma or rate of renal excretion, although A rita  e t a l .(1971), 
in a study involving two sulphonamides, reported that protein binding 
did e ffec t th e ir  glomerular f i l t r a t io n  ra te . P en ic illin s  have a
very high clearance value re flec tin g  tubular secretion which
would support the finding that th e ir  t i  values are re la tiv e ly
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insensitive to protein binding (N otari, 1973). In contrast, i t  has 
been stated that the renal clearance of tetracyclines decreases with 
increased protein binding (Fabre et al_., 1971). Bluestone et a l . 
(1969) have reported increased excretion of urate following its  
displacement from plasma binding sites by aspirin  and phenylbutazone.
The e ffe c t of plasma protein binding on b il ia ry  excretion is 
largely a matter for conjecture (Keen, 1971; Smith, 1971). Several 
highly bound anions (e ,g , bromosulphthalein, b iliru b in ) have been 
shown to be rapidly excreted in the b ile  (Bradley et al^., 1952). 
and a number of highly protein bound radio-opaque compounds were 
shown to be excreted in the b ile , whereas only re la t iv e ly  poorly 
bound compounds were excreted in the urine (Lasser, e t al_., 1962). 
This would tend to suggest that protein binding may assist b i l ia r y  
excretion. However, Czok et aj_. (1970), have recently shown that a 
number of poorly bound compounds (phenolphthalein glucuronide, 
succinysulphathiazole) were excreted in the b ile  in unchanged form. 
Furthermore, i t  has been suggested that binding to plasma proteins 
may a ffec t the uptake of the drug by the liv e r  ce lls  (P r ie s tle y  
and O 'R e illy , 1966; Osorio and Myant, 1965).
Physiological Factors Affecting the Plasma Protein Binding of Drugs.
i )  Species differences
Goldstein (1949), mentioned a number of reported in ter-species  
differences in serum binding capacity. However, no consistent 
pattern was apparent, although rabbit sera appeared to exh ib it 
superior binding c ap ab ilities . Despite the large number of reported
binding studies since then, few have been concerned with evaluating
either in te r - or intra-species differences in the plasma protein  
binding of drugs and no basis for prediction has emerged.
Sturman and Smith (1967) found that monkey, rabbit and guinea 
pig, lik e  man, bound s a licy la te  to the extent of 60-80% at the same 
to ta l plasma concentration. Witiak and Whitehouse (1969), noted 
species differences in the binding of several acid ic drugs and 
suggested that the ra t may be an unrepresentative species as fa r  
as drug binding to albumin is concerned. They also observed 
differences between ra t serum and isolated ra t albumin. Species 
differences have been demonstrated in both the number of phenyl­
butazone binding sites and th e ir  a f f in it ie s  fo r the drug,with 
human, ra t, dog and rabbit albumins (Chignell and Starkweather, 1971). 
Differences in the binding to d iffe re n t preparations of albumins 
(e .g . c rys ta llin e  and fraction  V) have also been reported fo r some 
drugs (e .g . w arfarin , s a lic y la te ), however, no consistent in te r ­
pretation is possible from these studies (Kostenbauder et al_., 1970; 
Meyer and Guttman, 1970b; O 'R eilly  and Motley, 1971). Species 
differences in the binding of basic drugs; desipramine (BorgS et a l . 
1968), and amphetamine (Baggot et a2- 1972) have been observed, such 
differences may account fo r reported species differences in  
dis trib u tio n .
In ter-in d iv id ua l differences in the plasma protein binding in man 
of the tr ic y c lic  antidepressant drug, n o rtr ip ty lin e  were observed 
(Alexanderson and BorgS, 1972). I t  has been reported that the 
protein bound iodine in Negro pre-adolescent children is s ig n ific a n tly  
greater than that of white children (S tarr et al_., 1967) . Differences 
in the thyroxine binding globulin, to ta l gamma globulin and albumin 
concentration, but not thyroxine binding prealbumin were noted.
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In contrast to the lack of unanimity on the binding 
consistency among healthy individuals, i t  is generally agreed 
that binding is decreased in disease (Goldstein, 1949; Reynolds and C! 
C lu ff, 1960; Anton, 1968; Anton and Corey, 1971; Andreason, 1973).
An increase in c ircu lating  metabolites, e .g . b iliru b in , fa t ty  
acids, drugs, decreased albumin concentration, and altered protein  
structure have been suggested as possible causes fo r the binding 
deficiency, but the exact mechanism(s) has not been id e n tif ie d .
For drugs that are mainly bound to albumin,a decrease in albumin 
concentration in disease has been shown to account fo r the 
proportionate decrease in the binding found with some drugs 
(Reynolds and C lu ff, 1960; Wishinsky et , 1962; Rolinson and 
Sutherland, 1965). Anton and Corey (1971) have suggested that 
th is may be the reason for known decreases in the sulphonamide 
binding in anephric patients. Andreason.(1973), recently reported 
decreased binding of the drugs acety ls a lic y lic  acid, s a lic y lic  acid 
phenylbutazone, diphenylhydantoin, sulphadiazine and thiopental 
in patients with acute renal fa ilu re . Such decreases in protein  
binding could not be completely explained by lower albumin 
concentrations, although the drugs have been reported not to bind 
s ig n ifican tly  to other plasma proteins. In te res tin g ly , Reidenberg 
et al_. (1971), although demonstrating decreased plasma protein  
binding fo r diphenylhydantoin in uraemic patients, found no e ffec t  
on the binding of desmethylimipramine.
The concentration of unbound tryptophan in the plasma is thought 
to influence the concentration of tryptophan in the brain and hence 
the turnover of the putative transm itter 5-hydroxytryptamine (5HT). 
Recently, Coppen et aj_. (1972) have reported a lower unbound tryp to ­
phan concentration and increased percentage binding in depressive
patients, and postulated that i t  may account fo r the reduced 
cerebro-spinal f lu id  tryptophan levels and brain 5HT levels .
Rheumatic patients have also been reported to have a higher unbound 
level of tryptophan in the plasma and a decreased percentage 
binding (McArthur e t aj_., 1971). I t  is of in teres t that 
administration of anti rheumatic drugs have an antidepressant action 
in rheumatic patients, and that the decrease in depression is 
correlated with an increase in plasma free tryptophan, (Aylward 
and Maddock, 1973). The binding of tryptophan to patients with 
Down's syndrome has also been shown to be reduced (Airaksinen and 
Airaksinen, 1972) and a s im ilar e ffe c t was noticed fo r s a licy la te  
binding (Ebadi and Kugel, 1970). However, Airaksinen and Airaksinen 
(1972) suggest that th is may be due to reduced plasma albumin levels .
Age
Ganshorn and Kurz (1968) reported that the plasma binding 
of several sulphonamides was greater in adult than cord plasma, and 
Chignell (1971) has shown that sulphaphenazole has a lower a f f in i ty  
fo r plasma albumin isolated from cord and neonatal blood than fo r  
adult human plasma albumin. They suggest that differences could 
be due to the presence of a t ig h tly  bound endogenous compound, such 
as b iliru b in , on fe ta l and neonatal albumin. The work of P ru itt  
and Dayton (1971) suggests that other factors such as quantita tive  
or q u a lita tive  differences in albumin or binding to other proteins 
may also be operative. The physiological significance of the decreased 
binding capacity of fe ta l and newborn albumin is d i f f ic u l t  to assess. 
Reduced binding capacity of albumin in the neonate could play a ro le  
in drug d istribu tion  and may therefore contribute to the extreme 
s e n s itiv ity  of the newborn in fan t to various drugs.
Conclusions - Plasma protein binding may a ffec t a drugs pharmacology,
pharmacokinetics and toxicology. I t  is apparent that the detailed  
characterisation of drug-protein interactions are fundamental to 
our understanding of drug action. Such information is a necessity 
i f  we are to in terp re t in te r -  and intra-species d ifferences, and 
the e ffec t of age and disease states on the binding process. Only by 
such detailed knowledge of the plasma protein-drug in teraction  can 
the. consequences of drug competition in the pharmaceutical and 
pharmacological phases of drug a c tiv ity  be ra tiona lised . The 
practical implications of binding may necessitate determination of 
the degree of binding as a prerequisite to the use of plasma levels 
as a guide to drug therapy in man and screening tests in animals.
Binding of Drugs to Tissues 
i )  General
I t  is usual to assume that the fraction of unbound drug in 
the tissues is the same as the unbound fraction  in the plasma.
However, the s ituation in vivo may be complicated by binding to 
tissue proteins, and a series of eq u ilib ria  w ill  have to be 
established between the tissues of various organs and the tissue  
f lu id . Evidence to support the id en tity  of tissue f lu id  
concentration with the unbound plasma level in the case of protein  
bound drugs was produced by Verwey and Williams (1962 a,b) in dogs. 
These authors measured the concentration of protein bound p en ic illin s  
in lymph and related these to plasma concentrations. Furthermore, 
Scholtan and Schmid (1962) provided experimental evidence in mice 
which indicated that the levels of unbound p e n ic ill in  and p ro p ic illin  
in serum were very s im ilar to those in tissue f lu id , even though 
levels of to ta l drug were quite d iffe re n t. Kunin (1965) has shown 
that the d istrib u tio n  of p en ic illin s  in the tissues of rabbits
was inversely related to th e ir  known binding to rabbit serum. Further
support came from McQueen (1968) who, using an in vivo d ia lysis  
technique, has reported that the concentration of sulphormethoxine 
. in the peritoneal f lu id  of the ra t corresponded well with the 
unbound fraction  in serum. However, in the case of drugs which are 
highly bound to tissues, drug levels per unit weight of tissue may
well be in excess of the concentration of free drug in the plasma.
Brodie (1952) demonstrated that 3 hours a fte r  an intravenous 
in jection of the u ltra  short acting barb iturate , thiopentone, levels  
in the fa t  were 10 times higher than in plasma and Burns et a l .(1953) 
reported higher unbound phenylbutazone levels in lung, heart and 
muscle than in plasma. Lullman and Van Zweiten (1969) demonstrated
that the cardiac glycosides were both highly bound to plasma 
proteins and to isolated a trica  and showed that tissue-binding was 
not d ire c tly  proportional to biological a c t iv ity , indicating that 
plasma-binding and tissue-binding may be s im ilar processes each 
sequestering drug and thereby lowering free drug concentration.
Drug displacement from tissue binding sites can also occur, 
and has been demonstrated by the in teraction between the a n ti-  
malarial drugs, mepacrine and pamaquine in patients (Brodie, 1966). 
This in teraction potentiated the toxic effects of pamaquine, which 
exhibits a small margin between toxic and therapeutic concentrations. 
I t  is apparent that consideration of red is tribu tional drug in te r ­
actions must take into account both displacement from plasma 
protein, and tissue binding s ites . The p o ss ib ility  of displacement 
from both intravascular and extravascular albumin, which is 
approximately three times that of the intravascular pool (Sellers  
et al_., 1966), should also be considered.
Binding may occur at the level of the ce ll membrane or w ithin  
the ce ll on the nucleus, on cytoplasmic organelles or in the 
cytoplasmic f lu id . This binding may be with proteins or to 
polypeptides, lip id s , and polysaccharides (Woolley and Gommi, 1966).
A number of binding proteins to which both endogenous and 
exogenous molecules are known to associate have been isolated from 
cells  of various organs. Rat kidneys have been found to contain 
aldosterone-binding proteins (Guidollet and Louisot, 1969).
Two hepatic cytoplasmic proteins (Y and Z) have been iso la ted , 
purified  and characterised (Levi et £l_., 1969; Reyes e t al_., 1971) 
and shown to bind sulphobromophthalein, b iliru b in , corticosteroids  
and carcinogens and various dyes. The amount of the protein
(ligandin) (Litwack et al_., 1971 ) was increased s ig n ific a n tly  
in ra t l iv e r  by phenobarbitone pretreatment (Reyes et_ aK , 1969).
The cytoplasmic proteins, Y and Z are found largely  in the liv e r  
in a great variety  of animals although they may be present in 
other tissues (Reyes et a l . ,  1971; Ockner et al_., 1972). The 
function of these various binding proteins is not known, but they 
may be involved in the uptake of small molecules from the plasma, 
in tra c e llu la r  transport or in mediating biological action in the 
case of some hormones.
I t  is lik e ly  that the physico-chemical factors which govern the 
plasma protein binding of drugs also predispose towards tissue  
binding. Some drugs may be more highly bound to tissues than to 
plasma proteins (Borg§ et^  al_., 1969), and this may be fo r such 
drugs,a more important determinant of the d is trib u tio n  and 
persistence of a drug within the body, than plasma protein binding.
I t  is apparent that the fu l l  scope and importance of the tissue  
binding of drugs, and other biological substances, necessitates 
more extensive study. Because of the practical problems associated 
with such studies, e .g . iso lation  of binding proteins, i t  may be 
that studies with other read ily  obtainable, re la tiv e ly  well 
characterised proteins, may serve as a basis fo r understanding 
tissue-drug in teractions. Thus the study of the binding of drugs to 
plasma proteins might lead to a better understanding of the features 
governing the in teraction of drugs with the drug metabolising 
enzymes, especially cytochrome P-450. A b r ie f review of cytochrome 
P-450 and the nature of its  spectral interactions is presented.
Cytochrome P-450
Klingenburg (1958) and Garfinkel (1958) f i r s t ,  independently, 
demonstrated the presence of the carbon monoxide binding pigment 
in liv e r  microsomes la te r  called cytochrome P-450, which appears 
to be involved in mixed function oxidase hydroxylation (Mason, 1957), 
of both endogenous and exogenous compounds. (Cooper and Brodie, 1955; 
Gi 11 ette  e t al_., 1957; Conney et al_., 1957; Omura and Sato, 1964; 
Cooper e t al_., 1965; G ille t te , 1966).
Cytochrome P-450 is a b-type haemoprotein in tim ate ly  associated 
with the endoplasmic reticulum membrane, i t  is mainly comprised 
of a protohaem, phospholipid and protein. Tissue and species 
differences in cytochrome P-450 and substrate s p e c ific it ie s  are 
lik e ly  to ex is t, due to variations in the association of cytochrome 
P-450 with the microsomal membrane or in q u a lita tiv e  or quantitative  
differences, in other components of the enzyme system. I t  is also 
possible that cytochrome P-450 may exist in d iffe re n t forms.
The importance to cytochrome P-450 s ta b il i ty  of hydrophobic 
in teractions, has been demonstrated by the potency with which 
dialkyl ureas convert cytochrome P-450 to P-420 (Ichikawa and 
Yamano, 1967), also alcohols in high concentrations cause the 
conversion. The observation that cytochrome P-450 can be solubilized  
by detergents, but not by proteases which so lu b ilise  about h a lf of 
the microsomal protein (Omura and Sato, 1964) also favours the 
concept of a strong in teraction of lip id  and protein .
Although administration of phenobarbital to animals increases 
the level of cytochrome P-450, the haemoprotein nevertheless 
resembles that found normally. However, administration of 3-methyl-  
cholanthrene (3MC) and certain other polycyclic hydrocarbons, causes
the induction of a P-450 haemoprotein which d iffe rs  from that seen 
normally (Sladek and Mannering, 1966, 1969). This species of 
cytochrome P-450 was named cyt.P-j-450 (Alvares et a]_., 1967; 
Hildebrandt et £l_., 1968). This 3MC induced haemoprotein appears 
not to bind type I compounds (Sladek and Mannering, 1966).
Schenkman et al_. (1969) suggested that cyt. ■. Pp450 was simply 
an irrevers ib le  complex of the polycyclic hydrocarbon,or its  
metabolites,with the type I binding s ite  of native cytochrome 
P-450. However, a considerable amount of evidence has suggested 
that th is is not the case and that i t  re flects  the formation of a 
new type of haemoprotein (Alvares al_., 1967; Kuntzman et al_., 1969 
Mannering, 1971; Fu jita  et al_., 1973).
a) Substrate-induced spectral changes
A large number of compounds have been shown to produce 
characteristic  absorbance changes in the difference spectrum of 
l iv e r  microsomes, which are thought to re fle c t  in teraction  with 
cytochrome P-450 and these changes have been used to assess 
both the quantitative and q u a lita tiv e  character of drug P-450 
interactions.(Remmer et a ! . ,  1966; Imai and Sato, 1966). Such 
spectral changes have been categorised into three types 
(Schenkman et aj_., 1967, Fig. I ,  4-), type I ,  type I I  and Reverse 
type I (type R I, also termed modified type I I  or Inverse type I ,  
Diehl e t a]_., 1970). The type I spectral change which is  
characterised by an absorption peak at about 385 nm and a trough 
at about 420 nm is typical of spectra produced by hexobarbital, 
aminopyrine, chlorpromazine, carbon te trach lo ride . The type I I  
spectral change is indicated by an absorption peak in the region 
425-435 nm, and a trough at about 390 nm, e .g . a n ilin e , pyridine
Fig. I, 4.
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and nicotinamide. The type RI spectrum (peak a t about 
420 nm and trough about 390 nm) is normally a m irror image 
of a type I spectrum (Schenkman et aj_., 1972) examples of 
compounds e lic it in g  this type of spectral change a re :-  
agroclavine, ethanol (Orrenius et al_., 1972). The magnitude 
of the spectral change observed in each case is dependent upon 
the concentration of substrate added, and can therefore be 
analysed by means of a Lineweaver-Burk (type) p lo t, fo r  
determination of the spectra lly  apparent dissociation constant 
(Ks) (see Chapter Two).
Oxidised cytochrome P-450 is considered the locus of these 
actions which are rapid, reversible and proceed substrate 
oxygenation. Several lines of evidence support the assumption 
that these spectral changes re fle c t the in teraction of the added 
substrate with cytochrome P-450; a relationship between the 
magnitude of spectral change and the concentration of cytochrome 
P-450 has been demonstrated (Schenkman e t aj_., 1967), also close 
s im ila r itie s  for a number of substrates between maximal type I 
spectral change (K ;^) and hydroxylation values(Imai and Sato, 
1967; Schenkman et a K , 1967). Solubilised and p a r t ia lly  purified  
P-450 (Coon and Lu, 1969) preparations also show the same drug- 
induced spectral changes as native microsomes. However, the 
situation is complex fo r some compounds have been found to 
e l ic i t  difference spectra in d iffe re n t tissues (Orrenius e t a l . ,  
1970) or a t d iffe re n t concentrations (von Bahr and Orrenius, 1971), 
and furthermore, substrates of the microsomal mono-oxygenase 
systems may cause various types of spectral change (types I , I I  orRI 
Schenkman et al. 9 1967), The significance of the drug-induced
spectral changes is thus often d i f f ic u lt  to assess.
The type I spectral change,generally acknowledged to be due 
to the binding of substrate to the apoprotein of cytochrome P-450, 
is probably caused by an increase in the e lectronegativ ity  of one 
ligand of the haem. I t  has been suggested (Schenkman and Sato, 
1968) that two forms of cytochrome P-450 e x is t, one as the 
unreacted enzyme and the other bound to an endogenous type I 
substrate (substrate-bound form). Type I interactions possibly 
occur by replacement of this endogenous substrate by a more 
strongly bound exogenous compound (Temple, 1972). The type I 
interactions apparently involve P-450-associated phospholipid.
This view is supported by the finding that the type I s ite  is 
destroyed by microsomal iso-octane extraction or digestion with 
phospholipases C and D (Chaplin and Mannering, 1970; Leibman 
and Estabrook, 1971). DiAugustine et al_. (1970) and Eling and 
DiAugustine (1971) in a study employing the fluorescent probe 
ANS, a type I compound, also suggested that the binding locus 
involved a phospholipid, possibly phosphatidylcholine. They 
postulated that binding may involve both hydrophobic in teraction  
and an e lec tro sta tic  in teraction with the cationic group of 
phosphatidylcholine. The type I spectral change can ail so be 
interpreted as a promoted tran s ition  of oxidised cytochrome P-450, 
from a low to a high spin electronic s ta te , the converse high to 
low spin stransition results from type I I  in teractions (Mitani 
and Horrie, 1969; Gunsalus et aJL, 1971; Jefcoate and Boyd, 1971).
Although a close correlation between K$ and Km is often 
found for type I interactions a large number of cases have also 
been reported where Ks and Km are not related fo r type I compounds
(Krantz and Staudinger, 1968; Degkwitz, 1969; Diehl e t al_., 1970). 
Likewise an iline  and other type I I  compounds generally have
d issim ilar Kg and Km values (Guarino et al_., 1969; Schenkman, 1967)
Also non-substrates have been shown to give rise  to type I spectral 
changes, e .g . 2-hydroxydesmethylimipramine (von Bahr and 
Orrenius, 1971). Since Km values fo r microsomal drug metabolism 
encompass the individual kinetics of several components of a 
complex system, the poor correlation that often exists between 
Km and Ks is not surprising; especially i f  the optical changes 
defined by Ks values resu lt prim arily  from conformational changes
in cytochrome P-450, merely one component of the monoxygenase
system (Schenkman and Sato, 1968). Also divergence between the 
two parameters w ill be even more lik e ly  i f  only a proportion of 
the cytochrome P-450 is engaged in formation of a spectra lly  
apparent substrate complex and in subsequent oxygenation (Guarino 
et a l . ,  1969; U llr ic h , 1969).
The type I I  spectral change has been suggested to be 
associated with ferrihaemochrome formation involving electron  
transfer between the sixth ligand of iron and the nitrogen of 
the added compound (Schenkman et al_., 1967). The type I I  
in teraction therefore would appear to be competitive with carbon 
monoxide and in a ll p robab ility  oxygen as w e ll. I t  is l ik e ly  
that true type I I  changes are only given by basic amines, some 
e.g. an iline  type I I  compounds are also substrates of the mono­
oxygenase system. Although an ilin e  and ethyl iso-cyanide both 
compete fo r oxidised and reduced P-450, there is evidence that 
the an iline  type I I  and ethyl iso-cyanide sites are d iffe re n t  
(Alvares et a l - , 1971; Imai and Sato 1966 and 1967).
Type I I  compounds have been shown to competitively in h ib it  
the type I spectral change, they also in h ib it other type I I  in te r ­
actions, but apparently never com petitively. Type I compounds 
are mutually in h ib ito ry , but not always com petitively. The type 
I I  in teraction has been shown to be enhanced by type I compounds 
(Leibman et al_., 1969; Orrenius et a]_., 1970). The enhancement 
effects of type I compounds on type I I  spectral changes has led 
to the view that the type I I  spectral change may contain a hidden 
type I component (Orrenius et al_., 1970). Such a type I component 
has apparently been demonstrated fo r an iline  (Schenkman, 1970).
The possible presence of a type I in te ra ttio n  may well explain 
the correlation found between the K$ values fo r the type I I  n-alkyl 
amines and chain length. Such a correlation indicating the hydro- 
phobic nature of the in teraction between the n-alkylamines and 
cytochrome P-450.
The reverse type I (type RI) formerly referred to as the 
modified type I I  spectral change (Schenkman e t al_., 1967), or the 
Inverse type I (Diehl e t al_, 1970), has been shown to be the 
reverse of the type I spectral change in both absolute and 
difference spectra. The type RI appears to be as sp ec ific , with 
respect to wavelength, as the type I change. Because of the 
spectral s im ila r itie s  of type RI with type I I ,  type RI spectral 
spectral changes have often been incorrectly  in terpreted as type I I ,  
however, whereas type I I  compounds w ill displace carbon monoxide 
from reduced cytochrome P-450, type RI compounds w ill not. The 
type RI would therefore appear to be the spectral manifestation  
of a class of compounds, not necessarily substrates, which bind 
to the apo-enzyme of the mixed function oxidase system (Schenkman 
et_ a1_., 1972). The type RI group of compounds appear to be as
chemically heterogenous as those producing type I spectral 
changes, and includes various drugs, a lka lo ids , alcohols, steroids 
and the amino acid tryptophan (Wilson and Orrenius, 1972).
Several hypotheses to account fo r the type RI change have 
been proposed:- i t  could resu lt from the displacement of some 
endogenously bound substrate (Schenkman et al_., 1969; Schenkman, 
1970; Diehl e t al_9 1970). This work was supported by the finding  
of Schenkman et al_., (1972) that the magnitude of the RI change 
can be markedly increased by the prior addition of a type I 
compound to the microsomal preparation since i t  provided more 
substrate-bound enzyme (394 nm form). Also the formation of the 
type RI decreased the rate of P-450 reduction, as would be expected 
since the formation of a type I change enhances the rate of P-450 
reduction. Schenkman et al_ (1972) have more recently suggested 
that the type RI s ite  on substrate bound form of cytochrome P-450 
is at a s ite  other than the type I s ite . They suggest that this  
in teraction sh ifts  the equilibrium  between the substrate bound 
form (394 nm) and the free (419 nm) form towards the free form 
(419nm). . The type RI spectral change does not appear to be 
related to substrate metabolism, lik e  most type I spectral changes 
(Jansson e t al_., 1972). However, that some type RI compounds are 
substrates has been observed (Orrenius e t a K , 1972). To account 
fo r the type RI spectral change observed fo r the monoxygenase 
substrates: phenacetin and agroclavine, Orrenius e t a l .(1972)
proposed that a type I in terac tion , related to metabolism, was 
present in th e ir  type RI spectral changes. They suggested that 
the lack of a type I component in the type RI spectral change may 
distinguish non-substrates from substrates. Evidently much remains 
to be elucidated about the nature of the 'drug' microsomal binding 
sites .
Methods of Studying Protein Binding
In his review Goldstein (1949) outlined three basic principles  
upon which the binding of drugs to proteins could be studied:-
1. The concentration of free drug and its  thermodynamic a c tiv ity  
are reduced, and its  biological action may also be diminished.
2. The drug may show changed properties, which can be measured with 
greater or less precision. Some of the effects  may also be 
attributed  to reduction of thermodynamic a c t iv ity .
3. The protein component may be measurably a ltered with respect to 
its  properties.
Only those established techniques s t i l l  in frequent use, and the newer 
ones, the true potential of which is s t i l l  to be fu l ly  assessed, w ill be 
discussed here. For summary see Tables I ,  3 and I ,  4.
Several comprehensive discussions on the methods of studying protein  
binding have been published including Goldstein (1949), Edsall and 
Wyman (1958), Rosenburg and Klotz (1960), Steinhardt and Reynolds (1969) 
and Chignel1 (1971).
Non-spectroscopic approaches include the classical techniques of 
equilibrium d ia lys is , u l t ra f i l t ra t io n  and gel chromatography.
i ) Equilibrium dia lysis
Confining the protein within a semi permeable membrane through 
which only unbound drug molecules can free ly  diffuse is one of the 
oldest and most widely used methods of studying binding (Osborne, 
1906). Drugs are routinely dissolved in e ith er the protein or 
solvent (buffer) containing compartments and dialysed against the 
same solvent un til analysis shows that equilibrium has been attained.
The approaches which have been used fo r equilibrium d ialysis  studies 
range from the use of simple cellophane or cellu lose bags (K lotz, 
1946; Rosenburg and K lotz, 1960) to specially  designed apparatus 
employing 'dialysis c e lls ' (S te in , 1965; Farrell e t al_., 1971;
Weder and B ickel, 1970).
Equilibrium dialysis  is well suited for quantitative measurements 
of binding, but does have a number of problems (Goldstein, 1949; 
Steinhardt and Reynolds, 1969). Thus the presence of the membrane 
introduces the problem of Donnan inequalities  (Donnan, 1924;
Karush and Sonnenburg, 1949), or i f  the la t te r  are supressed by 
sa lts , possible competition effects between s a lt  and drug (K lo tz, 
1953). Many buffers (e .g . trism aleate, veronal, chloride, acetate) 
used in in v itro  experiments compete with the binding of drugs and 
other small molecules to bovine serum albumin,although l i t t l e  
competition is apparent with phosphate (Klotz and Urquhart, 1949; 
Klotz, 1953; Keen, 1966). Adsorption of the drug onto the membrane 
can also occur (Agren, 1968; Steinhardt and Reynolds, 1969) although 
the binding of protein is generally neglig ib le (Bennet and Kirby, 
1965; Meyer and Guttman, 1970a). The time taken to a tta in  
equilibrium is variable depending on s t ir r in g , pretreatment of 
membrane, protein concentration, temperature, nature of the b u ffe r, 
and volumes on both sides of the membrane (Steinhardt and Reynolds, 
1969; Meyer and Guttman, 1970a). D ilu tion of the protein containing 
solution during dialysis may cause a change in the equilibrium  of 
the drug-protein complex.
Several rapid non- equilibrium d ialysis  techniques have
been described which have the advantage of much shorter experimental 
times. The methods described by Stein (1965),and Agren and Elofsson,
(1967) and Colowick and Womack (1969) a ll  employ automated flow
through systems, the rate at which unbound compound enters 
the buffer containing compartment being proportional to the 
concentration of unbound compound in the protein-containing  
compartment. Data comparable to that obtained with equilibrium  
dialysis  has been achieved and providing sensitive drug assays 
e x is t, th is method provides a rapid method fo r studying binding.
U ltra f i lt ra t io n  and d ia f i lt ra t io n
U ltra f i lt ra t io n  (Flexner, 1937; Grollman, 1926) is in princip le  
identical with equilibrium  d ia lys is , except that a single solution, 
containing drug and protein in equilibrium , is used. By f i l t r a t io n  
under pressure a small volume of a p rotein -free phase is separated 
(u l t r a f i l t r a t e ) ,  the concentration of which closely corresponds to 
the unbound drug concentration in the orig inal protein solution.
No d ilu tion  of the protein containing phase, apparent in the 
equilibrium dialysis technique, occurs. However, the continually  
changing protein concentration may resu lt in a possible uneven d is tr i  
bution of protein and drug (Grollman, 1926). Some workers consider 
that the volume of u l t r a f i l t r a te  should not exceed 10-15% of the 
to ta l sample volume (T a it and Burstein, 1964; Sandberg et al_., 1966), 
otherwise the equilibrium position may be disturbed through an 
increased protein concentration. However, Pearson et^  al_. (1967) 
found for cortisol binding,that the removal of up to 70% of o rig inal 
volume as u l t r a f i l t r a te  did not a ffec t the in i t ia l  equilibrium  arid 
they considered th is to be in agreement with the considerations of 
Toribara et a l . (1957)^ based on mass action theory.
U lt ra f i lt ra t io n  employs the same type of membrane as used in 
d ia lys is , and the results obtained by u lt r a f i l t r a t io n  are therefore  
subject to the same potential sources of error as d ia ly s is . The
technique is basically  simple and many type of apparatus (Lavietes, 
1937; Mali now and Karzon, 1947; Toribara et a l . ,  1957; Anton, 1960) 
and various methods of achieving the necessary u lt r a f i l t r a t io n  
pressure, e .g . vacuum, gas pressure, mercury columns, centrifugal 
force and even spring tension (Ames and Sakamore, 1964)  ^ have been 
described. The apparatus of Toribara et £]_. (1957) is especially  
suited to maintaining constant pH for studies on plasma samples.
Bennet and Kirkby (1965) using a specially  designed vacuum 
u lt ra f i l t ra t io n  c e ll ,  showed that whereas s t ir r in g  ra te , ionic  
strength and viscosity did not markedly a ffec t the kinetics of 
f i l t r a t io n ,  temperature, pH, volume of solution and size of u l t r -  
f i l t r a t io n  ce ll did. In th e ir  study the compounds investigated  
did not bind to the membrane. Their findings c o n flic t with the 
view of Davis (1946) that because of the build up of protein on 
the membrane during u l t ra f i l t r a t io n , ag itation is necessary.
U lt ra f i lt ra t io n  requires considerably shorter experimentation t i  
than d ialysis yet s im ila r itie s  in binding data obtained by the two 
techniques have been reported (Steinhardt and Reynolds, 1969). 
U ltra f i lt ra t io n  probably approximates most closely to the physio­
logical process of glomerular f i l t r a t io n  since the hydrostatic 
pressures employed are usually of a magnitude comparable to the 
renal f i l t r a t io n  pressure (Goldstein, 1949; Dixon et al_., 1967).
The technique has been widely used to study the binding of drugs 
to plasma proteins (Anton, 1960; Reider, 1963; Keen, 1965;
Meyer and Guttman, 1968)
A recently introduce technique is that referred to as 
'd ia f i l t r a t io n ' (B la tt et aj_., 1968). The introduction of th is  
technique stems largely from the advent of a new type of semi- 
permeable membrane ( 'D ia f lo 1, Ami con, Lexington, Mass., U .S.A .)
which exhibits considerably higher flow rates than the classical 
membranes and are available with a range of c u t-o ff values. In 
th is technique the rate at which the protein or serum sample is 
u ltra f i l t ra te d  is exactly balanced by the rate at which drug is 
replaced, thus protein is u lt ra f i l t ra te d  at a constant volume. 
Providing the rate of u lt ra f i l t ra t io n  is slow enough fo r equilibrium  
to be maintained between unbound and the protein-bound drug, the 
analysis of the eluate from the u lt ra f i l t r a t io n  ce ll enables 
the determination of the unbound drug concentration fo r a given 
addition of drug. The p o ss ib ility  should therefore ex is t of 
determining binding over a wide range of drug concentration in a 
single experiment of short duration. This technique is reported 
to combine the advantages of u l t ra f i l t ra t io n  and d ia lysis  without 
th e ir  concomitant disadvantages. However, the number of applications  
of this technique are as yet lim ited (B la tt e t a]_., 1968; Danon 
and Sapira, 1972; Crawford et a l . ,  1972; Ryan and Hanna, 1971; 
Thompson, 1973) and findings such as those of Ryan and Hanna (1971), 
that the percentagebound of testosterone to bovine serum albumin was 
approximately 25% higher than compared with conventional equilibrium  
dialysis, require explanation.
i i i )  U ltracentrifugation
In a strong gravitational f ie ld  sedimentation of protein and 
protein small molecule complexes can be obtained, whereas the 
unbound concentration remains unchanged. This technique has the 
advantage that i t  dispenses with the use of membrane. However, 
protein concentration changes also occur when p r o lo n g e d  centrifugation  
periods are required (Steinberg and Schachman, 1966). Care must also 
be exercised in removal of the unbound gradient to avoid contamin­
ation by the protein containing frac tio n . However, results in
agreement with those obtained by equilibrium dialysis  have been 
reported (Kerp and S te inh ilber, 1962) although the number of 
reported studies using th is technique to study plasma protein  
binding is lim ited (Steinhardt and Reynolds, 1969; Weder and 
Bickel, 1970).
Gel chromatography
Since Lathe and Ruthven (1956) and la te r  Porath and Flodin (1959) 
described the use of columns of cross-linked dextrans ('Sephadex') 
in the separation of d iffe re n t molecular weight compounds, many 
workers have applied th is technique to study small molecule- 
protein interactions (Meyer and Guttman, 1968; K rieg ls te in , 1969; 
Wood and Cooper, 1970).
The application of th is technique to study drug-protein in te r ­
actions u tiliz e s  the molecular sieve properties of dextran gel, in 
which only the unbound drug is able to penetrate into the in ternal 
volume of the gel m atrix. A varie ty  of gels are now available fo r  
proteins of d iffe re n t molecular weight. The use of th is  method 
involves application of a drug-protein mixture to a column of 
sephadex followed by zonal e lution with bu ffer. However, fo r  
reversible equilibrium  the ra te  of elution is generally much slower 
than the rate of dissociation of the drug-protein complex (Wood and 
Cooper, 1970) and thus results obtained by th is  approach may there­
fore often be misleading due to possible dissociation effects  
(DeMoor et a l . ,  1962). This method has been used to study the 
binding to plasma proteins of barbiturates (Barlow £ t  al_., 1962), 
p en ic illin s  (Acred e t ^ K ,  1963), salicy lates  (Hardy and Mansford, 
1962; Sturman and Smith, 1967; McArthur and Smith, 1968). The use 
of dextran gels in a batchwise procedure has also been reported
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(Scholtan,, 1964; Ahtee et aj_., 1967; Saris, 1963; Von Hattenberg 
and Klausj 1966; Pearlman and Crepy. 1967). Recently Cooper 
and Wood (1968), Burke (1969) and Krieglstein and Kuschinsky (1968) 
have extended the use of fronta l analysis chromatography on gel 
columns to study drug-protein in teractions. The technique of 
frontal analysis has been suggested (Cooper and Wood, 1968) to 
circumvent the problem of drug adsorption onto the gel and 
dissociation of the protein-drug complex. S im ilarly  th is  d if f ic u lty  
can be overcome (Hummel and Dreyer, 1962) by applying protein-drug  
mixtures to a gel column previously equilibrated with a solution  
containing the same ligand concentration as the mixture, elution  
being carried out with the same solution. Recently the binding to 
serum albumin of phenothiazines (Nambu and Nagai, 1972) and bromo- 
sulphthalein (Crawford et a l . ,  1971) have been investigated with 
th is  method and good correlation (Nambu and Nagai, 1972) with 
equilibrium dialysis  reported. However, although th eo re tic a lly  
sound, this method is extravagent with drug (Clausen, 1966), also 
integration of the protein and drug areas is required which can be 
laborious and imprecise, especially in those instances in which 
these areas are e ither diffuse or il l-d e f in e d . Careful selection  
of experimental conditions are also required to re-estab lish  the 
equilibrium base-line.
v) Electrophoresis
Electrophoresis has been used to study the plasma binding of a 
large number of drugs, hormones and vitamins (Goldstein, 1949; 
Desgrez and DeTraverse, 1966; Meyer and Guttman, 1968; Cohen, 1971).
The technique is re la tiv e ly  simple and may provide valuable 
q u a lita tive  information on which proteins in the plasma are
responsible fo r binding. While the re la tiv e  percentages of a 
small molecule or drug bound to individual proteins can be 
determined, molar binding ratios are not easily  ascertained 
(Goldstein, 1949). I t  has an obvious advantage in that only very 
small samples are required. However, th is also necessitates a 
sensitive assay fo r the compound and thus i t  is common-place fo r  
radioactively labelled compounds to be used.
Bickel and Bovet (1962) studied the in teraction between proteins 
and a number of drugs by 'crossing electrophoresis'. In th is  a 
band of the free drug is la id  perpendicularly to the protein s tr ip ,  
as the protein moves that portion which is continually exposed to 
drug binds the compound, its  net charge may be altered and a change 
in m obility is exhibited as an acceleration or deceleration of that 
p articu lar area. This approach is useful fo r rapid q u a lita tiv e  
evaluation of the re la tiv e  binding potential of a series of drugs.
The in teraction with drugs may or may not modify the electrophoretic  
m obility of the proteins (Murari, 1966). One serious drawback of 
paper electrophoresis is the d if f ic u lty  of accurate assessment 
of rad io ac tiv ity  in the respective protein bands. To overcome th is  
problem Murray (1956) has suggested a technique which involves 
producing an autoradiogram of the electrophoresis s tr ip  and then 
measuring the optical density of dark spots on the radiographic film .  
This method has been extensively used by Cohen et al_. (1965).
Immunoelectrophoresis combined with autoradiography has also 
been used by Clausen (1966) to study the serum protein binding of 
^^S-sulphamido-6-methoxypyridazine. Two dimensional immunoelectro- 
phoresis has been employed to investigate the binding of drugs 
(Freeman and Pearson, 1969; Kramer and Richens, 1973), and using
a continuous flow electrophoresis method the binding of warfarin
(O 'R e illy  and Kowitz, 1967) and dig itoxin  (Lukas and DeMartino, 
1969) has been studied. Disc gel electrophoresis (Ornstein, 1964) 
does not, as y e t, appear to have found much application to the 
study of drug-protein in teraction .
Electrophoresis has the disadvantage that with present methods 
the best separation is achieved at the non-physiological pH of 8 .6 . 
At th is pH the binding characteristics of the protein may be 
modified and cause red istribu tion  of the drug to occur, resulting  
in d iffe re n t binding patterns to that a t in vivo pH 7 .4 . D ilu tion  
by the buffer, possible competition effects between the drug and 
the electrophoresis buffer and binding to the electrophoresis paper 
may also cause problems. D ig itoxin , fo r example, was found to bind 
to starch gel (Lukas and DeMartino, 1969) with the resu lt that i t  
fa ile d  to migrate with the plasma proteins, but continuous flow  
electrophoresis on paper revealed that the glycoside migrated 
almost exclusively with albumin (Lukas and DeMartino, 1969).
The application of spectroscopic techniques in the study of 
drug-protein interactions has been discussed by Steinhardt and 
Reynolds (1969) and Chignell (1970b, 1971, 1972).
U ltra v io le t and v is ib le  spectrophotometry
The methods employed to study small-molecule protein in te r ­
actions by absorption spectrophotometry can be broadly categorised 
in to: those where binding a lters  the absorption characteristics
of the drug, and those in which the absorption of the protein is 
affected.
A number of small molecules show changes in th e ir  v is ib le  
spectrum on binding. Klotz (1946) used the reduction in the lig h t
absorbance of azosulphathiazole at 500 nm, and the concurrent 
s lig h t red s h if t ,  on binding to BSA to measure binding parameters 
and to indicate the nature of the in teraction . I t  has been common 
practice to compare dye spectral changes in the presence of the 
protein with that when the dye was dissolved in organic solvents 
or detergents (Green, 1965). Marked species differences in the 
absorption spectrum of the anionic dye 2-(4'-hydroxyphenylazo)- 
benzoic acid (HABA) when bound to albumin has been observed 
(Baxter, 1964) which may imply that the dye-binding sites had 
d iffe re n t hydrophobic character.
Moriguchi e t al_. (1970) suggested that HABA spectral a lterations  
on binding (metachromasy) are due to in teraction with a lower 
p o la rity  environment in the in te r io r  of the protein in which HABA 
is converted to the hydrazone form having a lower absorption 
maximum wavelength. This metachromasy of a number of dyes, 
including HABA^has been u tiliz e d  fo r the quantita tive  determination 
of serum albumin (Rustein e t al_., 1954; Doumas et al_., 1971).
Binding of a range of sulphonamides to BSA has been determined by 
monitoring the displacement of the dye HABA (Moriguchi e t al_., 1968) 
assuming, perhaps without ju s t if ic a tio n , that competition fo r the 
same binding sites are involved.
For a drug exhibiting s ig n ifican t u ltra v io le t absorption the 
spectral changes in this wavelength region which accompany binding 
are often small and d i f f ic u l t  to iso la te  from the absorption of the 
protein. Such interactions are best observed by means of u lt ra ­
v io le t difference spectrophotometry which employs 'tandem' or 
's p l i t '  ce lls  (Herskovits and Laskowski, 1962; Herskovits, 1967; 
see also Chapter Two). Difference spectral studies can provide
information on both the environment of the binding s ite  and also 
possible conformational changes consequent on binding. This la t te r  
phenomenon can be detected as a resu lt of absorbance changes 
(perturbation) of the amino acid chromophore (Herskovits and 
Laskowski, 1962). Conformational changes in albumin induced 
by the binding of a varie ty  of compounds have also been studied 
(e .g . sodium dodecyl suphate) (Steinhardt and Reynolds, 1969; 
Steinhardt and Stocker, 1973) and the spectral perturbations of the 
amino acid tryptophan produced by the binding of various steroids 
(Ryan, 1968; Ryan and Gibbs, 1970). The binding of phenylbutazone 
and flufenamic acid to albumin has also been studied by th is method. 
The use of laser Raman spectrophotometry has recently been used to 
study the binding of methyl orange to bovine serum albumin (Carey 
e t al_., 1972). However, while a p o ten tia lly  promising technique, 
in s u ffic ie n t studies have as yet been performed to allow meaningful 
evaluation of its  application.
) Fluorescence Spectrophotometry
Fluorescence stands out amongst the optical techniques used to 
investigate macromolecules in that the life -t im e  of the excited state  
is s u ffic ie n tly  long fo r a varie ty  of chemical and physical in te r ­
actions to occur. These include: rotational motion, solvent
reorientation , complex formation, proton transfer and transfer of 
the excited state energy to another chromophore. Fluorescence 
excitation and emission spectra, fluorescence p o la riza tio n , quantum 
yields and decay times can thus provide information about these 
processes and therefore about the microenvironment of the chromophore 
(Brand and Gohlke, 1972).
Weber (1960) divided proteins into two classes according to th e ir
native fluorescence:- Class A proteins containing phenylalanine 
and tyrosine but no tryptophan. In these proteins, phenylalanine 
fluorescence is absent and the fluorescence spectrum is character­
is t ic  of tyrosine with an emission maximum at 303 nm. Class B 
proteins containing tryptophan, as well as tyrosine and alanine.
In a ll these proteins the fluorescence of tryptophan dominates 
the emission spectrum. Blasma albumin is known to be a Class B 
protein (Teale, 1960; Longworth, 1971).
When a given population of molecules is irrad ia ted , not a ll  
w ill re-em it th e ir  absorbed energy as fluorescence. The quantum 
y ie ld  (Q) of fluorescence is therefore defined as the frac tion  of 
lig h t absorbed that is re-em itted, i .e .
p _ number of quanta emitted 
number of quanta absorbed
The binding of a compound to a protein may cause changes in one 
more of the following parameters:
i )  The fluorescence in ten sity  (Q) of the protein , 
usually quenched,
i i )  The fluorescence in ten sity  (Q) of a probe molecule, which 
may or may not be a drug, attached(covalently or otherwise) 
to a protein,
i i i )  The fluorescence po larization of the drug.
When any or a ll of these changes accompanies drug binding to the 
protein , then fluorescence spectroscopy can be used to study the 
in teraction .
a) Fluorescence quenching
Quenching is defined simply as reduction of the 
quantum y ie ld  and may be due to e ither 's ta t ic ' or 'dynamic' 
mechanisms. A s ta tic  quencher acts upon the fluorophores in 
the ground s ta te , while a dynamic quencher in teracts in the 
excited s ta te . In both cases th e ir  e ffec t is to reduce the 
lig h t re-em itted. L ife-tim e measurements can distinguish  
between s ta tic  and dynamic quenching, the former is not 
accompanied by a change in c (fluorescence l i fe - t im e ) ,  while 
in dynamic quenching the decrease in quantum y ie ld  is proportional 
to a decrease in C . Several discussions of quenching mechanisms 
have appeared (Fdrster, 1951; Teale, 1960; Williams and Bridges, 
1964; Honikel and Madsen, 1973), see also Chapters Four and Five. 
Some examples of compounds which have been reported to quench 
protein fluorescence on binding to albumin are: steroids
(Attalah and Lata, 1968); fa tty  acids (Spector and John, 1968); 
Warfarin and dicoumarol (Chignell, 1970a); anilinonaphthalene 
sulphonates (Daniel and Weber, 1966); d ig itox in  (Lukas and 
DeMartino, 1966); carbenoxolone (Lindup, 1971).
b) Fluorescent probes
Fluorescent probes may be defined as small molecules 
which undergo changes in one or more of th e ir  fluorescent 
properties as a resu lt of in teraction with a protein or other 
macromolecule (Edelman and McClure, 1968). Fluorescent probes 
such as l-anilino-8-naphthalenesulphonate (ANS) and 2-p- 
toluidino-6-naphthalenesulphonate, along with others, have been 
used by many workers, with a variety  of macromolecules 
(S tryer, 1970; Brand and Gohlke, 1972; Long and Hsia, 1972; 
Flanagan and Hesketh, 1973; Ma et al_., 1973; Sudlow e t £ l_., 1973,
see also Chapters Five and S ix ) . Studies with fluorescent 
probes can be used to investigate both the structure and 
function of macromolecules, and in particu lar provide 
information on th e ir  binding sites and in teraction . Radda (1971) 
in an excellent review, discussed the rationale  behind the design 
and use of probes fo r membrane studies. He also summarised 
the information available from such studies in terms of the 
p o la rity  and f lu id i ty  of the binding s ite s , the molecular 
proximity of specific  groups and the a v a ila b il ity  of the s ite s . 
Insight into the rotational and translational m obility , 
distance and orientation between pairs of chromophores and 
quantitative information on the a f f in ity  of binding can also 
be obtained. Stryer (1970), Chance et al_. (1971 ) and Brand 
and Gohlke (1972) have further considered the application of 
fluorescent probes to the study of macromolecules.
Fluorescent polarization can also be used to study drug 
in teractions. However, th is method is only applicable to drug 
molecules which are highly fluorescent both before and a fte r  
binding to the macromolecule,
v i i i ) Optical Rotatory Dispersion and C ircular Dichroism
In addition to fluorescence spectrophotometry other techniques 
finding increasing application to the study of small molecule- 
protein interactions include optical rotatory dispersion (ORD) 
and c ircu lar dichroism (CD).
When plane polarised lig h t, consisting of a l e f t  and r ig h t  
c irc u la rly  polarized component enter a medium containing asymmetric 
molecules the le f t  and rig h t components are transmitted a t  
d iffe re n t speeds ( i . e .  they have d iffe re n t re la tiv e  indices) and
the plane o f the polarised lig h t is rotated. Such molecules are 
said to be o p tic a lly  ac tive . When optical ro ta tio n  is measured 
as a function of wavelength, the resu ltant ORD curve is generally  
p la in  (N. B. the curve may be plain positive  or p lain  negative' 
depending on whether i t  rises or fa l ls  with decreasing wavelength.) 
However, in the wavelength region where the o p tic a lly  active  
compound absorbs lig h t , the ORD curve becomes anomalous, often  
changing sign. This anomalous behaviour is termed a Cotton 
e ffe c t (F ig . I ,  5a). In th is  wavelength region there is also 
an unequal absorption of the rig h t and le f t  c irc u la r ly  polarised  
components of plane polarised lig h t , i . e .  f  Cr where £|_ and 
are the extinction coeffic ien ts  fo r the le f t  and r ig h t c irc u la r ly  
polarized components. This phenomenon gives rise  to c irc u la r  
dichroism (CD) which is a second facet of the Cotton e ffe c t . When 
the d if fe re n tia l dichroic absorption of a simple Cotton e ffe c t is  
plotted as a function of wavelength, i t  w ill have the shape shown 
in Fig. I ,  5b, with the c ircu la r dichroism maximum and the 
absorption a t the same wavelength. Detailed discussions of ORD and 
CD have been presented by Crabbe (1955), Veiluz e t  aT. (1965), 
Chignell and Chignell (1972).
Both CD and ORD have been extensively used to study the in te r ­
action of detergents with proteins (Jirgensons, 1952, 1962; Foster, 
1960; Perrin and Hart, 1970). However, the interpretation of CD and 
ORD spectra from the detergent-protein complexes is often d i f f i c u l t ,  
since detergents may increase a -h e lica l content, convert a -h e lic a l 
to 3 -structure , abolish 3- but not a -h e lica l or simply act as 
denaturing agents (Chignell and Chignell, 1S72). Several workers 
have used the techniques to study dye-protein in teractions (Markus 
and Karush, 1958; Winkler and Markus, 1959; Blout and S tryer, 1959; 
Helmer et a l . ,  1968; Daniel and Yang, 1973).
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Fig. I, 5
ORD and CD Curves Associated with an O ptically  
Active Chromophore
a) ORD+
a
Absorption
£
+
]
or
Ac
Absorption
e
Positive Cotton e ffec t ( -------) .  negative Cotton e ffec t (------- )
The lower curves represent the absorption spectra of the 
o p tica lly  active chromophore
a  = optical ro tation ; 0 = molar e l l ip t ic i t y  (deg.cm2 decimeter"1) 
Ac = d iffe re n tia l dichroic absorption (ej_ -  cr)
(N.B. 6 = 3,300 Ac)
From Chignell (1971)
The application of this technique to the study of drug-protein 
interactions was demonstrated by Chignell (1968) who showed that 
extrins ic  (induced) Cotton effects were observed on the binding 
of phenylbutazone and several anions to BSA, and that introduction  
of hydrophilic groups, e .g . OH ; N02 ; CH3S02 into the phenyl 
groups of phenylbutazone reduced the extrins ic  Cotton effects on 
binding to albumin. In contrast, the introduction of hydrophobic 
substituents, e .g . Cl ; F into the phenyl rings or modification  
of the n-butyl side chain had a much smaller e ffe c t on optical 
a c tiv ity . Rosen(1970) showed how CD data could be used to derive
association constants (k ) and number of binding sites (n) fo r the
binding of phenylbutazone and oxyphenbutazone to human serum 
albumin and in teresting ly  found an extra binding s ite  fo r oxyphen­
butazone compared with phenylbutazone. A number of other drugs 
have also been studied, e .g . flufenamic acid; meclofenamic acid; 
mefanamic acid (Chignell, 1968, 1969 a ,b , 1971); fenoprofen 
(Perrin , 1973); b iliru b in  (Wooley and Hunter, 1970); tryptophan 
(Sjbholm and Grahnen, 1972); sulphonamides (Kostenbauder e t a l . ,
1971; Wood and Stewart, 1971); indomethacin, 4-hydroxycoumarin, 
w arfarin , s a lic y lic  acid (Perrin and Nelson, 1972); benzodiazepines 
(M llller and W ollert, 1973).
The main advantage of CD techniques in the study of drug-protein
interactions is the rap id ity  with which measurements can be made, 
and that both q u a lita tiv e  and quantitative information on the binding 
sites and interaction can be obtained. A disadvantage is that only 
those binding sites causing a change in optical a c t iv ity  ( e l l ip t ic i t y )  
are revealed, and data in terpreta tion  is sometimes d i f f ic u l t .  Since 
a large variety  of biological molecules as well as some drugs, are 
o p tica lly  active, ORD and especially CD are lik e ly  to play an
important role in future drug-macromolecule in teraction studies.
Nuclear Magnetic Resonance
When a small molecule is bound to a protein, the relaxation  
characteristics of one or more of e ither its  hydrogen atoms or 
those of the protein may be a ltered . This a lte ra tio n  may show 
up as a 'chemical s h i f t ' ,  a frequency change, or as the broadening 
of a lin e , in the proton magnetic resonance spectrum. Selective  
broadening of some of the proton resonances of a drug is always 
observed when i t  is bound to a protein and th is is considered to 
indicate an intim ate contact between such protons, or the groups 
to which they belong, and the macromolecule. The chemical sh ifts  
are small and d i f f ic u lt  to measure; they arise from rapid 
reversible changes of the state of the small molecule from bound 
to unbound, and re fle c t not only the sh ifts  in the nuclei which 
are caused by binding, but also the time average of the fraction  
of small molecule bound (Steinhardt and Reynolds, 1969).
The application of nuclear magnetic resonance to pharmacological 
problems was exemplified by the pioneering studies of Fischer and 
Jardetzky (1965) on the binding of p e n ic illin  G, and Jardetzky and 
Wade-Jardetzky (1965) on the binding of sulphonamides,to BSA. They 
found that the phenyl ring of p e n ic illin  and the p-aminobenzene 
sulphonamide moiety of sulphonamides were the functional groups 
partic ipating  in the binding. The binding of diphenylhydramine 
and some methyl analogues to BSA (van der V lies , 1970), and of 
a ce ty lsa lisy lic  acid to HSA (Sykes, 1970) has been studied.
Chemical sh ifts  apparent on binding can also be used to monitor
drug-protein in teractions. At present, however, re la t iv e ly  few 
interactions between drugs and proteins have been studied by NMR 
techniques. The major d if f ic u lty  which has prevented the use of 
NMR in the study of other drug interactions is the re la tiv e  
in se n s itiv ity  of the technique, and th is has often necessitated 
the use of high concentrations of m ateria l. However, the 
development of computer techniques such as signal averaging and 
Fourier transform spectroscopy have helped to improve the s e n s itiv ity  
Thus there is l i t t l e  doubt that NMR spectroscopy w ill become an 
important tool fo r studying drug protein in teractions.
x) Summary of techniques
In Table I ,  2 is summarised the well established and newer 
techniques for studying the in teraction between small molecules 
and proteins, with comments on the re la tiv e  theoretical advantages 
and disadvantages of each technique. Reference should be made to 
Chapters Three, Five, Six and Seven, where fu rther discussion of 
the practical application of equilibrium  d ia ly s is , u l t r a f i l t r a t io n ,  
gel chromatography and fluorescence is presented. Table I ,  3 
provides a l i s t  of miscellaneous methods which have been used to 
study protein binding. Although some of these may have considerable 
application in future studies, th e ir  v a lid ity  remains to be 
demonstrated. For others the lim ita tio n  of the method is read ily  
apparent and they are therefore unlikely  to find widespread 
application.
Table I ,  2 Principal Methods of Studying Protein Binding
Technique Advantages Disadvantages
Selected
References
Equilibrium Thermodynamically sound, accurate reproducible
Dialysis quantitative data.
Most used technique, therefore comparison easy
Dynamic . 
Dialysis
In Vivo 
Dialysis
Rapid
Probably the most physiological method available.
D ia filtra tion  No protein dilution or concentration effects. 
More rapid than equilibrium dialysis.
' U ltra filtra tio n  Thermodynamically sound and rapid. Suggested to 
closely approximate in vivo situation. 
Specialised apparatus ideally suited for 
plasma samples
Ultra­
centrifugation No membrane binding or Donnan inequalities
Quantitative information only, which is subject 
to errors from binding to membrane and Donnan 
inequalitities. Non physiological and prolonged 
equilibration time may cause bacterial 
contamination and protein denaturation.
Equilibrium disturbed by dilution.
Essentially same disadvantages as equilibrium 
dialysis.. New method, therefore valid ity  not 
fu lly  established.
Klotz (1953
Rosenburg and 
Klotz (I960)
Stein (1965)'
Meyer and 
Guttman (1970a)
Assumes unbound drug in serum = peritoneal flu id  
= concn in peritoneal dialysis sac McQueen 1968,
New method largely untested. 1969
Binding to membrane and quantitative data only.
New method therefore validity not established 
Membrane binding and Donnan inequalities. 
Calculations lengthy and involved.
Quantitative data only.
Binding.to membrane and Donnan inequalities. 
Equilibrium disturbed by protein concentration
Theoretical basis not sowell established as for 
dialysis or u ltra filtra tio n .
Prolonged experimental time •
Quantitation more d iff ic u lt  
Cannot use protein mixtures
Blatt et^  al_. 1968 
Crawford 
et al_. 1972
Toribara et a l .
(1957T
Bennet and Kirby 
(1965)
Steinberg and 
Schachman(1966)
Steinhardt and 
Reynolds (1969)
Gel Separation of several binding proteins possible
Chromatography Thermodynamically sound
Electrophoresis Qualitative data.
Can separate multi-protein mixtures and only 
small samples required. Can be combined with 
autoradiography and immunoelectrophoresis.
U ltraviolet and Sensitive technique can monitor absorption 
Visible Spectro- changes in either drug or protein consequent 
upon binding. Can detect conformational 
changes and qualitative information on 
chromophore's binding s ite .
Homogenous system, only microquantities of 
material required.
Sensitive technique.
Can monitor fluorescence changes in both 
drug and/or protein consequent upon binding.
Can provide both qualitative and quantitative 
information, although quantitation can involve 
lengthy calculation.
Homogenous system and only microquantities 
of material required.
Optical Rotatory Sensitive technique.
Dispersion and Can serve as a probe for binding sites and
Circular provide both qualitative and quantitative data,
Dichroism although quantitation not simple
photometry
FIuorescence 
Spectro­
photometry
Nuclear
Magnetic
Resonance
Sensitive to changes in molecular geometry.
Adsorption to gel may disturb equilibrium 
can largely be circumvented by Frontal Analysis 
and Hummel-Dreyer methods. Although these 
methods require large samples.
Dilution occurs
Quantitation d iff ic u lt  
Non-physiological
Interpretation can be d iff ic u lt  and may be 
complicated-by binding to support medium.
Cannot be used i f  interaction causes no spectral 
change.
Non-physiological
May need to compensate for compound's 
absorbance.
Cannot be used i f  interaction causes no 
spectral change.
Non-physiological
'In n e r -f ilte r ' effects may occur and make 
interpretation d iff ic u lt
Non-physiological 
Equipment expensive
Interaction must generate cotton effect.
Interpretation may be d iff ic u lt  
Equipment expensive 
Non-physiological
Scholtan 1964 
Cooper and Wood, 
(1968) 
Wood and Cooper, 
(1970) 
Hummel and 
Dreyer (1962)
Bickel and 
Bovet (1962)
Clausen (1966)
O'Reilly and 
Kowitz (1967)
Klotz (1946)
Herskovits(1967)
Chignell (1971)
Steinhardt and 
Reynolds (1969)
Teale (1960)
Attalah and 
Lata (1968)
Radda (1971)
Chignell (1972)
Ee’rrin  and 
Hart (1970) 
Chignell and 
Chignell(1972) 
Jirgensons(1963)
Jardetzky and 
Wade-Jardetzky 
(1965) 
Steinhardt and 
Reynolds(1969) 
Buruen and 
Metcalfe (1970) 
Hollis (1972)
Table I ,  3.
Miscellaneous Methods fo r Studying 
Small Molecule -  Protein Interactions
Method
1. Biological action
2. Diffusion
3. Physical properties, e.g. 
osmotic pressure, vapour pressure, 
surface tension, v iscosity , 
electrophoretic m obility ,
sedimentati on of protei n.
4. S o lu b ility  of small molecule
5. Adsorption of small molecule
6. Precip itation
7. S tab iliza tio n
a) of small molecule
b) of protein
8. Equilibrium p a rtitio n  of small 
molecule
9. Autoradiography
10. Polarography
11. Conductivity and E.M.F. methods
12. Pulse radiolysis
13. ApH method
14. Heatburst microcalorimetry
15. Refractive index
16. D ie lec tric  increment and dispersion
17. X-Ray d iffra c tio n
18. Saturation Analysis
19. Iso e lec tric  focussing
Reference 
Goldstein (1949) 
Goldstein (1949)
Goldstein (1949)
Goldstein (1949)
Westphal (1961)
Goldstein (1949)
Heyns e t aj_. (1967)
Goldstein (1949)
P ries tly  and O 'R e illy  (1966)
a) Goldstein (1949)
b) Colombo et aK  (1968)
Goodman (1958)
Spector e t al_. (1969)
Meyer and Guttman (1968)
Steinhardt and Reynolds (1969)
Goldstein (1949)
Steinhardt and Reynolds (1969)
P h illip s  e t al_. (1970)
Scatchard and Black (1949) 
Steinhardt and Reynolds (1969)
O 'R eilly  e t al_. (1969)
Reynolds e t al_. (1973)
Steinhardt and Reynolds (1969)
Steinhardt and Reynolds (1969)
Steinhardt and Reynolds (1969)
Zettner (1973)
Van Baelen and De Moor (1972)
Introduction to Present Work
I t  is apparent from the above discussion that although a large 
number of binding studies have been reported we are s t i l l  a long way 
from being able to predict how a novel compound w ill in terac t with 
plasma proteins^and how this w ill a ffec t its  pharmacological action.
The aim of this study has therefore been directed a t providing 
information on the answer to some of the fundamental questions posed 
by Scatchard et aj_. (1954) concerning small mol ecu!e-protein in te r ­
actions, namely: 'How many? How tightly?  Where? Why? and What of i t? '
No consistent guide-lines are apparent from the lite ra tu re  to assist in 
the selection of the most appropriate technique, we have therefore  
considered the question of 'How best to measure i t? ' C learly  the 
nature of the information required ( i . e .  mainly q u a lita tiv e  or 
quantitative) w ill largely determine the type of technique to be used.
The three classical techniques of equilibrium d ia lys is , u l t r a f i l t r a t io n  
and gel f i l t r a t io n  were comparatively evaluated by studying the binding 
to albumin of a number of drugs d iffe rin g  markedly in th e ir  degree of 
binding and physico-chemical properties. The v a lid ity  of these an v itro  
methods to the in vivo s ituation was evaluated in a comparative study of 
the binding of sa licy la te  to ra t serum by in vivo d ia lysis  and in v itro  
u lt ra f i l t r a t io n .
The possible importance of lip o p h ilic ity  as a major determinant 
in the binding of a number of small molecules and drugs to albumin has 
over the las t few years received increasing prominence. However, the 
possible involvement of other binding forces has made in terpre ta tion  
d i f f ic u lt  and prompted disagreement about the re la tiv e  importance of the 
contribution from lip o p h ilic ity  to the free energy of binding. We have 
therefore investigated the binding of a series of carbamates which
possess a wide range of physico-chemical properties, which make them 
suitable as model compounds fo r the study of protein binding. This 
homologous series,R-O-CONH2 was stable and non-ionised in aqueous 
solution and showed a regular increase in p a rtitio n  c o e ffic ie n t as the 
chain length was incrementally extended by addition of a methylene 
group. I t  would seem lik e ly  therefore, that th e ir  in teraction with 
plasma proteins would be largely  hydrophobic in nature. Furthermore, 
the regular increase in chain length for the series should allow an 
assessment of the contribution of a single methylene group to the 
thermodynamic free energy of binding. The increase in p a rtitio n  
co effic ien t between the methyl and n-hexyl group was calculated and 
considered to be s u ffic ie n t to provide a sound basis fo r assessing the 
e ffec t of more subtle molecular modifications, such as branching of side 
chain or introduction of aromatic ring , on the binding parameters 
(percentage bound, number of binding sites and apparent association 
constant). The p o ss ib ility  that binding of the carbamates to albumin 
might induce a conformational change in the protein was investigated by 
u ltra v io le t and fluorescence spectrophotometry. The ro le  of molecular 
dimensional parameters in hydrophobic bonding was studied by comparison 
of the binding to albumin of butyl and pentyl acetates with the 
respective carbamate. The acetates were calculated to have s ig n ific a n tly  
higher p a rtitio n  coeffic ients than the carbamates, but l i t t l e  difference  
in th e ir  molecular dimensions.
Hydrophobic bonding has also been suggested to play a ro le  in the 
binding of the drug warfarin to albumin. However, other forces may be 
involved (O 'R e illy  and Kowitz, 1967). Although the e ffe c t of various 
substituents in the warfarin molecule, on its  binding, has been 
investigated, l i t t l e  is known about the structure of its  binding s ite  
on albumin. Warfarin is a p a rtic u la rly  appropriate drug to study in 
view of the large numbers of drugs known to displace warfarin from its
binding s ite  and the importance of the c lin ic a l implications of this  
displacement. Information on the nature of the binding to albumin and 
the structural properties of displacing agents should o ffe r a more 
re lia b le  basis fo r predicting drug interactions. In th is study use was 
made of the finding that w arfarin 's  fluorescence characteristics a lte r  
with change of solvent p o la rity . Such fluorescence behaviour can be 
used to obtain both q u a lita tive  and quantitative information on the 
binding process and therefore offers d is tin c t advantages over conventional 
'non-spectroscopic' techniques for such a study. The possible in te r ­
species differences in the binding of w arfarin , its  binding to chemically 
modified albumins, and a study of its  displacement by other drugs, were 
studied in an attempt to characterise the warfarin binding s ite  on 
albumin.
The possible use of drug-albumin interactions as a model system 
fo r the tissue binding of drugs was investigated. A flu o rim etric  study 
in which the binding of R(+) and S (-) w arfarin, l-an ilino-8-naphthalene- 
sulphonate, and benzidine, to albumin was compared with th e ir  in te r ­
action with hepatic microsomal preparation was carried out. The nature 
of th e ir  difference spectral in teraction with the microsomal preparation 
was also determined to further characterise the tissue binding s ite s .
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Materials  
i ) Chemicals
C rystalline (batch no. 79B-8080),Cohn fraction  V 
(batch no. 12C-2920) and Essentially Fatty Acid Free Cohn fraction  V 
(batch no. 31C-7470) preparations of bovine serum albumin were 
purchased from Sigma Chemical Co.Ltd., St. Louis, Mo., USA, as was 
ra t serum albumin (Cohn fraction  V, batch no. 42C-2980).
C rystalline human plasma albumin (batch no. TV 49641) was obtained 
from AB Kabi, Stockholm, Sweden. A ll c rys ta llin e  albumins contained 
not less than 99% of to ta l protein as albumin, a fa tty  acid content 
0.1 -  0.2% and moisture content of not more than 2%. Fraction V albumins 
contained at least 97% albumin, the remainder being globulins. The 
essentia lly  acid free albumin had a fa tty  acid content of less than 0.005%. 
A ll albumins were stored in a desiccator at 4°C.
The sulphonamides:- sulphormethoxine (F an as il), and sulphamethoxazole 
(Gantanol) were kindly supplied by Roche Products L td ., Welwyn Garden 
C ity , H erts ., England; sulphaphenazole (O risul) was kindly donated by 
Ciba L td ., Basle, Switzerland; and sulphanilamide was of Analar grade 
from BDH L td ., Poole, Dorset, England; as was sodium s a lic y la te v C lo fib ra te  
(Atromid-S) was kindly donated by IC I, Alderley Park, M acclesfield, Cheshire, 
England; and tryptophan (batch no. 90C-3310) was purchased from Sigma 
Chemical Co.Ltd. The carbamates:- Methyl (Koch-Light Labs. L td ., Colnbrook, 
Bucks., England), ethyl (BDH L td .) , n-propyl and n-butyl (Kodak L td .,
Kirby, Liverpool, England) and benzyl carbamate (Aldrich Chemical Co., 
Milwaukee, Winsconsin, USA) were obtained commercially and used without 
further p u rific a tio n . Iso-Butyl (2-methylpropyl; m.pt. 61°C), t e r t - butyl 
(1 ,1-dim ethylethyl; m.p. 104-6°C) ,  te rt-p en ty l (2,2-dim ethylpropyl; m.pt. 
80°C), n-pentyl (m.pt. 53r4°C), t e r t - hexyl (3 ,3-dimethyl b u ty l; m.pt. 55-6°C ), 
n-hexyl (m.pt. 59°C), n-heptyl (m.pt. 62°C) and n-octyl (m .pt. 67°C) were 
synthesised by the Chemistry Division of the Chemical Defence Establishment.
Porton Down, Salisbury, W iltsh ire , England The purity  of a l l  the 
carbamates used was checked by in fra -red  spectroscopy and GLC, and 
was found in a ll cases to be >99%.
The acetates n-butyl and n-pentyl, were obtained from BDH L td ., and
re d is t il le d  before use. Racemic (±) w arfarin , was purchased from Sigma 
Chemicals Ltd. (batch no. 50C1 600). The isomers R (+) and S (-) warfarins 
were kindly donated by Dr. A. Breckenridge, Royal Postgraduate Medical 
School Hammersmith, London, England. 1 -a n il ino-8-naphthalenesulphonate 
(ANS, ammonium s a lt) and benzidine (batch no. B-3503) were obtained 
from Sigma Chemical Co. Ltd.
The compounds used in the in teraction studies with warfarin (Chapter F ive ), 
were obtained from the following sources:- phenylbutazone (B .P .) and 
imipramine were g ifts  from Biorex Laboratories L td ., London; chlordiazepoxide 
(Librium) and diazepam (Valium) were kindly donated by Roche Products L td .; 
pentobarbitone (B.P) was a g i f t  from May & Baker Limited, Dagenham, England; 
iprindole (Prondol) was donated by AB Kabi Ltd. (batch no. 4713). Biphenyl 
(m.pt 69-70°C) and the metabolites 2-hydroxy (m.pt. 56-57°C) and 4-hydroxy
(m.pt. 166-i7°C) were obtained from BDH L td ., and were recrys ta llised  from
96% ethanol, 100-120° lig h t petroleum and methanol respectively. Carbon 
monoxide (CP grade) and the gas mixture C02:02 (5.95%) were obtained from 
the B ritish  Oxygen Company L td ., Crawley, Sussex, England. Buffers 
(phosphate and tr is -H C l, pH 7.4) were prepared as described in 'Data for  
Biochemi cal Research1.
A ll other chemicals used were of e ith er general or analytical grade and 
were used as supplied.
Sephadex G-25 (f in e , Lot no. 233) p a rtic le  size 20-80u , and Biogel P-2
(batch no. 101482) p a rtic le  size 50-100u, were obtained from Pharmacia L td ., 
London, England, and Bio-Rad Laboratories, Richmond, C a lifo rn ia , USA 
respectively. A ll gels were pre-swollen overnight in 0.1M phosphate
b u ffer, pH 7.4 and the 'fin e s ' removed by decantation before use.
Visking d ialysis  membrane used with both equilibrium  dialysis and 
u lt ra f i l t ra t io n  techniques, was obtained from S c ie n tific  Supplies 
Co. L td ., London, England, and prepared by soaking overnight in several 
changes of deionized water to remove surface glycerol and other 
contaminants, followed by a further period (overnight) in changes of 
the appropriate molarity phosphate buffer.
) Animals
Male Wistar-albino rats (Porton s tra in ) from a randomly bred colony, 
weighing e ith e r 350-400 g (16-17 weeks) were used in the in vivo d ialysis  
studies, and rats from the same stock approx. 130g (5-6 weeks) were used 
fo r the microsomal binding studies. Breeding nucleus was obtained from 
Laboratory Animals Centre, Carshalton, Surrey. England. Syrian hamsters 
(approx. 50g, 12-14 weeks) pure lin e  golden s tra in , category 2, were also 
used fo r microsomal binding studies.
Animals were randomly a llo tte d , p rio r to experimental work 
(minimum 2 weeks) as l i t t e r  mate cage groups (te s t and control) and 
bedded on S te ro lit  (Engelhard Corp., Edison, N .J ., USA) with water and food 
(Spratts No. 1 autoclaved animal d ie t , Spratt's  Patent L td ., Barking,
Essex, England), ad lib itu m . A ll animals were housed under conditions 1 
of constant temperature (20°C), humidity (re la tiv e  50%) and lig h tin g  
on a 12 hour lig h t/d ark  cycle (06.30-18.30 lig h t phase). The weight 
of the animals was routinely recorded throughout the experiments.
Methods
Albumin solutions (0.5 to 29.0 x 10"5M based on to ta l protein concn) 
were prepared in pH 7.4 phosphate buffer; (0.1 or 0.15 M) or 0.1 M t r is  HC1. 
pH 7.4 . Solution was achieved in each case by allowing the albumin to 
dissolve overnight at 4°C. For fluorim etric  studies this procedure was 
found to be s u ffic ie n t for s tab ilisa tio n  of albumin fluorescence (Teale, 1960). 
Phosphate and tris-HCl buffers (pH 7.4) were prepared in e ith e r glass d is t i l le d  
water, or double glass d is t i l le d  water fo r flu orim etric  studies, as described 
in 'Data fo r Biochemical Research' (1969).
i ) Gel Chromatography
All column chromatography studies employed glass columns which 
contained a glass s in te r (porosity Grade 1) fo r gel support. Columns 
were made by the University glass-blowers and had minimal 'dead space1. 
Column performance was checked a fte r  packing using a 1% (w/v) blue 
dextran 2000 (Pharmacia L td .) solution in d is t i lle d  water.
(a) Batch method
The long acting sulphonamide, sulphormethoxine, which is known 
to be re la tiv e ly  highly bound to bovine serum albumin (Engel and 
M e lv ille , 1966; Elofsson et a l . ,  1971), was selected as a suitable  
compound for a preliminary evaluation of the batch method. The 
use of pre-swollen gel was selected as i t  is more closely analagous 
to equilibrium dialysis than dry gel. (N.B. In practice there 
may be l i t t l e  difference between the results obtained using dry 
gel and those employing pre-swollen g e l.)
To 200mg of Sephadex G25 fine (calculated in ternal volume,
V i, of 0.5 ml) in 10 ml glass stoppered tubes, was added 1.0 ml 
of 0.1 M phosphate b u ffer, pH 7 .4 , and the gel allowed to swell 
overnight at room temperature. 1 . 0  ml of a bovine serum albumin
solution (29.0 x 10 5M) containing sulphormethoxine(concentration 
range 16.0 - 80 x 10 5M) was added and mixed f i r s t  on a rotary  
shaker fo r 30 minutes, then in a shaking water bath fo r a further 
30 minutes to allow the gel to s e tt le . At the end of each 
incubation 0.5 ml. of the supernatant (external phase) was 
removed and assayed. The sulphonamide concentration was 
determined by the Bratton and Marshall procedure (1939) and 
protein by the procedure of Lowry e t aj_. (1951). An attempt to 
determine the concentration of sulphonamide imbibed in the gel 
(in ternal phase concentration) was made by using the separation 
procedure employed by Saris (1963). The sephadex gel was f i l te re d  
through a Blichner funnel and the sulphonamide concentration 
assayed in the presence of the sephadex gel.
Zonal method
The binding of the drugs sulphormethoxine, c lo fib ra te  and 
sulphamethoxazole to BSA was used to evaluate this method. As an 
alternative  to sephadex, a cross-linked polyacrylamide gel Biogel 
P2, was also employed.
Columns (1.2 cm diameter) were packed with gel to various 
column heights. The sample volume was varied according to the bed 
volume of the column, but was ty p ic a lly  e ither 2 .0 , 1.0 or 0.5 ml 
of a drug-BSA (BSA concn. = 29.0 x 10 5M) mixture. Sample was 
applied to the column in the standard manner and subsequently 
eluted with 0.1M phosphate bu ffe r, pH 7.4 Column eluate was 
collected using a Central fraction  co llecto r (Central Ig n itio n  Co. 
London, England) employing a constant volume co llecting  syphon 
(5m l., 2m l., or 1m l.). A ll experiments were performed at room 
temperature 20° ± 1° C and a t pH 7 .4 .
(c) Frontal analysis
The frontal analysis method used was essentia lly  that described by 
Cooper and Wood (1968). In th is method a large volume of protein- 
drug solution is applied to a sephadex column a t a constant rate  
and eluted with a bu ffer. The steady-state e lution p ro file  
reveals two plateaus, the f i r s t  ( 3 ) corresponding to the to ta l drug 
concentration in the solution applied to the column and the second 
(y) to the unbound drug concentration. Unlike other gel f i l t r a t io n  
methods the most important advantage of th is procedure is that i t  
permits estimation of the degree of binding in the orig inal 
solution.
Sephadex G-25 (fin e ) was packed into precision-bore glass 
columns (in ternal diameter 0.6 cm.) to column lengths of 15-20 cm.
The glass columns were f it te d  with a polypropylene o u tle t valve, and 
contained a glass s in te r a t the end o f the column. They had the 
advantage of minimal dead space, and showed acceptable elution  
p ro file s . The top of the column was connected to a LKB perpex . 
pump 10200 (LKB Instruments L td ., South Croydon, Surrey, England) 
which gave a non-pulsating flow a t the rate of ~10ml/hr. The column 
o u tle t was connected to a LKB Ultrarac 7000 frac tion  c o lle c to r, set 
to co llect 7 drop fractions ( -  0.42 m l.) . To evaluate the v a lid ity  
of the frontal method, the binding o f sulphormethoxine to BSA was 
studied. Protein-drug solutions (12 ml, sulphormethoxine concn.range
7.5 -90 x 10“5M; BSA 29.0 x 10~ 5 M) were applied to a Sephadex 
G-25 column previously equilibrated with 0.1M phosphate buffer and 
then eluted with the same bu ffer. Each fraction  was assayed fo r  
both sulphonamide and protein; experiments were performed at 
20° ± 1° C.
Elution of protein-containing solutions resulted in a 
variation  in fraction size due to the e ffe c t of the protein on the 
surface tension of the solution. This was allowed fo r by weighing 
the collecting tubes, however, i t  was found by calculation of 
binding data that providing a steady-state plateau region had been 
obtained, th is precaution was probably not necessary.
Equilibrium Dialysis
In our studies the commercially available Kontron Diapack 
equilibrium  d ialysis  system was used, (the author is  indebted to Anachem 
L td ., Luton, Beds., England, fo r the loan of this equipment). This system 
is based on an orig inal design by Weder (Weder and Bickel 1970). The 
equipment consisted of a series of individual dialysing ce lls  located in  
four ce ll blocks, which f i t  into a rotational drive assembly, and allowed 
the cells  to be rotated at selected speeds. This system allowed 20 
separate dialyses to be performed simultaneously. Each dialysing cell 
consisted of two Teflon h a lf-c e lls  between which a dialysing membrane was 
inserted. Samples were inserted or removed through two in jec tio n  ports 
located in each h a lf -c e ll .
The chief advantage of th is  system over conventional d ia lys is  is  
that small volumes can be used (lO O ul.-2m l.), and by employing a d ialysis  
volume less than the h a lf-c e ll volume a re la tiv e ly  large 'a c tiv e ' 
membrane area is obtained with rotation; th is results in f a ir ly  short 
dialysing times (e .g . 5hrs.) thus reducing the lik e ly  risk  of protein  
denaturation and bacterial contamination. The use of Teflon also tends 
to minimise drug adsorption onto ce ll components.
1 8
Visking d ialysis  tubing ( /■$£.!")9 cut so that i t  opened to a
single membrane surface, was pre-soaked as previously described. A fter
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F ig . I I ,  1 Calibration of the Equilibrium Dialysis System:-
Determination of Equilibrium Time for Dialysis of 
Sulphormethoxine (4.5 xlCT^M) against Phosphate 
Buffer (0.1 M, pH 7.4)
Half ce ll volume = 1.0 ml 
Temp. = 20°C, Rotation = 7 r.p.m . 
Membrane: Visking dialysis
(regenerate cellulose  
0.025mm thickness)
Inside
Outside
Time (hours
soaking i t  was wiped with tissue paper, dried by blowing compressed a ir  
gently over its  surface, and placed between the h a lf-c e lls  of the dialysis  
system. A fter assembly the cells  were f i l le d  by the addition of 1ml. of 
solution (drug-protein) to one h a lf-c e ll using a syringe followed 
immediately by the addition of 1ml. of 0.1M phosphate b u ffer, (pH 7.4) 
solution to the other side of the membrane. Solutions were dialysed a t 
20° C in a therm ostatically controlled water-bath while being continually  
rotated at 7 r.p.m .
In i t ia l  experiments fo r the d ia lysis  of sulphormethoxine (45 x 10 5M) 
in the presence of e ither 0.1M phosphate buffer pH 7.4 or BSA (29.0 x 10 5M) 
against the same buffer showed that equilibrium was reached by approx. 4 hrs. 
whether protein was present or not (Fig. I I ,  1 ). A dialysing time of 5 hrs. 
was therefore selected fo r fu rther experiments to ensure that equ ilib ra tio n  
had been attained.
( i i i ) U lt ra f i lt ra t io n
All u l t ra f i l t ra t io n  studies were carried out using a centrifugal 
u lt ra f i l t r a t io n  technique. Two d iffe re n t u l t r a f i l t r a t io n  units were 
employed depending on whether pH control was by buffer or a C02 :0 2 (5:95) 
mixture ( i . e .  whether albumin solutions or serum samples were used).
(a) Of albumin solutions
The apparatus used for u lt ra f i l t r a t io n  of drug-BSA solutions consisted 
of a sintered glass disc (porosity grade 1 ) ,  supported in  a glass tube 
of suitable diameter to form a unit which f it te d  into a 50ml. 
polycarbonate centrifuge tube (M.S.E. L td ., London, England) (F ig . I I ,  
2a). The sintered disc-glass tube units were o r ig in a lly  purchased 
from S c ie n tific  Supplies L td ., but more robust units were subsequently 
manufactured by the University glass-blowers. These simple units were 
selected in preference to the more commonly used, re la t iv e ly  elaborate,
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Toribara apparatus (Toribara, e t al_. 1957), fo r studies where buffered 
albumin solutions were used as they could be removed from the 
centrifuge tube which allowed thorough cleaning. Bor binding studies 
involving BSA solutions visking d ialysis  tubing ( 18 / 32 ") was used and 
prepared as previously described. A knot was then carefu lly  tie d  at 
one end of the tubing and the bag gently in fla te d . Drug-BSA (6 ml) 
mixtures were transferred into the d ialysis  bags by means of a 10ml 
glass syringe f i t te d  with a blunt luer-lock needle. As much a ir  as 
possible was excluded from the bag and a second knot tied  in the open 
end. A fter being folded into a 'U'-shape^with the two knotted ends 
uppermost,the bag was gently pushed down onto the sintered glass disc 
as shown in Fig. I I ,  2a. Care was exercised throughout to minimise 
handling and to avoid damage to the bag. The sintered glass tube 
contained in a 50 m l. polycarbonate centrifuge tube was centrifuged 
at 2,500gav (2,700 r.p .m .) in a M.S.E. M istral 6 L centrifuge
(employing a 6 x 1 L swing-out rotor with 24 x 50 ml. rubber adaptors) 
fo r 1 hour a t therm ostatically controlled temperature up to 45° C. The 
centrifugation procedure adopted was found by experimentation to 
produce s lig h tly  less than 1 0 % of the orig inal solution as u l t r a f i l t r a t e ,  
at such a low percentage removal, Donnan-equilibrium effects were 
shown to be small. Experiments also showed that s lig h t variation  in  
the centrifugation time did not s ig n ific a n tly  a lte r  the resu lts , 
nevertheless the procedure outlined above was routinely followed.
Of serum samples
For u lt r a f i l t ra t io n  of serum samples, modified Toribara tubes were 
used (Toribara, et , 1957; Fig. I I ,  2b). These were made by the 
University glass-blowers and had the advantage over conventional 
Toribara tubes in that they required smaller sample volumes ( i . e .  l-2 m l.)
and were also more robust and convenient to centrifuge. Serum 
samples containing added drug were transferred (using 2ml syringe) 
into d ialysis  bags, prepared from 8 " / 3 2  d ialysis membrane, and placed 
in the modified Toribara tubes. Individual Toribara tubes were then 
assembled in series and gassed with C02 :0 2 (5 :95 ), i t  was found that 
approximately 15 minutes was s u ffic ie n t to restore the serum pH to
7 .4 . The individual tubes were then sealed (as shown in Fig. I I ,  2b)
and centrifuged in a M istral 6 L a t 2,500 g3 fo r 20 minutes. This—a v .
time was found s u ffic ie n t to produce a suitable volume of 
u l t r a f i l t r a te ,  the pH at the end of u lt ra f i l t r a t io n  was invariably
7 .4 . No correction was found necessary fo r Donnan-6 quilibrium  
effects o r, fo r the volume occupied by the protein and other solutes 
(see section 2 ,XIV th is  Chapter). Membrane binding was checked by 
control experiments ( i .e .  absence of protein) and recovery values. A
large number of d iffe re n t techniques have been suggested for the
preparation of d ialysis  membrane e.g . soaking in d is t i l le d  water or 
bu ffer, b o ilin g , e tc . The procedure used in these studies was-found 
to give reproducible results and no s ig n ifican t membrane adsorption 
could be detected for any of the compounds studied.
Comparative Study of Equilibrium D ia lys is , U lt r a f i l t r a t io n  and Frontal 
Analysis
The binding of the drugs: c lo fib ra te ; s a licy la te ; sulphamethoxazole; 
sulphanilamide; sulphaphenazole and sulphormethoxine, to BSA was studied 
by the three techniques. Experimental, procedures were as previously 
described, aind.the binding to BSA (29.0 x 10 5M) was investigated over
the drug concentration range (7.5 -  90.0 x 10 5M) at 20° C, a ll  drugs and 
BSA solutions were prepared in 0.1 M phosphate b u ffe r, pH 7 .4 .
(v) In Vivo Dialysis
This method involves the implantation of a small d ia lysis  sac into  
the peritoneal cavity of an animal. I t  is a ta c it  assumption that the 
concentration of unbound drug in the plasma re flec ts  the peritoneal 
f lu id  drug concentration provided a steady plasma level o f the drug is  
attained by suitable manipulation of the dosage regime. The measurement 
of the steady plasma level and the concentration inside the d ialysis  
sac, should therefore re fle c t the degree of binding. In our study the 
binding of sodium sa licy la te  to ra t serum by in vivo d ia lys is  was 
compared with its  in v itro  in teraction as determined by the 
u lt r a f i l t ra t io n  technique described above (2 i i i  a ). The method of in  
vivo d ialysis  employed in our study was essentia lly  that described by 
McQueen (1968), the only modification being that we selected 
in trag astric  administration of the drug r&ther than mixing with the d ie t ,  
in order to obtain a more re lia b le  record of the dose in take.
Male Wistar albino rats (350-400g), housed in groups of four, were dosed 
with sa licy la te  (in  isotonic saline) a t a dose level of e ith e r 10  or 20  
mg/kg. body w t., once d a ily  fo r eight successive days, the control group 
received saline (1ml/kg. ) .  4 hours a fte r  dosing, on the seventh day of
treatment, d ia lysis  sacs were implanted in the peritoneal cavity  the 
sacs were removed 24 hours la te r  (4 hrs a fte r  dosing on day 8 ) .  The 
sacs were made from s te riliz e d  Visking d ia lysis  tubing ( 8/ 32) and 
contained 1 ml. of 6 % dextran (Pharmacia, T 700) in isotonic saline.
Each d ia lysis  sac was implanted into the peritoneal cavity under ether 
anaesthesia with s te r ile  precautions, through a small abdominal in c is ion , 
which was then carefu lly  closed by stitch ing and suturing. A fter 24 
hours the sacs were removed, again under ether anaesthesia, a t the same 
time blood samples were obtained from the ta i l  vein and by heart 
puncture, and serum obtained by centrifugation. In agreement with the
findings of McQueen (1968), very l i t t l e  ir r i ta t io n  of the peritoneum 
was apparent and no excess of free f lu id  was observed.
S alicy late  concentration in the serum and the d ia lysis  sac contents 
was determined by the flu orim etric  method of Oie and F r is tid  (1970), 
serum albumin concentration was determined by the method of Doumas, 
s t al_. (1971). The presence of sa licy la te  in the serum was found not to 
a ffe c t the assay of serum albumin. The variation of serum sa licy la te  
concentration with time in rats under the above experimental conditions 
was also determined. Blood samples (approx. 0.8 ml) were removed by 
t a i l  puncture at in tervals  over a 24 hour period, and the serum obtained 
by centrifugation. A fter removal of approximately 3 ml. of blood (a fte r  
about 4 h rs .) , subcutaneous isotonic saline was injected on further  
blood sampling to compensate fo r the reduction in blood volume. Serum 
was assayed fo r both sa licy la te  and albumin.
The binding of sa licy la te  to ra t serum was also determined by in v itro  
u lt r a f i l t r a t io n . Blood was removed from the aorta of normal, ether 
anaethetized, rats (male Wistar a lb ino, 350-400 g) and the serum 
obtained. S alicylate  was added to the serum to give a s im ilar  
concentration range to that obtained in vivo ( i . e .  10-50 yg/m l.) and 
u lt ra f i l t r a t io n  performed a t 37° C.
(v i)  U ltra v io le t Difference Spectrophotometry
The approach used here to study carbamate-BSA (Cohn, frac tio n  V) 
in teraction (Chapter Four) was based on that described by Herskovits and 
Laskowski (1962). Althoughvtheir procedure employed s p li t  absorption 
cells  to compensate fo r any uv absorption of the drug, conventional 
stoppered single quartz ce lls  were used in our study fo r the carbamates 
had no s ig n ifican t uv absorption. Albumin concentrations were e ith er  
0.58 or 5.8 x 10”5M in phosphate bu ffer, pH 7.4 and were t it ra te d  with
either 5 or 50 x 10 3m carbamate depending on the carbamates 
s o lu b ility  in phosphate buffer.
2.5ml. volumes of albumin solutions (BSA V) were pipetted into both 
the tes t and reference cuvettes, f it te d  with Suba-seal stoppers, 
(Gallenkamp L td ., London) and placed in the Pye-Unicam SP1800 
spectrophotometer, (Pye-Unicam L td ., Cambridge, England). The base-line  
was then recorded between 250-350nm,adjusted for a fu l l  scale deflection  
of 0.2 extinction units, with s l i t  widths at l.Onm. Small volume (y l)  
additions were then made from a 10yl Terumo syringe (S c ie n tific  Supplies 
L td ., London, England) through the Suba-seal stoppers. Mixing was 
performed by inversion and the scan between 250-350nm obtained. 
Sequential m ic ro litre  additions up to 20 yl were continued u n til the 
carbamate-albumin ratios  as used in the u lt ra f i l t r a t io n  studies (Chapter 
Four) had been reached. Studies were performed a t 28 ± 2° C.
( v i i )  Fluorescence
All fluorim etric  studies and estimations were performed in  a 
Perkin-Elmer MPF 3 spectrophotofluorimeter coupled with a Perkin-Elmer 
model QPD-33 Recorder (lOmv fu lls c a le ) (Perkin-Elmer L td ., Beaconsfield, 
Buckinghamshire, England). The recorded spectra were not corrected fo r  
the spectral dispersion of excitation energy, nor fo r the spectral 
characteristics of the dispersion system. (Parker and Rees, 1960; 
Melhuish, 1961; Chen, 1967). The s ta b il i ty  of the xenon lamp was 
regularly  checked by use of a fluorescent standard (5yg/ml quinine 
sulphate in 0 . IN sulphuric a c id ), although day to day variations were 
observed, during the course of an experiment the instrument remained 
re la tiv e ly  stable. Standard readings were therefore only checked a t the 
beginning and end of an experiment.
In Fig. I I ,  3(a and b) are represented the common modes of 
measuring sample luminescence. For a ll studies on e ither albumin-drug 
binding or assays where optical densities were low, luminescence was 
measured at an angle of 90° to the exciting lig h t (Fig. I I ,  3a). For 
microsomal studies (Chapter Six) because of the high tu rb id ity , 
measurements were made using a ce ll in the front-surface reflectance mode, 
( i . e .  samples were measured at an angle of 45° to the exciting lig h t  
(F ig. I I ,  3b) in a specially  designed ce ll holder, constructed in the 
department).
For a ll investigations the following instrument settings were used; 
excitation and emission spectral band width of 5nm, and when e ith er  
wavelength was being scanned, a scan speed of 180nm/min. and a recorder 
chart speed of 30mm/min. These settings were found to give a suitably  
high resolution.
Fig. I I ,  3
a) b)
Sample
XI Exciting) Sample
A i(Exciting)
or less
uorescent)
A i(Reflected)
All cells  (stoppered lOnm, c e lls , Spectrosil, ChemLab, London, England) 
and glassware were routinely cleaned (_except fo r studies amploying ANS, 
Rosen and Weber, 1969), in d ilu te  n it r ic  acid to remove any fluorescent 
contaminants.
Fluorescence quenching
A 2ml. volume of albumin solution was pipetted into a round
stoppered cuvette and capped with a Suba-seal stopper. Emission
wavelength scans were recorded at the excitation maximum wavelength
X (determined from scan of excitation wavelength at an emission sx
wavelength in the region of the fluorescence maxima). The
fluorescence value a t the emission wavelength maximum (Aern) was
a rb it ra r i ly  assigned a value of 100%. The A0X and Aen? are
dependent upon the species and nature of the albumin being studied,
but are usually in the region of 290 and 340 nm respectively. Small
volume (p i) additions were made from a lOpl Terumo syringe through
Subaseal stoppers. The solutions were mixed by shaking and the
emission wavelength scanned at X 290nm, changes in e ith e r theex
in tensity  of fluorescence or X were being recorded. Successiveem
m icro litre  additions were performed to achieve suitable albumin^ 
drug ra tio s .
The fluorescence a fte r  each addition was measured at room 
temperature 28 ± 2°C, and corrected fo r d ilu tio n  from a control 
t i t ra t io n  with the appropriate buffer ( i . e .  0.1M tr is -H C l, 0.1M 
phosphate bu ffe r, pH 7 .4 ). Measurements revealed no sample 
photodecomposition.
Fluorescent probe studies
The t it ra t io n  procedure was s im ilar to that described by Daniel 
and Weber (1966).
Albumin studies Fluorescence in ten s ities  of the probe-protein  
complex as a function of probe concentration (0 .5  -30 x 10”6 M) in  
pH 7 .4 , 0.1M phosphate b u ffe r, 2ml of each protein solution and
phosphate buffer was t itra te d  through Suba-seal stoppers with 
successive additions of 1 x 10~3M (fo r low concentrations) or 
5 x 10~3M (high concentrations) of probe in e ith er 0.1M phosphate 
buffer or ethanol, depending on the probe used. A fter mixing 
fluorescence in ten sities  were measured at the respective excitation  
and emission wavelengths fo r the probe in e ith er protein or buffer 
solution. Measurement of the quenching of albumin fluorescence 
(previous section) on additions of the probe was also recorded during 
these t itra t io n s . D ilu tion effects were corrected fo r by control 
titra tio n s  of albumin solutions with buffer or ethanol. At the 
volumes added (0 . 2 % v/v )  ethanol was shown not to a ffe c t the protein  
fluorescence apart from the d ilu tio n  e ffects .
For drug interaction studies e ither probe or competitor were 
added f i r s t  and titra tio n s  of the albumin-drug complex with the other 
performed as described. A ll experiments were performed a t room 
temperature 28 ± 2QC.
Microsomal experiments T itra tio ns  of microsomal suspensions ( 2mg/ml) 
and bu ffer, by the probe were performed in an analogous manner to 
that with albumin solutions except that observations were recorded with 
the ce ll in the front surface reflectance mode. Possible quenching 
of microsomal fluorescence by the probe was not recorded.
Increase of quantum y ie ld  accompanied by a fluorescence emission 
maximum (and possibly excitation maximum) s h if t  to a lower wavelength 
on decrease of solvent p o la rity , was used to select suitable  
fluorescent probes. To properly characterise the probe's properties  
equimolar concentrations of the compound were prepared in several 
solvents of d iffe re n t po la rity  (e .g . phosphate buffer ethanol, butanol,
hexane (spectroscopic grade, BDH L td .) and the emission and 
excitation maxima in each case, determined as previously described. 
Quantum yields were determined by the method of Parker and Rees (1960).
Treatment of fluorescent probe data
Enhancement of the fluorescence of the probe upon addition to 
albumin at two d iffe re n t concentrations, and the subsequent 
alte ra tio n  of fluorescence in the presence of binding competitors,was 
used to calculate the binding constants of both probe and competitors. 
The fraction of probe bound X, was calculated using the following  
equation (Brand, e t al_., 1967):
x - (Io / If) - 1 
(lb / If) - 1
where Io and I f  re fer to the fluorescence in ten s ities  of a given 
concentration of probe in solutions of low' protein concentration 
and in solutions without protein , respectively; and lb refers to 
the fluorescence in tensity  of same concentration of probe in solutions 
of high protein concentration. Thereby, lb gives the fluorescence 
in tensity  of the probe in the presence of excess binding s ite s . A fter  
the value X was found for each point along the t it r a t io n  curve the 
Scatchard equation (Scatchard, (1949) was applied to calculate the 
association constant of the probe.
The type of in h ib ition  apparent fo r fluorescence probe 
competitors was analysed by reciprocal (K lo tz, et a l . ,  1946) 
or Dixon (1953) plots.
( v i i i )  Animal Pretreatment and Microsomal Preparation
Hamsters (approx. 50g) or rats (approx. 130g) were dosed with sodium
phenobarbitone lOOmg of a 0.1% solution (in  0.9% NaCl aq. so ln .) per 
Kg. body weight in trap erito n ea lly , once d a ily  fo r 3 days. Respective 
controls were injected with 0.9% NaCl (1ml. per Kg body weight). 
Injections were performed at approximately the same time of day ~ 10 a.m. 
± 1 hour, and the las t dose administered 24 hours before s a c rific e . 
G ille tte  s te r ile  needles (25G x §) were used fo r in jections. The 
microsomal fraction  was' prepared as described by Burke (1972).
Determination of Spectrally Apparent Cyt. P-450 Interactions
This method is a modification of that described by Schenkman, e t a l . 
(1967).
2.5 ml. of a 2mg. protein/m l. liv e r  microsomal suspension was 
pipetted into a matched pair of glass round-stoppered spectrophotometer 
cuvettes and the cells  placed in the sample position nearest the 
photom ultiplier of a Unicam SP 1800 or Perkin-Elmer 356, dual beam 
spectrophotometer. A base lin e  of equal lig h t absorbance was then 
recorded between 350 and 500 nm. The cuvettes were then capped with 
Subaseal stoppers and addition of m ic ro litre  volumes of substrate 
solutions, in ethanol, performed by in jection  through the stoppers from a 
lOyl Terumo syringe. Sequential m ic ro litre  additions up to 20 y l of 
substrate solution were performed to give a substrate concentration 
range 0 .04-1.0  x 10 3M. The addition of up to 20yl volumes produced a 
neglig ib le volume change in the cuvette components. For each addition of 
substrate to the sample cuvette an equal volume of ethanol was added to 
the reference c e ll .  A fter each addition the cuvettes were shaken to 
achieve mixing, and the difference spectra generated between 350 and 
500nm recorded.
For substrates having an absorption spectrum which in terfe red  with
the 'binding1 difference spectrum, determinations were performed using a 
matched pair of s p lit  c e lls . These consisted of a pair of 2 x 1 cm. c e lls ,  
each partitioned with a thin quartz wall into two 1 x 1cm. in d iv id u a lly  
stoppered compartments (Lightpath Optical Co. Ltd). For th is  procedure
2.5 of microsomal suspension was pipetted into one compartment of each 
cell and 2.5 ml. of phosphate buffer into the other compartment. A fter  
recording a base lin e  equal m ic ro litre  volumes of substrate solution were 
in jected into the reference c e ll .  The same volume of ethanol was then 
injected into the microsomal suspension in the reference ce ll and the 
buffer in the sample c e ll .  For estimating the e ffec t of spectral 
m odifiers, the competing substrate was injected into both sample and 
reference microsomal suspensions before recording the base lin e . Additions 
of substrate were then performed in usual manner. Types I ,  I I ,  and RI 
compounds were distinguished experimentally by the characteris tic  spectral 
wavelength changes they produced on in teraction with microsomes. Types I I  
and RI were further d iffe ren tia ted  by the in a b ility  of the la te r  type 
compounds to displace an iline  in oxidised, or carbon monoxide in reduced, 
microsomes.
Analysis of spectral binding data
Spectral binding data was analysed by means of the Lineweaver-Burk 
plot (Fig. I I ,  4) with the following changes of notation: greatest spectral 
change £ ,  instead of in i t ia l  ve loc ity ; maximal spectral change AEmav,
INclX
instead of Vmav, spectral dissociation constant K . instead of K . aE max s m
represents the extinction difference between the maximum and minimum of 
the difference spectrum.
Fig. I I ,  4 Lineweaver-Burk Plot
in i t ia l  velocity
max
S (Substrate concn.)
(x) Protein Determination
(a) Total protein
Protein concentrations were normally determined by the method of 
Lowry, e t a l . ,  (1951). For a ll studies9 except fronta l analysis, 
proteins were determined by the manual procedure. For fronta l 
analysis, however, because of the large number of samples requiring  
analysis, determinations were performed automatically on an 
autoanalyzer [Technicon Instrument Co., New York, U .S .A .], the 
manifold used was essentia lly  that of Gaunce and D 'lo rio  0 9 7 0 ). 
Manual and autoanalyser determinations were shown to give s im ilar 
resu lts .
(b) Albumin
The method used was that described by Doumas, et a l . ,  0 9 7 1 ].
Chemical Modification of Albumin and Determination of Modified Groups
C rystalline BSA and HSA preparations were chemically modified with 
acetic anhydride and diethylpyrocarbonate and used in the fluorescent 
probe studies of the binding of warfarin (Chapter F ive ). Controls (in  
the absence of modifying reagent) were carried through the same 
experimental procedure.
Acetic anhydride treatment
The method used to acetyl ate the albumins was essentia lly  that of 
Bethune, e t al_. (1964).
2 ml. of acetic anhydride was slowly added to albumin (Ig ) in 20 0  ml. 
of 0.02M phosphate buffer (pH 7.4) and the pH was maintained a t 7.4 fo r  
0.5hour at 0° C.
Diethylpyrocarbonate treatment
The method used was that of MUhlrad, e t a_l_., (1967). Solutions
Solutions of albumin (2%) in 0.1M acetate buffer pH 6 .0 , were reacted
with d iffe re n t concentrations of a 1 0 % alcohol solution of
diethylpyrocarbonate: 10 and 100 fo ld  excess per mole of albumin. The 
reaction time was 12 hours at 20°C.
A ll albumin solutions a fte r  chemical modification were dialysed 
against several changes of d is t i l le d  water at 0°C. fo r 2-3 days and then 
freeze dried (ChemLab Manifold Freeze Drier SB3, ChemLab, I l fo r d , Essex, 
England) and stored in a desiccator at 4°C.
The following assays were used to detect protein chemical group
m o d i f i c a t i o n : -  A ll albumin solutions.were prepared in 0.1M phosphate 
buffer pH 7.4.
Amino: The degree of amino group modification was determined by
the ninhydrin method (Kabat and Mayer, 1961),
To 0.1 ml. of albumin solutions (modified and control) in 0.1M 
phosphate buffer (1 to 20ygN) and blanks (buffer) was added 0.5ml. 
of freshly prepared ninhydrin reagent. The solutions were mixed and 
tes t tubes stoppered (10ml. screw«top Sovirel test tubes, V,A. Howe 
and Co. L td ., London, England) and heated In boiling water bath fo r  
20 minutes. 2.0ml. of H20~propanol solution (equal volumes of H20 
and .n-propanol) was added and the solutions mixed and centrifuged. 
Absorbance was then read at 570nm.
The ninhydrin reagent was prepared as follows:^
40mg SnCl2 .2H20 were dissolved in 25ml. c itra te  buffer (0.2M. 
pH 5 .)  and added to 0.4g ninhydrin in 12.5ml. of methyl celloso lve. 
Free lysine residues in diethylpyrocarbonate treated albumins were 
also determined by the trinitrobenzenesulphonic acid procedure of 
Habeeb (1966). To 1ml. of albumin solutions (0.6-lmg/min) and 
blanks was added 1ml. of 4% sodium bicarbonate, pH8.5 and 1ml. of a
0.1% aqueous solution of TNBS (2,4,6-trinitrobenzenesulphonic acid) 
The solutions were incubated at 40°C fo r 2 hours and then 1ml. of 
10% sodium lauryl sulphate was added, followed by 0.5ml. of N HC1. 
Absorbance was determined at 335nm. and the molar extinction  
co effic ien t of one free amino group by the TBNS method was assumed 
to be 0.995 x 101* (Habeeb, 1966).
Phenol Acylation of tyrosine residues was determined by the 
decrease in absorbance at 278nm (Simpson, et aj_., 1963).
(c) Imidazole The degree of h istid ine substitution was determined 
from the absorbance at 240nm (Ovadi, 1967).
(d) Guanidino These were determined by a modified Sakaguchi reaction  
(Gilboe and Williams, 1956).
A ll reagents were cooled to 0-2°C before commencement of 
determination.
To 5ml of albumin solutions or arginine standards (5J30yg 
arginine/m l) was added 1ml of 0 . 0 2 % 8 -hydroxyquinoline and 1ml. of 
10% sodium hydroxide. The solutions were whirli-m ixed and replaced 
in an ice-bath fo r 2 m ins., 0 . 2ml. of 1% sodium hypobromite was 
then rapidly added to develop the colour. A fter mixing and w ithin  
15 seconds, 1ml of 40% urea was added to destroy the excess 
hypobromite and prevent fading of the developed colour. One minute 
a fte r addition of the hypobromite, 5ml. of cold d is t i l le d  water was 
added, the solutions mixed and adsorbance read at 506nm w ithin 5 
minutes of colour development.
( x i i ) Drug Assays
(a) Sulphonamide
The method used was based on that described by Bratton and Marshall 
(1939).
(b) C lofibrate
Suitable aliquots of the c lo fib ra te  containing solution were taken 
(e .g . 0.1 ml. containing 0 .01-0.02 p moles] and 0.5 ml. of 3N HC1 
was added followed by 3.0 ml of 5% absolute alcohol in
trimethylpentane (B.D.H. Spectroscopic grade). The solutions were 
then rotary shaken fo r 10 minutes and the absorbance of the organic 
layer measured at 226 nm. Blanks were 0.1 M phosphate bu ffer, 
pH 7.4 and c lo fib ra te  standards(0 .1 -2 .Op mole/ml) in phosphate bu ffer.
S alicylate
The method used was that of Oie and F ris tid  (1971) which employed a 
flu orim etric  estimation of to ta l sa lic y la te .
A standard range of s a licy la te  (Na) concentration (6-500 nm ol/m l), 
was prepared both in aqueous solutions and ra t serum (obtained by the 
same procedure as tes t serum, as the fluorescence was observed to be 
lower in haemolysed serum).
Tryptophan
The procedure used was essentia lly  that described by Denckla and 
Dewey (1967), with the modification that the use of trich lo ro acetic  
acid (TCA) in th e ir  procedure was replaced with perchloric acid (PCA). 
This modification was found to elim inate sample ‘ cloudiness1 a fte r  
incubation apparent when using TCA, due to the formation of an 
insoluble condensation product, and therefore dispensed with the need 
to centrifuge samples before fluorescence estimation. The reduction 
in carbon dioxide formation by the use of PCA also reduced the need 
to readjust sample volume a fte r  incubation. A ll glassware, 
centrifuge tubes and spectrofluorimeter cuvettes were routine ly  
soaked in d ilu te  n it r ic  acid, to remove in terfe rin g  fluorescence 
contaminants, and then thoroughly rinsed in double-glass d is t i l le d  
water before use.
To duplicate aliquots (0.1m l) of serum, dialysates and tryptophan
standards (0.2 -  20 yg/ml. in 0.1 N ammonium hydroxide) was added 
9ml. of PCA/FeCl3 solution (3 x 10 FeCl3 in 10% w/v  PCA) and 
then mixed. The solutions containing serum were then centrifuged in 
10ml, polyethylene centrifuge tubes in a M.S.E. Super Speed 50 
centrifuge using a 10 X 10 ml. angle rotor a t 20,000gow (21,000 rpm),
av
fo r 10 minutes at 20°C.Aliquots (1 .8  ml were then removed in 
duplicate from each of the samples and transferred into 10ml.
Sovirel screw-top test-tubes, (calibrated at a volume of 2m l.). 
Formaldehyde (0.2ml of a 1.8% v/v  aq. soln) was then added to each and 
the tubes firm ly  stoppered, the solutions were then incubated fo r  
2 hr. in an oven at 110°C. A fter cooling, the solutions were 
readjusted to the 2ml. volume mark with 10% PCA, and the fluorescence 
measured (excitation wavelength, 373 nm; emmission wavelength,
452 nm). -
Norharman yields by the above procedure were routinely  70-80%.
Gas-Liquid Chromatography
A glass column, with J-type configuration (53cm. long by 0.4 cm. i .d . )  
packed with Porapac P (mesh-size 100-120, batch no. B-941, Phase 
Separations L td ., F lin ts h ire , Wales) was used fo r both carbamate 
and acetate determination. A fter packing the column was conditioned 
by heating at 230° fo r 24 hrs. with "oxygen fre e 11 nitrogen (20 ml./min 
as the ca rrie r gas. Several in jections of a standard solution  
(carbamate or acetate) were made and the column reconditioned (th is  
continued un til reasonable e ffic iency  was obtained).
(e) Carbamate determination
Column conditions Gas flow rate (ml/min)
'Oxygen-free' nitrogen: 120
A ir flow: 80
Hydrogen flow: 35
In jec to r temperature: no heating was used.
Carbamate Column temp.°C Retention time
Methyl 160 4 min.
Ethyl 160 6 min.
n-Propyl 180 4.5 min.
n-Butyl 180 7 min.
i-Butyl 180 , 6  min.
t-Butyl 20 0  6 min.
n-Pentyl 200 6 min*
t-Pentyl 200 6 min.
n-Hexyl 200 9 min.
t-Hexyl 2 0 0  9 min.
n-Heptyl 220 7.5 min.
Benzyl 220 15 min.
The detector temperature was approximately 50° C above column 
temperature. Samples (2y l) were in jected onto the column, with a 
Hamilton microsyringe. Appropriate standards in 0 .15M phosphate 
bu ffer, pH 7.4 were run in a s im ilar manner. Peak areas were 
calculated by triangu la tion .
(f) Acetate determination
The same column and packing material as used fo r carbamate 
determination, was used fo r the assay of butyl and pentyl acetate, 
the only difference being in the operating conditions used.
Column conditions Gas flow rate (ml/min)
'Oxygen-free' Nitrogen: 200
A ir flow: 120
Hydrogen flow: 45
Column temperature: 150°C 
Detector temperature: 200°C 
Retention times:
Butyl acetate 1.75 min.
Pentyl acetate 3.5 min.
No in jec to r temperature was used, and the attenuation was varied 
according to concentration.
Because of the v o la t i l i ty  of the acetates, 0.2 ml. of u l t r a f i l t r a te  
and standards (0.5-4mM) were rapidly transferred into small stoppered 
glass via ls  (1m l.) kept at 0°C. A fter addition of 40yl of in ternal 
standard (corresponding acetate, in 0.15M phosphate bu ffer) the 
solutions were mixed and the v ia ls  stoppered and kept at 0°C u n til 
in jection onto the column.
The alternate analogue was routinely used as in ternal standard 
in the manner previously described. Because of the two acetates 
butyl and pentyl showed good peaks ( i .e .  low 'w' values, peak width 
at ha lf height) (Scott, 1960) and s u ffic ie n t difference in th e ir  
retention times they could be used as the corresponding in ternal 
standard. They also had the advantage of s im ilar v o la t i l i t y .
(xiii) Determination of Apparent Partition Coefficient
The apparent p a rtitio n  coeffic ients fo r the carbamates series 
R-0-C0-NH2 were determined in duplicate at 37°C using n-octanol and 0 .15M 
phosphate b u ffe r, pH 7 .4 . Both the octanol and buffer were saturated 
with the relevant aqueous or organic phase before use. Several carbamate 
concentrations (5-15mM) were then prepared in e ith er the buffer (R=G-C5) 
or the octanol phase (R = C6) .  Equal volumes (25 m l.) of both phases 
were then mixed and shaken in stoppered conical flasks fo r 6 hours to 
achieve equilibrium (Leo, et al_., 1971). The concentration of carbamate 
in both phases at equilibrium was then determined and good agreement 
(> 99%) found between duplicates.
The use of octanol for the determination of p a rtitio n  coeffic ients  
and its  use as a reference system fo r a liv in g  biophase have recently  
been discussed (Hansch and Dunn, 1972). In support of the use of 
octanol Hansch has published numerous examples of excellent correlation  
between biological a c tiv ity  and octanol water p a rtitio n  coeffic ien ts  
(Hansch, 1971; Hansch and Clayton, 1973; Hansch and Dunn, 1972).
The determined p artitio n  coeffic ients  fo r the homologous series of 
carbamates (R-0-C0-NH2) are presented in Table I I ,  1; The addition of 
a methylene group to the R side chain resulted in a regular increase in  
p artitio n  co effic ien t as determined by log. P (logarithm of apparent 
p artitio n  co e ffic ien t) or the Hansch n constant (Hansch and F u jita , 1964),
i . e .  log P or H = 0.5 fo r addition of CH2 group in the s tra ig h t chain 
homologous series where n is defined as:
= log. PR = Ca _ C£ - log. PR = Ci
In Fig I I ,  5 is shown the lin ea r correlation obtained between log. P 
and the number of carbon atoms (x) in the R side chain fo r  s tra ig h t-
Tab le  [ [ ,  I . Partition Coefficients for Straight Chain
Aliphatic Carbamates CR~0*-C0-NH2)
R Group
g
P a r t i t i o n  C o e f f i c i e n t l o g .  P bTT TT *  °
M eth y l 0 . 2 2 - 0 . 6 6 0 0
E th y l 0 .7 0 - 0 , 1 6 0 . 5 0 . 5 0
n - P r o p y l 2.30 0 .3 6 1.02 0 . 5 2
n - B u t y l  • 7-10 0 .8 5 1.51 0 . ^ 9
n - P e n t y l 2 2 .5 1.35 2.01 0 .5 0
n -H e x y l 70.8 1.85 2.51 0 . 5 0
A p p a re n t  p a r t i t i o n  c o e f f i c i e n t s  d e te r m in e d  u s in g  n - o c t a n o l  and 
0.15M phospha te  b u f f e r  (pH 7 . ^ 1  9 t  3 7 QC.
tt d e r i v e d  f r o m  (n = log  PD r  r  - l o g  Pn r  )
K=L 2" ,b 6  K=L i
C
t t *  d e r i v e d  f ro m  tt *  = l og  P^ -  log  P ^
Table 11,2. Partition Coefficients for Branched Chain and
Aromatic Carbamates (R-0-C0-NH2)
R Group
g
P a r t i t i o n  C o e f f i c i e n t l o g . P b, tt TT *  C
i - B u t y l 4 .5 0 . 6 5 1.31 - 0 . 2 0
t - B u t y l 3 . 0 0 . ^ 7 1.13 - 0 . 3 8
t - P e n t y l 8 . 7 0 .9 4 1 .6 0 -0 .4 1
t - H e x y l 28 .0 1.45 2.11 - 0 . 4 0
Benzyl 17.0 1.23 1.89 - 1 . 1 2
t
A p p a r e n t  p a r t i t i o n  c o e f f i c i e n t s  d e t e r m in e d  u s in g  n - o c t a n o l  and 
0.15M ph osph a te  b u f f e r  CpH 7 . 4 1  a t  37°C .
tt d e r i v e d  f r o m  Or = log  PD r  ^ " l o g  Pn r  )K=u 2 “U 8 K=u 1
Q
u *  d e r i v e d  f r o m T r *  = log  PD -  log  P .K K“ I
where R1 i s  t h e  r e s p e c t i v e  s t r a i g h t  c h a in  ana lo g u e
For  benzy l  ca rbam ate  R1 = h e p t y l  ca rbam ate  ( l o g  P = 2 . 3 5 ,
tt =  3 . 0 1 )
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chain homologues. The line of best f i t  (calculated by the method of 
least squares) had the following regression equation:
log. P = 0.50 (± 0.0025) x -  1.152 (± 0.0013) 
n = 6 , r  = 0 .9 9 9 ,  s = 0.0169
where n is the number of data points, r  is the regression coeffic ient  
and s is the standard deviation of the l in e .  Figures in parenthesis are 
the standard deviations of the constants. The slope of this equation 
corresponded to the n value for addition of a CH2 group (Table I I ,  1 ).
The partit ion  coefficients of the branched chain, is o -b u ty l; t e r t - b u ty l, 
t e r t - pentyl, t e r t - hexyl, and aromatic benzyl carbamate were also 
determined and demonstrated the e ffect of s teric  factors in the 
partitioning process (Table I I ,  2 ) . Although the p a rt it io n  coeffic ients fo 
the branched chain carbamates were lower than th e ir  respective stra ight  
chain analogues they nevertheless displayed a regular increase in log. P 
and n. For a single branch log. P and n were found to be lowered by 0.2  
with respect to the straight chain analogue, whereas for a double branch 
values were loweredcby 0 .4 , fo r  benzyl carbamate values were lowered by 
1.12.
(x iv) Experimental Design of Albumin Binding Studies
Phosphate buffer (0.1 or 0 .15M, pH 7.4) was used for a l l  binding 
studies involving gel f i l t r a t io n ,  equilibrium dialysis and u l t r a f i l t r a t io n  
techniques, although unrepresentative of a physiological bu ffe r , i t  has 
been shown to exhibit low competitive effects on the binding of small 
molecules to albumin (Klotz and Urquhart, 1949, Keen, 1966).
Experimental binding data from the three techniques; frontal  
analysis, equilibrium dialysis and u l t r a f i l t r a t io n  was calculated 
according to the methods of Cooper and Wood (1968), Rosenburg and Klotz
( I960 ), and Toribara, ert al_. (1957), respectively.
Under certain conditions (Karush and Sonnenburg, 1949), the Donnan 
effec t may not be negligible and corrections to allow for such effects  
must be made (Higuchi, et £l_., 1954, Scatchard et a K , 195o). Possible 
Donnan equilibrium effects for the three systems used were studied by the 
sodium ion distribution procedure of Keen (1965). Sodium determination 
by flame photometry, within experimental error, revealed negligible  
Donnan e ffects . However, calculation of the Donnan ra tio  (r )  from 
Tanford, et a lls  (1955) data on the net charge on the albumin molecule a t  
d iffe re n t pH's revealed an r  value of 1.03. Keen (1965 and 1966) has 
also suggested that correction for the volume occupied by the protein and 
other solutes should be made when determining small molecule unbound and 
protein-bound concentrations. To account for this he suggested the 
following correction factor ( f )  for the concentration in albumin 
containing compartment or zone;
f  = 1 0 0
f(99.6 -  (g albumin/lOOml. )0.75j
this assumes that the specific gravity of albumin is 1.33 and that 0.4% 
of the solution volume is occupied by solutes other than protein (McLean 
and Hastings, 1935).
Similarly for diffusate concentration of small molecule
m ultip lication by J00 = 1.004 to allow for the space occupied by the 
99.6
buffer solution. Therefore to account for both protein solute volume and 
Donnan effects the following equation can be used:-
bound concentration = total concentration x f  - d iffusate concn. x 1.004
For our experimental systems the equation was resolved to :-
bound concentration = total concn. x 1.02 - diffusate concn. x 0.97
Similar corrections were needed for a l l  three techniques, in view of 
this and the theoretical nature of r  i t  was considered that the use of 
the formula:- bound concn. = to ta l concn. -  unbound concn. 
was within experimental error and su ff ic ie n t ly  accurate, and was therefore  
used for a l l  data calculation.
Experimental data was routinely interpreted by the use of the 
Scatchard plot (Scatchard, 1949, see next section), however fo r some 
studies (competition experiments, Chapter Five, tryptophan binding,
Chapter Three, microsomal substrate interactions, Chapter Six) other 
plots i . e .  reciprocal (Klotz, 1946) or Lineweaver-Burk (1934), or 
Langmuir-isotherm plots (Langmuir, 1917) have also been employed.
Treatment of Data from Binding Studies
The reversible interaction of both endogenous and exogenous 
compounds with plasma proteins is a dynamic equilibrium and as such is 
considered to obey the law of mass action su ff ic ie n t ly  to allow 
treatment of the data by methods derived from this law (Goldstein, 1949, 
Edsall and Wyman, 1958, Kruger-Thiemer, 1968, Meyer and Guttman, 1968, 
Klotz and Hunston, 1971).
From a consideration of the law of mass action, in which certain  
assumptions are made, for a single s ite  or class of sites reversible  
binding can be described by the equation:-
1 + k Df
where r  = moles of small molecule bound to tota l moles of protein in
the system
= molar concentration of unbound small molecule 
n = number of binding sites
k = apparent association constant (also termed a f f in i t y  constant) for  
the binding of the small molecule.
I t  is apparent that the binding of a charged molecule a lters  the 
overall e lectrosta tic  environment of the macromolecules, which increases 
the d i f f ic u l ty  of adding another s im ilar ion. Values can be corrected 
for such e lectrostatic  interaction factors by using a rather complex 
equation (Scatchard, et a K , 1950). Most authors, however, report 
uncorrected data and the association constants are therefore only 
'apparent'v
The assumptions made in the equation (1) a re :-
a) All sites within a class are equivalent in binding a f f in i t y
b) Binding of a small molecule a t one s ite  does not a ffec t binding a t  
another s ite  i . e .  no interaction occurs between binding sites
c) Concentrations are assumed to be equivalent to thermodynamic 
a c t iv i t ie s .
The ea rl ie s t  method of plotting data was adsorption isotherm methods 
of Freund! ich (1907), and Langmuir (1917), however for several
reasons discussed in detail by Goldstein (1949), Kruger-Thiemer (1968), 
Edsall and Wyman (1958), they are no longer the methods of choice.
A method of plotting according to Karush (1950) has also been used 
however i t  makes the assumption that the binding sites f i t  into two 
and only two, d is tinct groups, and involves long extrapolations to obtain 
in  and£nk. For evaluation of the parameters of equation (1 ) ,  two 
l inear transformations have been widely used, the reciprocal and
Scatchard plots. Equation 2 shows the equation for the so called  
reciprocal p lo t, (Klotz, 1946), Fig. I I ,  6 which is analogous to the 
Lineweaver-Burk p lot.
i  = i  + i
n nk D.
( 2 )
in which J_ is plotted as a function of 1_ . I f  the binding sites are 
r  Dj.
equivalent and independent, then n and k can be estimated d ire c t ly  from
the slope and intercept values. Deviation from l in e a r i ty  in this p lot,
may however, be apparent.
Fig. I I ,  6
Reciprocal Plot
slope = 1
intercept = -k
Fig. 1 1 , 7
Scatchard Plot
(For single class of 
binding s ite )
L
D slope = -kf
r
Scatchard (1949) proposed a d iffe rent form of equation (1)
  = nk - rk .................................. (3)V
Where > /v n is plotted as a function of r .
• f -
For a single class of binding s i te ,  the plot w ill  be l in ea r, and extra­
polation to the abcissa gives the number of binding sites in the class, 
and extrapolation to the ordinate allows estimation of nk. (Fig. 1 1 ,7 ') .  
Curvature of the Scatchard plot is frequently encountered and this  
produces d i f f ic u lt ie s  of in terpretation. Curvature may result from one 
or more of the following causes:-
a) Binding sites are not equivalent i . e .  there exists more than one
class of s ite  each with characteristic values for n and k thus -
r = nikiDf  + n2k2Df  + n3k3Df
1 + kjD. 1 + k2 Df  l+ k 3 Df  • ' ’ • ' W
b) Binding sites are not independent i . e .  interaction occurs between
the sites e.g. from electrostatic  forces.
c) Curvature may result from a small molecule-induced conformational
change in the protein.
d) A small molecule having several groups involved in binding may bind
in d if fe ren t ways to the protein thus producing curvature.
I t  is apparent from (a) that for non-linear Scatchard plots no 
simple relationship between the intercepts and slopes and n and k values 
fo r  the d iffe ren t sites w il l  ex is t .  In this case the intercepts and 
slopes w il l  be composites of contributions from the various s ites , and 
th e ir  respective n and k values must be segregated out (Klotz and Hunston, 
1971).
Such curves may also be f i t te d  as the summation of two or more
straight lines each due to a d if fe ren t class of binding s i te .  Several 
manual methods of curve f i t t in g  have been described. (Hard, 1965, 
Rosenthal, 1967, Weder and Bickel, 1970, Feldman, 1972, Halfman and 
Nishida, 1972). However the complexity and tediousness of this procedure 
has led to computerised curve f i t t in g  procedures based on non-linear 
regression analysis (Fletcher and Spector, 1968, Crothers, 1968, Raz and 
Goodman, 1969, Rodbard, e t aj_., 1969, Feldman, 1972). The reciprocal 
plot heavily weights those experimental points at low values (Klotz,
^ t  a K ,  1946, Meyer and Guttman, 1968) often non-1 inearity  is observed .
and can therefore lead to misinterpretations concerning binding at 
high Dj.. The Scatchard plot does not suffer from this disadvantage, and 
although curvature of the plot makes resolution complex, i t  is the 
graphical method of choice, (Meyer and Guttman, 1968, Krieglste in , 1969).
The reciprocal and Scatchard plots cannot be applied to experimental 
data obtained from experiments in which the amount and molecular weight 
of the protein involved in the binding are unknown. However, Sandberg, 
et a l . (1966) and Rosenthal (1967) have proposed a Scatchard-type plot  
based on equation (5 ) : -
-rep . ,= , nk pt  -  kDb .....................
Where Db = concentration of unbound drug
P^ . = total molar concentration of protein
A plot of Db (orcj-jnate) a9 ain^t Db, is independent of protein
Dt '
concentration and allows estimation of nkPt , nPt  and k, from the 
ordinate intercept, abscissa intercept and slope respectively.
Curvature of the plot results when more than one species of binding 
protein is present or when there is more than one class of binding s ite
on the protein.
A number of detailed accounts of equation derivation and 
discussion of graphical methods of data treatment have appeared 
(Goldsteins 1949; Edsall and Wyman, 1958; Rosenburg and Klotz, 1960; 
Sandberg, et al_., 1966; Goldstein, et a l . ,  1968; Meyer and Guttman, 1968; 
Steinhardt and Reynolds, 1969; Davison, 1971; Gutfreund, 1972).
S ta tis tics
Linear regression analysis, based on the method of least squares, 
was performed on an O live tti  101 programmeable calculator. Binding data 
exhibiting curved Scatchard plots was analysed by non-linear regression 
analysis performed using a Fortran computer programme, very kindly 
supplied by Dr. J. Francis, Roche Products L td ., Welwyn Garden C ity ,  
Herts.
Where appropriate data has been expressed as e ither mean ± S.E.M., 
or in the case of regression equations as mean ± S.D. Tests for  
s ta t is t ic a l  significance were performed using e ither the regression 
correlation coeffic ient or s tudent-t-test.
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CHAPTER THREE
A C O M P A R A T I V E  E V A L U A T I O N  
OF  S E V E R A L  M E T H O D S  OF  M E A S U R I N G  
P R O T E I N  B I N D I N G
. Introduction
A wide variety of methods have been employed to study drug-protein 
interactions and th e ir  re la tive  theoretical merits and disadvantages reviewed 
(Goldstein, 1949; Edsall and Wyman, 1958; Rosenburg and Klotz, 1960;
Steinhardt and Reynolds, 1969; Chignell, 1971). Although authors have stated 
th e ir  preference for one approach in favour of another, few extensive practical 
studies have been performed comparing available techniques. There is 
therefore, l i t t l e  experimental data to support the selection of one technique 
in preference to another for studying the binding of a novel compound to a 
protein.
Equilibrium dialysis is at present the most widely1used technique in 
studying protein binding, but the methods of u l t r a f i l t r a t io n  and gel f i l t r a t io n  
have also received considerable attention. There is a clear need for a 
detailed comparison of these techniques in order to ascertain th e ir  
appropriateness for studying particu lar drug-protein interactions.
The c r i te r ia  we selected for such an evaluation were that the results  
obtained with each method should be reproducible over given variations in 
degree of binding, and changing physical parameters of the drug, such as l ip id  
s o lu b il i ty ,  functional groups and pKa. Factors such as experimental duration, 
sample volume requirement, temperature control and pH control were a l l  im p lic it  
in these considerations. The three commonly used methods of gel f i l t r a t io n ,  
namely the batch, zonal and frontal analysis methods were evaluated in order to 
select the most suitable for comparison with the techniques of equilibrium  
dialysis and u l t r a f i l t r a t io n .
The drugs; c lo fibrate  (Atromid-S); sodium sa licy la te ; sulphamethoxazole 
(Gantanol); sulphanilamide (Prontosil Album); sulphaphenazole (Orisul ) i  and
sulphormethoxine (Fanasil), were selected for this study not only because 
th e ir  physical properties were well documented and. th e ir  protein binding to 
albumin known to show the desired large variation in degree of binding at 
comparable concentrations, but also the .fact that they were re la t iv e ly  re lia b le  
and simply assayed. Bovine serum albumin (BSA) was selected as a suitable protein
One valid critic ism  of the above technique is that binding is determined 
under non-physiological in v itro  conditions. L i t t le  data is available to 
establish the pertinence of such determinations to the in vivo s ituation.
McQueen (1968), described an in vivo method of investigating the protein 
binding of drugs which involved the implantation of a d ialysis sac in the 
peritoneal cavity of a ra t .  He reported good agreement for the binding of  
sulphormethoxine to ra t  serum albumin between this method and conventional in 
v itro  ,- equilibrium dia lys is . Unfortunately only the binding of 
sulphormethoxine appears to have been investigated by this method, i t  was 
therefore included in our comparative study of in v itro  binding techniques.
The determination of salicy late  binding by in vivo dialysis was also 
investigated and compared with in v itro  derived results. Sa licylate  was 
selected because i ts  metabolism, pharmacokinetics and in v itro  binding are well 
. documented (Moran and Walker, 1968; McArthur and Smith, 1969), and i t  has 
d iffe ren t functional groups and physico-chemical properties to the sulphonamide 
(sulphormethoxine) selected by McQueen (1969). In particu lar sa licy la te  has a 
plasma h a l f - l i f e  of considerably shorter duration than sulphormethoxine 
(Ritschel, 1970), and may therefore be of value in exposing any possible 
lim itations of the in vivo technique in determining the binding of drugs with 
re la t iv e ly  short plasma half l ives . The use of this method to study the 
in vivo displacement from serum protein binding sites of the tryptophan by 
salicy late  was also investigated.
2 * Experimental Approach
In the following experiments a l l  drug and BSA solutions were 
prepared in 0.1 FI phosphate buffer, pH 7 .4 , and a l l  experiments performed at  
20° C.
a) Comparative Study of the Batch, Zonal and Frontal Analysis Methods of 
Gel Chromatography
A comparative study of the binding of the drugs sulphormethoxine 
(24.0 X 10" 5 M) and c lo fib rate  (31.0 X 10“ 5 M) to BSA (29.0 X 10" 5 M) was 
performed with these three gel chromatography methods. Sephadex G-25 (f in e )  
was used as the gel f i l t r a t io n  medium, although the use of a polyacrylamide 
gel (Biogel P2) was also investigated in the zonal chromatography studies.
b) Comparative Evaluation of the techniques of Equilibrium D ia lys is , 
U lt r a f i l t r a t io n  and Gel Chromatography (Frontal Analysis)
The binding of the drugs; c lo fib ra te ; sodium sa licy la te ;  
sulphamethoxazole; sulphanilamide; sulphaphenazole and sulphormethoxine to 
BSA (29 X 10 ” 5 M) was studied over a wide concentration range (7.5 to 90 X 
10 5 M )by the three techniques.
c) Comparison of Salicylate Binding to Rat Serum by In Vitro and in yivo 
Techniques
The binding of sa licy late  to ra t  serum and its  a b i l i t y  to displace 
bound tryptophan was determined by the in vivo dialysis technique.
Sa licy la te , 1n isotonic saline, was in tra g a s tr ica lly  administered to 
male $ is ta r  albino rats (10 or '20 mg/Kg. body w t . ) ,  control rats received 
isotonic saline only, once da ily  for seven days before implantation of 
dialysis sacs. The dosage regime was continued until removal of the sacs 24 
hours a fte r  implantation ( i . e .  day 8 ) .  Sacs were implanted and removed 4 
hours a fte r  oral dosing, blood samples were obtained from the t a i l  vein and
by heart puncture, at the same time as the sacs were removed, and serum 
obtained by centrifugation. The concentration of tryptophan in the serum 
dialysis sac was also determined. Serum salicylate-tim e curves were also 
determined over an equivalent 24 hour period in a sim ilar group of ra ts .
Results
Table HI, 1
Use of the Bath Method of Gel Filtration to study the Binding
o f  S u lp h o r m e t h o x in e  t o  Bov ine  Serum A lb u m in 8 : -  
D i s t r i b u t i o n  o f  S u lp h o r m e th o x in e  between i n t e r n a l  and E x t e r n a l  Phases
I n i t i a l  
Sulphonamide  
Cone11. ( x 1 0 - 5 M)
I n t e r n a l  Phase 
(F ree  Cone11. )  
x 10 “ 5M b
E x t e r n a l  Phase 
x 1 0 " 5M
Recovery
%
16.1 1 0 . A 7.9 56.9
±0 . 8 ±0 . A ±2.3
2 A. 2 12.3 1 1 . 6 A9 .A
±0.5 ±0.3 ±1 .A
3 2 . 2 1A.7 1 5 . 0 A6 . 1
±1 .A ±0.5 ±2 . 1
A8.3 2 5 . 8 19.9 A7.3
±0.9 ±2 . 6 ±A.3
6A.5 37.A 2 8 . 6 5 1 . 2
±0.7 ±0.9 ±3.3
8 0 . 6 A2 . 1 35.6 A8 . 2
±A.7 ±1.3 ±2.7
C o n t r o l
A8.3 5 0 . 2 35. A 88.6
i n  b u f f e r ±6.0 ±3.9 ±8. A
a 2 9 .0  x  10 SM BSA in  0.1M phospha te  b u f f e r  (pH 7*A)  
b C o n c e n t r a t i o n  imbided in  Sephadex ge l  a f t e r  e q u i l i b r a t i o n .  
A l l  v a l u e s  mean ± S.E.M.  o f  3 d e t e r m i n a t i o n s .
E xp e r im e n ts  pe r fo rm e d  a t  20°C.
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USE OF ZONAL GEL CHROMATOGRAPHY TO STUDY THE BINDING OF DRUGS TO 
BOVINE SERUM ALBUMIN (Figs. I l l ,  1-3)
Fig. I l l ,  1 Elution Profiles of Sulphormethoxine in the presence of
Bovine Serum Albumin or Phosphate Buffer
Column : Sephadex G-25 ( f in e ) ,  20 x 1.2 cm
Sample volume : 2 ml
(24.0 x 10“~M Sulphormethoxine 
29.0 x 10”5M BSA)
BSA
80
60
Sulphormethoxine 
+ BSA (•------ -40
ulphormethoxine + Phosphate 
\  Buffer (pH 7 .4 , 0.1M) ( • -  — -♦)20
40 60 80 100 1200 20
Elution volume (ml) (5ml fractions)
Fig. I l l ,  2 Effect of Reduction of Column Length on the Elution 
Profile  of BSA-Sulphormethoxine Mixture.
Column: Sephadex G-25 (f in e )8  x 1.2 cm
Sample volume: 1 ml (24.0 x 10"5m
Sulphormethoxine; 
29.0 x 10“5m BSA)
100
BSA
80
60
Sulphormethoxine 
+ BSA40
20
0
Elution volume (ml)
Fig. I l l ,  3 Elution Profiles of C lofibrate in the presence of Bovine
Serum Albumin or Phosphate Buffer
Column: Sephadex G-25 ( f in e ) 8 x 1.2 cm
Sample volume: 1 ml (31.0 x 10 M C lofibrate;
29.0 x 10"5m BSA)BSA
Clofibrate + Phosphate Buffer 
(pH 7.4 , 0.1M)CD
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Table III, 3.
Comparison of the Percentage Binding3 of
Sulphormethoxine to Bovine Serum Albumin by Three Techniques
I n i t i a l  
SuTphonami de 
Cone11. 
x l O " 5 M
F r o n t a l  
Ana 1ys i s U l t r a f i 1t r a t i o n
E q u i 1 i b r  ium 
D i a l y s i s
%  Bound %  Bound %  Bound
7.5 74.6 74.6
± 1 . 2 ±4.8
15.0 57.5 55.4 54.1
±0.8 ±1.2 ±5.1
22.5 49.9 52.5 44.8
±1.7 . ±0.4 ±0.5
30.0 48.3 5U 1 43.1
±1.1 ± f .3 ±3.3
4 5 .0 46.1 48.1 41.6
±2.3 ±1.2 ±3.0
60.0 42.1 45.6 40.5
±1.6 ±1.3 ±2.8
75.0 40.6 45.0 41.3
±1.7 ±1.5 ±1.9
90.0 38.3 42.6 36.2
±1.1 ±0.7 ±1.2
Mean ± S.E.M.  o f  a t  l e a s t  two d e t e r m i n a t i o n s  u s i n g  a BSA 
c o n c n .  o f  29 *0  x  10” 5M.
Experiments were performed at 20°C.
Table III, 4
Comparison of the Percentage Binding9 of
Sodium S a l i c y l a t e  t o  B ov in e  Serum A1bumin by T h ree  T e c h n iq u e
I n i t i a l  
S a l i  c y l a t e  
Concn . 
x l 0”SM
F r o n t a l  
A n a l y s i  s U l t r a f i l t r a t i o n
E q u i 1i b r i u m  
D i a l y s i s
%  Bound %  Bound %  Bound
7.5 91.8 97.2
±0.5 . ±1 .3 '
15.0 93*6 91.1 94.5
±0.5 ±0.4 ±1.4
22.5 91.2 9 0 . 9 8 8 . 9
±0.4 ±0 . 7 ±0.7.
30.0 - 8 8 . 9 85.4
±0 . 1 ±0.3
45.0 87.6 8 3 . 9 80.4
±0.9 ±0 . 1 ±0.5
60.0 - 78.9 77.2
±0.4 ±0.3
75.0 77.8 75.4 75.1
±0.2 ±0.3 ±0.2
90.0 - 75.2 65.2
±0.2 ±0.7
9 Mean ± S .E .M.  o f  two d e t e r m i n a t i o n s } u s i n g  a BSA concn o f  2 9 .0
x  10" 5 m
Experiments were performed at 20°C.
Table I I 1, 5
Comparison of the Percentage Binding9 of
S u lp h a m e th o x a z o le  t o  B o v in e  Serum A lb u m in  by T h re e  T e c h n iq u e s   . 1     -
I n i t i a l  
Su lphonam ide  
Concn . 
x 10“ 5M
F r o n t a l  
A n a l y s i  s
U l t r a f i 1t r a t  ion E q u i 1 i b r i u m  
D i a l y s  i s
%  Bound %  Bound %  Bound
15 .0 6 8 . 4 6 9 .7 6 7 . 8
± 1 . 4 ± 1 . 3 ± 4 . 6
30 -0 6 5 .3 6 4 .3  . 6 4 . 0
± 0 . 6 ± 0 . 3 ± 2 .1
4 5 .0 57 .3 6 2 .6 5 8 .3
± 0 . 9 ± 0 . 4 ± 1 . 2
7 5 .0 5 4 .8 5 2 . 6 4 8 . 7
± 0 . 7 ± 0 . 2 ± 2 . 4
3 Mean ± S .E .M.  o f  two d e t e r m i n a t i o n s ,  u s i n g  a BSA co nc n .  o f
29 .O x  10"5m
E x p e r im e n ts  were  p e r fo rm e d  a t  20°C.
Table I I 1, 6
Comparison of the Percentage Binding8 of
Sulphamethoxazole to Bovine Serum Albimun by Three Techniques
I n i t i a l  
Sulphonami  de 
Concn . 
x  10“ 5M
F r o n t a l
A n a l y s i s U 1 t r a f i 1t r a t i o n
Equ i 1 i b r  ium 
D i l a y s i  s
%  Bound %  Bound %  Bound
15 .0 8 8 . 2 8 7 .3 85 -3
± 0 . 5 ± 0 . 4 ± 0 . 8
2 2 . 5 • - 85.1 84 .1
± 0 . 5 ± 0 . 9
3 0 .0 8 1 . 7 83.8 80.1
± 0 . 9 ± 0 .3 ±1 .1
4 5 .0 7 6 . 7 7 6 . 9 7 5 .6
± 0 . 6 ± 0 . 6 ± 0 . 9
7 5 .0 7 3 .7 72.0 6 6 .7
± 0 . 4 ± 0 . 4 ± 1 . 2
a Mean ± S . E . M .  o f  two d e t e r m i n a t i o n s ,  u s i n g  a BSA c o n c n .  o f
29.0 x  10"5m
Experiments performed at 20°C
Table III; 7
Comparison of the Percentage Binding9 of
S u l p h a n i l a m i d e  t o  B o v in e  Serum A lb u m in  by T h ree  T e c h n iq u e s
I n i t i a l  
Su lphonamide  
Cone . 
x 1 0 “ 5 M
F r o n t a 1 
A n a l y s i s U 1 t r a f i 1t r a t i o n
E q u i 1 i b r  i urn 
D i a l y s i s
%  Bound %  Bound %  Bound
7 . 5 2 7 .6 2 8 . 3 2 6 . 4
± 0 . 9 ± 0 . 7 ± 2 .1
15 .0 2 3 .5 2 4 . 5 2 2 . 3
± 0 . 8 ± 0 . 5 ± 1 . 4
3 0 .0 17 .4 15 .8 15-0
± 1 . 2 ±2 .1 ± 0 . 4
4 5 . 0 7 . 9 13 .9 11 .5
± 0 . 7 ± 1 . 4 ± 1 .1
a Mean ± S .E .M.  o f  two d e t e r m i n a t i o n s ,  u s i n g  a BSA c o n c n .  o f  *  -
- ' 29.0  x  10"5m,
Experiments were performed at 20°C 1
Table 111,8
3Comparison of the Percentage Binding of
Clofibrate to Bovine Serum Albumin by Three Techniques
I n i t i a l  
Cl o f  i b r a t e  
Concn . 
( x lO  5M
F r o n t a l  
A n a l y s i  s U 1 t r a f i 11 r a t  ion E q u i 1 i b r i u m  D i a l y s i s
%  Bound %  Bound %  Bound
4 5 .0 8 5 . 8 8 1 .0 80.1
± 2 . 0 ±1 .1 ± 1 . 6
6 0 . 0 8 1 . 9 8 5 .0 8 0 . 6
i,r. -*•«.. . f t* * * * * . '• • ± 1 . 5 ± 4 . 8 ± 2 . 2
75.0 7 4 .8 7 3 .2 7 0 . 3
± 0 . 9 ± 1 . 3 ± 2 . 4
90.0 6 6 . 2 6 4 . 8 6 3 . 3
± 1 . 7 ± 1 . 8 ± 0 . 9
Mean ± S .E .M.  o f  two d e t e r m i n a t i o n s ,  u s i n g  a BSA c o n c h ,  o f
2 9 .6  x  1 0 " 5M.
Experiments were performed at 20°C
- 135 -
Fig. Ill, 5
Comparison of Scatchard Plots of Data for the Binding 
of Sulphormethoxine to Bovine Serum Albumin by Three Techniques
Temp. = 20°C, pH 7.4
Frontal Analysis Data 
U lt r a f i l t r a t io n  Data
8
Equilibrium Dialysis Data5
6 Each point is the mean of at  
least two determinations.
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Fig. Ill, 6
Comparison of Scatchard Plots of Data for the 
Binding of Sodium Salicylate to Bovine Serum 
Albumin by Three Techniques
•  Frontal Analysis Data 
o U lt r a f i l t r a t io n  Data 
a Equilibrium Dialysis Data
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Table III, 10.
Binding of Salicylate to Rat Serum Proteins as determined
a
by In Vitro U lt ra f i l t r a t io n
In i t ia l
Salicylate
Cone
x l0 "5M
Unbound
Salicylate
Cone
x!0"5M
Bound
Salicylate
Cone
x10“ 5M
% Bound
r
(moles
salicy la te
bound/mole
albumin)
4.90 0.83 4.07 83.0 0.06
±0.05 ±0.03 ±0.9 ±0.0005
10.40 1.82 8.58 82.5 0.13
±0.01 ±0.03 ±0.15 ±0.0005
15.90 2.97 12.93 81.3 0.20
±0.02 ±0.15 ±0.1 ±0.002
21.20 4.32 16.88 79.6 0.26
±0.13 ±0.20 ±0.7 ±0.003
26.60 5.42 21.18 79.6 0.33
±0.09 ±0.21 ±0.4 ±0.003
All values ± S.E.M. of 3 determinations 
a At pH 7.4 and 37° C
b Rat serum albumin concentration = 4.44 g/100 ml (64.35 x 10 5M)
+0.05 + 0.725
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Fig. Ill, 7a Relationship between Unbound Salicylate and
Rat Serum Salicylate Concentration
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(individual values, albumin 
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"{mean of 3 determinations, 
albumin concn. =
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Fig. I l l ,  7b Relationship between Percentage Salicylate  Bound and
Rat Serum Salicylate Concentration
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Fig. Ill, 8a Relationship between r and Unbound Rat Serum
. Salicylate Concentration
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Fig.Ill, IQ Effect of 8 day Oral Administration of Salicylate on
T o ta l, Bound, Unbound and Percentage Bound Rat Serum 
Tryptophan In Vivo
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Discussion
Comparative Study of the Batch, Zonal and Frontal Analysis Methods of 
Gel Chromatography
The results for the study of the binding of the sulphonamide, 
sulphormethoxine, to bovine serum albumin by the batch method of gel 
f i l t r a t io n  are presented in Table I I I ,  1. For a compound which is 
sign if icantly  bound the concentration in the external phase, in the presence 
of protein,should be considerably higher than i ts  absence. This was not the 
case for sulphormethoxine, furthermore very low recovery values were obtained 
which could not be accounted for solely by experimental error. I t  is apparent 
that s ign ificant adsorption of the drug onto sephadex occurred. Estimation of 
the protein concentration in the external phase showed that there was no 
sign ificant adsorption of the protein onto the gel. The low recovery values 
demonstrated that attempts to accurately separate the internal phase from the 
external phase by the method described by Saris (1963) were unsuccessful. Not 
only was i t  d i f f i c u l t  to retain a l l  of the sephadex beads, but i t  also proved 
impossible to completely remove the external phase. The results obtained thus 
re f le c t  not only the problem of drug adsorption onto sephadex, but also the 
problem of external phase contamination of the in te r io r  phase samples. In 
similar experiments with the highly bound drug c lo fib rate  a marked adsorption 
onto the sephadex was again apparent^ (N.B. Reversible adsorption onto 
sephadex has also been demonstrated fo r  other compounds, see Gelotte, 1960, 
Pearlman and Crepy, 1967). Although such adsorption effects can be allowed 
fo r ,  to some extent, the poor reproducibility  makes any correction factor of 
questionable value. Although the batch method is po tentia lly  appealing because 
of i ts  sim plicity and faster equilibration time than equilibrium d ia ly s is ,  
because of the in tr in s ic  problems this method is c learly  not suitable for  
routine measurements of the protein binding of drugs and we therefore did not 
investigate i t  further.
The reversible adsorption of drug onto the sephadexs giving rise  
to a reduction in the degree of protein binding was also apparent in zonal 
chromatography studies using sulphormethoxine (Fig. I l l ,  1 ) .  Attempts to 
minimise this by shortening of column length (bed volume <12 cc) (Fig. I l l ,  2), 
or increasing elution ra te , appeared to reduce the degree of dissociation, but 
introduced the concommitant problem of poor separation of the elution peaks of 
protein, free drug and bound drug, thereby making interpretation d i f f i c u l t .  
Studies with other drugs; cl o fibrate (Fig. I l l ,  3 ) ,  sulphamethoxazole and 
succinylsulphathiazole also showed sim ilar dissociation e ffec ts . These results, 
which are in agreement with the findings of the batch method, demonstrate that  
sephadex adsorption and drug-protein dissociation on the column seriously  
re s tr ic t  the use of this technique for the study of reversible drug-protein  
interactions. McArthur and Smith (1968), adopted a novel approach to the problem 
by studying the binding of salicy late  to BSA, using sephadex columns of 
varying lengths, and then extrapolating the results back to a column of zero 
length. In this way they suggested that they could overcome the concomitant 
problems of drug adsorption and the d ilu tion  of the complex as i t  passed 
through the column. However, apart from being time consuming, this approach 
does have the added disadvantage that i t  is not always possible to accurately  
extrapolate back to zero column lengths. Great care is required to ensure that  
the elution profiles are not modified at shorter column lengths.
We also investigated the possib ility  that adsorption effects  could be 
reduced by the use of d if fe ren t gel f i l t r a t io n  medium. The binding of the 
drugs sulphormethoxine and sulphamethoxazole to BSA was studied using Biogel 
P2 which., uni ike sephadex, is a polyacrylamide gel. Unfortunately while less 
dissociation of the drug-protein complex was apparent, there was s t i l l  
suff ic ie n t adsorption onto the polyacrylamide to make assessment of the degree 
of binding inva lid . Certainly i t  is possible to correct for the degree of  
adsorption onto sephadex that occurs on column gel f i l t r a t io n  as Brumbaugh and
Ackers (1971) have shown using a d irect optical scanning method of columns, 
for binding studies. However the technique requires specific apparatus, is 
time consuming and the corrections are cumbersome. The zonal gel f i l t r a t io n  
method, because of the above problems was deemed unsuitable for further study.
The results for the study of the binding of sulphormethoxine to BSA 
obtained with the frontal analysis method are presented in Fig. I l l ,  4.
Elution of sulphormethoxine in the presence of BSA closely followed the elution  
of the protein. However, there was a s ligh t lag in the leading boundary 
( a region) which indicated that, some degree of dissociation of the albumin- 
sulphonamide complex had s t i l l  occurred. That this did not a ffec t the f in a l  
estimation of binding, however, was apparent from the presence of the two 
'steady-state' plateaus (3 and y ) .  The leading boundary (a region) for  
sulphormethoxine in the presence of BSA, represented the difference in elution  
profile  between the BSA and free sulphormethoxine. The nature of this leading 
boundary would suggest that the equilibrium between sulphormethoxine was rapid 
and reversible. (Cooper and Wood, 1968). The 3 plateau corresponded (within  
experimental error) to the concentration of sulphormethoxine and BSA in the 
original solution* The rate of attainment of this plateau depended to some 
extent on the degree of dissociation, and accounted for some of the non-idealised 
plateaus obtained. The t ra i l in g  boundary (y) corresponded to unbound 
sulphormethoxine. The elution p ro file  of sulphormethoxine would therefore  
appear to be in agreement with that expected from theoretical considerations 
(Nichol and Winzor, 1964; Cooper and Wood, 1968; Nichol, et al_., 1971). To 
further establish the s u ita b i l i ty  of this method the binding of four d if fe re n t  
concentrations of sulphormethoxine to BSA were studied. The results showed 
that increasing the sulphonamide concentration produced the expected decrease 
in percentage bound. (Table I I I ,  3 ). These experiments also confirmed that  
the position of the t ra i l in g  boundary (y region) which corresponded to unbound 
sulphonamide, was independent of sulphonamide concentration.
These findings substantiate the view that frontal analysis is a suitable  
method for studying drug-protein interactions. For routine measurements of 
binding i t  is only necessary to determine a s ta t is t ic a l ly  representative number 
of samples in the plateaus 3 and y (corresponding to total and free drug 
respectively). I t  is important, however, when the binding of a drug not 
previously studied by this method^is investigated,that the complete elution  
p ro file  is determined. So that the s u ita b i l i ty  of the plateau and the 
possib ility  of the dissociation of the drug-protein complex may be ascertained.
The above findings have shown that of the gel chromatography methods 
investigated, only frontal analysis is suitable for studying reversible  
drug-protein interactions.
Comparative Evaluation of the Techniques of Equilibrium Dialysis,
U lt r a f i l t r a t io n  and Gel Chromatography (Frontal Analysis) .
The physico-chemical properties and percentage bound to BSA (Table I I I ,  2) 
of the drugs selected for this study, confirmed that they satis fied  the 
selection rationale . In “Tables I I I ,  3-8, are presented the results obtained by 
equilibrium d ia lys is , u l t r a f i l t r a t io n  and frontal analysis for the determination 
of the percentage binding to BSA of the drugs; sulphormethoxine; sa licy la te ;  
sulphamethoxazole; sulphaphenazole; sulphanilamide and c lo fib ra te  respectively.
Of the three techniques studied, frontal analysis is to be theoretica lly  
preferred in that i t  determines the degree of binding pertaining in the 
original solution and is not subject to the concentration effects as in the 
case of u l t r a f i l t r a t io n ,  or d ilu tion  effects as with equilibrium d ia lys is .
Typical Scatchard plots (Scatchard, 1949) for the binding data of the drugs 
sulphormethoxine and salicy late  with the three techniques are shown (Figs. I l l ,
5 and 6 ) .  Analysis of the binding data suggested that the percentage bound value 
obtained by the three techniques were generally in good agreement. Although, 
slight differences were apparent in the values obtained by the three techniques, 
at some drug concentrations, no consistently s ign ificant differences were 
apparent for any of the drugs. Because only duplicate determinations were 
performed no detailed s ta t is t ic a l  treatment of the results has been presented. 
However, su ff ic ien t published data is available for each technique to verify  
i ts  repeatab ility . Furthermore the nature of the duplicates and preliminary  
analysis of the data by 'two-way* analysis of variance would support the 
v a lid ity  of these findings. The nature of the Scatchard plots obtained for  
sulphormethoxine and sa licy late  binding to BSA (Fig. I l l ,  5 and 6) also 
emphasised the s im ila r it ies  of binding data obtained by the three techniques.
I t  is apparent that the smaill differences observed in the percentage bound 
values did not detract from the common regression line  that could be f i t t e d  to 
the Scatchard plots. S im ilarly  good agreement was found for the other drugs
studied, when analysed by the Scatchard method. No attempt has been made 
to estimate e ither the number of binding sites (n) or the association constants 
(k) from these plots, as there were c learly  in su ff ic ien t data points to allow 
accurate regressional analysis determinations of the parameters.
The good correlation found using the three techniques for sa licy la te  
binding, disagreed with the observations of McArthur and Smith (1968). They 
reported higher percentage bound values with equilibrium dialysis than for 
u l t r a f i l t r a t io n  and fromtal analysis, however, th e ir  binding studies were 
performed a t  only one sa licy late  concentration. Recently Keresztes-Naav et a l . .  
(1972), confirmed our finding, showing good agreement for the binding of 
salicy late  by equilibrium d ia lys is , and frontal analysis. They also suggested 
that although equilibrium dialysis produced reproducible resu lts , larger 
experimental variations were apparent with this technique than for the frontal 
analysis. Some degree of support for this view might be concluded from our 
findings, but further studies would be needed to confirm th is . Cooper and 
Wood (1969) in a limited comparative study of the binding of three 
sulphonamides by equilibrium dialysis and frontal analysis also reported good 
agreement. Generally the data obtained by u l t r a f i l t r a t io n  has not shown 
serious disagreement from that obtained by equilibrium dialysis  (Steinhardt and 
Reynolds, 1969). Thus i t  can be concluded that even though the three 
techniques may a ffec t the drug-protein equilibrium to d if fe re n t  extents they 
would a l l  appear to be appropriate for measuring the protein binding of drugs 
exhibiting sim ilar physico-chemical properties to those studied here.
Preference of one technique in favour of another must therefore be made on basis 
other than the binding data obtainable by these techniques.
A serious practical critic ism  of frontal analysis and equilibrium dia lysis  
is the long experimentation times required by both techniques, Frontal 
analysis requires approximately 2 hours for each drug concentration, and
equilibrium d ia lys is , depending on the system used, from 5 to 24 hours. 
Non-equilibrium dialysis techniques (Stein, 1965; Meyer and Guttman, 1968) are 
generally fas ter, but can give cumbersome and sometimes questionable data 
analysis. Protein denaturation and bacterial contamination problems can c learly  
become manifest with such long experimental times, especially for experiments 
performed at 37° C. Frontal analysis also has the inherent problems of 
requiring large sample volumes, (although smaller volumes than used in this  
study could be employed) in order to a tta in  a 'steady-state' plateau.
In conclusion u l t r a f i l t r a t io n  was selected as the routine technique for  
further studies on protein binding because i t  was shown to produce data 
comparable with that of the other methods and to require much shorter 
experimentation times. The u l t r a f i l t r a t io n  procedure used also has the 
important advantage of easier control of temperature, and much closer 
maintenance of pH for serum or plasma studies.
In this study i t  was perhaps fortunate that none of the drugs selected 
showed any s ign ificant adsorption onto the d ialysis membrane. However, drugs 
and other compounds may bind to dialysis membrane (Klotz, 1953; Steinhardt 
and Reynolds, 1969; Meyer and Guttman, 1970,a ) .  Such adsorption phenomena 
are not easily  corrected for by 'blank1 determinations made in the absence of 
protein, for the presence of protein can s ign if ican tly  a ffec t  the degree of 
binding to the dialysis membrane (Steinhardt and Reynolds, 1969). In such 
instances adsorption problems can generally be minimised by careful preparation 
of the membrane prior to use (e.g . boiling in water, pre-soaking in de-ionized 
water, e tc . ) .  Opinion seems varied as to which is the most suitable  
preparation. Adsorption effects may possibly be overcome by the use of 
d if fe re n t  types of membrane (e.g. cellulose acetate, polyamide), although l i t t l e  
guidance is available from the l i te ra tu re  to aid the selection of an a lte rna tive  
membrane to the commonly used regenerated cellulose type. Where adsorption
phenomena cannot be reduced by pretreatment of the dialysis membrane, techniques 
not employing membranes should be investigated (e.g. frontal analysis, 
ultracentrdfugation). I t  is regrettable that no universally applicable 
technique appears to be available , and the best available approach may well 
involve a combination of methods.
Comparison of Salicylate Binding, to Rat Serum by in vitro and in.vivo
Techniques
The results presented (Table I I I ,  9) were obtained a f te r  rats were o ra lly  
dosed, da ily  for eight days with sa licy late  at e ither 10 or 20 mg/Kg body 
weight. Implantation, and removal of d ialysis sacs was performed 4 hours a fte r  
dosing. Despite the differences in to ta l ,  unbound (dialysis sac concentration) 
and bound salicy late  concentrations apparent at these two dosage leve ls ,  
no difference in the percentage bound was detectable. Although the determined 
serum albumin concentrations showed individual variation, no s ign if icant e ffec t  
of the sa licy late  on albumin level was apparent. The presence of sa licy la te  
did not appear to in terfere  with the estimation of albumin by the bromocresol 
green method.
Binding was also determined by in v itro  u l t r a f i l t r a t io n  using normal ra t  
serum to which salicy late  had been added to give a similar range of 
concentrations to that attained in the in vivo experiment. (Table I I I ,  10). A 
comparison of the binding of sa licy late  to ra t  serum by the in vivo and in v itro  
techniques showed good agreement (Tables I I I ,  9 and 10, and Figs. I l l ,  7a ,b).  
Calculated r values (moles sa licy late  bound/mole albumin), which correct for  
the small individual differences in albumin concentration, were well correlated  
for both techniques when plotted against e ither tota l or unbound sa licy la te  
concentration (Figs. I l l ,  8a ,b). The results would therefore suggest that  
in v itro  u l t r a f i l t r a t io n  gives a good re flection  of the in vivo s ituation for  
sa licy la te . However under the dosage regime employed^only a narrow 
concentration range of total serum salicy late  was achieved, such good 
correlation might not pertain at higher serum salicy late  concentrations. In 
practice higher serum concentrations may be d i f f i c u l t  to achieve without the 
concomitant problem of toxic side e ffec ts .
Serum salicy la te  concentrations for rats on the above dosage regime were
determined over a period of 24 hours (days 7-8, Table I I I ,  11; Figs. I l l ,  9a,b) 
Maximum serum concentrations were invariably reached within two hours of oral 
dosing, and although they slowly decayed over several hours, at the end of 24 
hours concentrations were low. A wide inter-animal variation in both maximum 
concentrations and h a lf- l iv e s  was apparent (Table I I I ,  11,)» 
h a lf- l ive s  were calculated assuming f irs t -o rd e r  kinetics (Bedford, et a]_., 1965 
Wagner, 1967; Cummings and Martin, 1968). From the nature of the sa licy late  
concentration-time curves in serum, i t  would appear that changes in the dosage 
regime had l i t t l e  e ffec t in reducing the rate of elimination and i t  is 
unlikely that a 'steady-state' serum salicy late  concentration was obtained. 
Although McQueen (1968) reported that sulphormethoxine attained a stable serum 
concentration, the majority of drugs appear to have shorter h a lf - l iv e s  than 
that for sulphormethoxine ( i . e .  approximately 30 hours; in man Kruger-Theimer, 
1962; Reider, 1963). I f  the attainment of a 'steady-state' plasma or serum 
drug concentration is a necessary prerequisite, then unless suitable dosage 
regimes can be employed, the application of this technique may well be lim ited .  
However, the good correlation obtained for the binding of sa licy la te  by this  
technique with that of in v i t r o ' studies, may suggest that a stable serum 
concentration, although desirable, is not essential. I t  may be that the main 
c r i te r ia  required is one of a slowly changing serum concentration at the time 
of sac removal. This time should be su ff ic ien t to allow e q u ilib r ia tio n  of 
serum and peritoneal f lu id  unbound drug concentrations,’ as well as attainment 
of equilibrium with the contents of the dialysis sac. (H ertz ler , 1919; Putnam, 
1922; Cunningham, 1926; Avey, 1963; Mattocks and El-Bassiouni, 1971). I f  this  
technique is to be widely used, information of the re la t iv e  rates at which 
equilibration is achieved between blood and peritoneal f lu id  and the peritoneal 
f lu id  and dialysis sac contents are essential. In view of the widespread use 
of peritoneal dialysis for the treatment of kidney fa i lu re  and fo r  removal of 
dialysable exogenous and endogenous poisons, i t  is surprising that more
attention has not been paid to the use of peritoneal f lu id  in re flecting  
unbound drug concentrations in in vivo binding studies.
The serum and dialysis sac contents obtained from the in vivo binding 
study were also assayed for tryptophan ( F i g .  I l l ,  lO). At both sa licy la te  
dosage levels ( i . e .  10 and 20 mg/Kg daily ) reduction in tota l and bound serum 
tryptophan occurred, but only in the case o f the unbound tryptophan 
concentration, was there any s ign ificant difference between the two sa licy la te  
dose levels. The nature of these changes was such that only the lower 
salicy la te  concentration showed a reduction in percentage tryptophan bound.
The results have shown that the presence in vivo of sa licy la te  has 
s ig n if ican tly  reduced the binding capacity of albumin for tryptophan. The lack 
of a detectable increase in free tryptophan may be due to alterations in the 
rates of metabolism or excretion of tryptophan. The differences in the free  
tryptophan level between the two dosage levels of s a licy la te , may suggest the 
importance of salicylate  concentration in affecting the metabolic fa te  of 
tryptophan. Although this remains to be v e r if ied , i t  may be of relevance in 
c lin ica l conditions of rheumatoid a r th r i t is ,  where prolonged sa licy la te  
treatment is required.
This study has therefore served as a further indication of the potential 
of in vivo dialysis in animal studies on protein binding and related  
displacement phenomena. Clearly this technique could have considerable 
potential in the study of the effects on protein binding and drug interactions  
on pharmacokinetics. Especially i f ,  as suggested by McQueen (1968), the drug 
concentration level in the dialysis sac located in the peritoneal cavity  
reflects tissue f lu id  levels . I t  should be noted however, that Keen (1970) 
has argued this is not the case because the e ffective  diameter of the pores 
in the dialysis tubing are very much less than that of cap il la ry  pores 
(Pappenheimer, 1953; Craig, et al_., 1957). The potential of the in vivo
dialysis method, would also be considerably extended i f  regular or
continual sampling of the contents of the dialysis sac during 
experimentation could be achieved. Theoretically there seems no reason why 
this should not be possible.
In summary, the techniques of equilibrium d ia lysis , u l t r a f i l t r a t io n  and 
frontal analysis have been shown to give comparable binding data fo r a number 
of drugs d iffe r in g  markedly in their(phyjsico-chemical properties. Comparison 
of the binding of salicylate  to ra t serum by in vivo dialysis and in v itro  
u l t r a f i l t r a t io n  would suggest that these in v itro  techniques give a good 
reflection  of the binding in vivo The
potential of the in vivo dialysis technique in studying the e ffec t of protein 
binding on drug action is suggested.
CHAPTER FOUR
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1 . Introduction
The determination of the protein binding of a series of s tructu ra lly  
related compounds is a potentia lly  valuable approach towards identify ing  
functional groups and forces involved in the small molecule-protein binding 
process.
The binding of a homologous series of alkyl carbamates to bovine 
serum albumin was investigated in order to determine the significance of 
l ipop h ilic  character in small molecule-albumin interactions.
U lt r a f i l t r a t io n  experiments were performed at both 37° C and 10° C to allow 
calculation of the thermodynamic parameters for the carbamate-albumin 
interaction. The alkyl carbamates studied had the general structure: 
R-0-C0-NH29 where R ranged from methyl to n-hexyl. The following were also 
included: t -b u ty l ; t -p e n ty l; t-hexyl; i-buty l and benzyl, to enable the 
effec t of branched chain and aromatic substituents on the binding to BSA to 
be evaluated. Carbamates were selected as appropriate model compounds 
because they are; stable, readily synthesised, purified and assayed, not 
ionized in aqueous solution and show a progressive increase in 
l ip o p h il ic ity  from methyl to n-hexyl. They are thus, very suitable model 
compounds, for a study of the role of the hydrophobic bonding in albumin-small 
molecule interactions. The protein binding of these short chain alkyl 
carbamates had not previously been reported, although Douglas, e t  a l .,(1964)  
and van der Kleijn (1969), have investigated the albumin binding of some 
dicarbamates.
To extend the scope of this study, the interaction of the a lip h a tic  
acetates, butyl and pentyl to BSA was also examined. Their molecular 
dimensions are sim ilar to butyl and pentyl carbamates, respectively, but the
l ip id  s o lu b il it ie s  of the acetates, as determined by partit io n  coe ff ic ien t,  
are considerably higher. I t  was hoped that a comparison of th e ir  binding, 
with the corresponding carbamates, would assist in interpreting the 
respective roles of lipop h ilic  character and molecular dimensional 
parameters, in the binding process.
The poss ib ility  that the carbamate-albumin in teraction, might induce 
conformational changes in the albumin structure was also investigated by 
u ltra v io le t  (uV) difference spectra (Herskovits, 19674 Polet and 
Steinhardt, 1968) and fluorescence studies.
Experimental Approach
All u l t r a f i l t r a t io n  studies of the carbamate-BSA (Cohn fraction V) 
binding were performed at both 37° and 10° C, while acetate binding studies 
were only determined at 10° C. Because of the problems associated with the 
low s o lu b il ity  i t  was not possible to use concentrations of carbamate in 
excess of lOmM, or to use straight chain homologues higher than n-hexyl 
carbamate. The detection l im it  of the GLC assay dictated that s tarting  
concentrations of carbamate lower than 1 mM, could not be used fo r the 
binding studies. In addition to th e ir  low s o lu b il i ty ,  the acetates were 
too v o la t i le  to be s a t is fac to r ily  studied at 37° C, therefore the binding of 
butyl and pentyl acetates was only measured at 10° C. The centrifuge tubes 
were routinely capped during the u l t r a f i l t r a t io n  to prevent losses by 
evaporation.
In the preliminary studies the concentration inside the bag a f te r  
u l t r a f i l t r a t io n ,  was also determined. This was discontinued as the presence 
of protein tended to deteriorate the performance of the GLC column used fo r  
carbamate assay. Controls in the presence of buffer (0.15 M phosphate), were 
routinely run, however, no s ign ificant binding to the dialysis membrane was
- 159 -
apparent for any of the compounds studied.
U ltrav io le t  difference spectra and fluorescence studies of the 
carbamate-albumin interaction were performed as described in Chapter Two. 
For these studies BSA solutions (2 x 10 5M in e ither 0.15M phosphate or 
tris-HCl buffer, pH 7.4) were t i t ra te d  with successive volumes ( y l . )  of
carbamate solution (lOmM in appropriate bu ffer).
*
Results
Table IV,1.
Relationship between the Percentage Carbamate Bound 
to Bovine Serum Albumin9 and Apparent Partition  
Coefficient for the series R-0-C0-NH2
R Group
Apparent 
Octanol/Buffer 
Partition  Coefficient
% Boundb
Methyl 0.22 5.47+0,15
Ethyl 0.70 10.47+0,15
n-Propyl 2.30 19.03+0.13
n-Butyl 7.10 33.2+1,70
n-Pentyl 22.50 41.80+1.33
n-Hexyl 70.80 64.33+0.33
t-Butyl 3.00 16.93+0,87
t-Pentyl 8.72 25.33+0.88
t-Hexyl 27.5 30.67
+0,93
i-Butyl 4.36 29.17+0.60
Benzyl 17.60 45.53+0,37
a0.29 x 10~3 M BSA in 0.15 M phosphate buffer (pH 7.4}
b Mean + S.E.M. of at least 3 determinations, using 1 x 10"3 M carbamate
solutions
U lt r a f i l t r a t io n  and partit io n  coeffic ient determination performed at 
37°C [pH 7 .4 ) .
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Fig. IV, 1.
The Relationship between Percentage Carbamate Bound 
to Bovine Serum Albumin and Apparent Partition  
Coefficient for the series R-Q-CO-NHq
Ejt Pr^  Byt P^ n Hpx
H  i H  r \
t-But i-But t-Pen Ben t-Hex
Me
R = L .
100
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In i t ia l  Carbamate
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0.1 10 100
Apparent Partition Coefficient (Octanol/Buffer)
Eqn. of regression l in e : -  log (% bound) = 0.40 (+0.12) log P + 1 .0 8  (+0.12); 
n = 11 (no. data points); r = 0.96 (corr. c o e ff ic ien t);  s = 0.27 (S.D.)
Figures in parentheses are S.D. of constants.
Sc
at
ch
ar
d 
Pl
ot
s 
of 
Da
ta 
fo
r 
the
 
Bi
nd
in
g 
of 
Ca
rb
am
at
es
 
to 
Bo
vi
ne
 
Se
ru
m 
Al
bu
m
in
4->fC
S-
CU4->
CU~o
CO
<4-O
CO
S- O
O O
CO
o cuQ.
in o 
tO *1- 
CU M-
Q.
cr> cu 
cu oC£ OLi_
CM
oCO
i . W e O L  X  i Q / - l
to+->c
cutocus-
Cl
CUS-
o
Q .
OO
co
+->n3
4-> fC
5- 4-5
4 -  (O
5-. 4-5
CM
CO
CU4-5 rtJ
E
(13jQ
5- fCo
co•1—
4->CO Oi— CO
CU •S- oS-.o IIo 4-5
sz co cu•1— •1—
to (J
to •P”
CU 4 -S- <4-cn a)cu o
DC. o
LO
CM
O
un
o
LO
o
i -WeOL x i a /J
Sc
at
ch
ar
d 
Pl
ot
s 
of 
Da
ta 
fo
r 
the
 
Bi
nd
in
g 
of 
Ca
rb
am
at
es
 
to 
Bo
vi
ne
 
Se
ru
m 
Al
bu
m
in
— 00
COco
• r “-P
rdc
•I—
E
s-
CU4->
CL)•o
CO
4 -O
cfOcu
to
+->ccu
COcu
s-
Q .cu
s-
■pc
•r~O
CL
u
COcu
o
o
I"-
CO
•p
rd
co
•r~
•P
COS-
•P
4 -
rds-
+->
cu
•P
rd
E
rdjQ
S -
rd
O
cu
lo
CD
cu+->
rd
E
rd
s-
rd
C_>
CU
jC
I
•P
CO
•I—
Ll .
CO
oo
o
II
-pccu
•I—u
+J q_ 
rd 4 -cu cu o  s- o  s- o  o
co
CM
00 CO CM
e0L x ^Q/-*
o
CO
4 -
4 -
o
CM
O
LOCO OO
CM
£0L X ± Q / J
Fig. IV, 6 Scatchard Plot of Data for Binding of Benzyl
Carbamate to Bovine Serum Albumin
Temp = 37°
Each point represents mean of
3 determinations
Regression Correlation  
Coefficient = 0 .9 7
2 3 4 5
r
Table IV, 2.
Binding Data fo r the In teraction o f A liphatic  
and Aromatic Carbamates with Bovine Serum 
Albumin at 37u C
Carbamate
a
k x 103 m" 1
a
n
a
nk x 103i\iT 1 Regression
Correlation
C oeffic ient
Methyl 0.18 1.28 0.23 0.80
±0.03 ±0.12 ±0.01
Ethyl 0.31 1.74 0.53 0.93
±0.05 ±0.17 ±0.03
n-Propyl 0.13 6.69 0.87 0.84
±0.02 ±0.67 ±0.04
n-Butyl 0.47 5.60 2.63 0.55
±0.16 ±1.64 ±0.82
n-Pentyl 0.85 4.40 3.74 0.85
±0.13 ±0.44 ±0.17
n-Hexyl 5.80 3.30 19.14 0.83
±0.89 ±0.36 ±0.88
t-Butyl 0.16 4.38 0.70 ' 0.62
±0.04 ±0.77 ±0.07
t-Pentyl 0.11 9.82 1.08 0.61
±0.04 ±2.29 ±0.11
t-Hexyl 0.49 4.27 2.09 0.76
±0.10 ±0.64 ±0.20
i-B utyl 0.56 3.66 2.05 0.75
±0.11 ±0.56 ±0.23
Benzyl 0.78 5.20 4.06 0.97
±0.12 ±0.51 ±0.51
a Mean ± S.E.M ., determined by regression analysis of a minimum
of 21 data points
n Number of binding sites
k Apparent association constant
nk Scatchard plot intercept at r  = 0 , termed here the ‘apparent
binding constant1
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Fig. IV , 9 . Fluorescence Spectra of Bovine Serum Albumin 
in the Presence of the A liphatic  Carbamates
  Emission maxn. 340nm obtained with BSA
alone and BSA plus methyl — ^ b u ty l, or 
benzyl carbamates
—  Emission maxn. 336nm obtained with BSA 
plus pentyl or hexyl carbamates
Excitation wavelength, 290nm
BSA concn 2 x 10“5 M in 0.1M Phosphate
bu ffer, pH 7.4
Carbamate/Albumin ra tio :
40 —
B lue-sh ift 
H  (4nm)
<U 20
B lue-sh ift
Li-
280 300 320 340 380360 400 420
Emission wavelength (A em)
- 174 -
Table IV, 7
Interatomic Distances fo r the Carbamate Series
R Group
Approx. 
Interatomic 0 
Distance (A)
Methyl 5.25
Ethyl 6.57
Propyl 7.89
n-Butyl 9.21
n-Pentyl 10.53
n-Hexyl 13.74
Benzyl 9.55
a Interatomic distances calculated assuming:-
and
^-------5.25A----------- *  ^-2.64A-^
H
/ N\  / ° \ ^ H 
h Nc r
o H
from data in Korolkovas (1970)
Discussion
The series o f carbamate homologues demonstrated a regular increase 
in lip o p h ilic ity , as measured by th e ir  octanol/buffer p a rtitio n  
co effic ien ts . The increase in log P (logarithm of p a rtitio n  co e ffic ien t)  
or Hansch n constant (Hansch and F u jita , 1964), fo r the addition of a 
methylene group was found to be 0 .5 , which was reduced to 0.4 and 0.2  
respectively, when primary and secondary branching occurred. The aromatic 
ring of benzyl carbamate was found to possess approximately the same 
l ip o p h ilic ity  as the n-butyl group. These values are in good agreement 
with theoretical values (Hansch and Dunn, 1972). The regular increase in 
l ip o p h ilic ity  fo r the series demonstrated that e ith er no s ig n ific a n t in te r -  
or intramolecular carbamate associations v/ere invo lvedor th a t they.were 
constant fo r the series, since such effects would detract from th e ir  lin ear  
relationship (see Materials and Methods, Chapter Two).
For the binding of ImM carbamate solutions to BSA (0.29mM, Cohn 
Fraction V ), an increase in the percentage bound was found to accompany an 
increase in chain length (Table IV , 1 .) .  When plotted as logarithmic  
functions the percentage bound correlated well with the apparent p a rtitio n  
co effic ien t fo r the series (Fig. IV , 1, regression correlation c o e ffic ie n t, 
= 0 .96 ). I t  would appear, at least under the experimental conditions used, 
that this correlation is also va lid  fo r the branched chain and aromatic 
carbamates. I t  is important that even the ImM carbamate concentration 
(the lowest concentration which could be re lia b ly  detected) represents a 
re la tiv e ly  high carbamate/albumin molar ra tio  (3 .4 5 :1 ), a fac to r  
predisposed to lower percentage bound.
The binding of the carbamate series to BSA was investigated over the 
concentration range (1 -  7.5mM), and the data evaluated by the method of 
Scatchard (Scatchard, 1949). A typical Scatchard plot fo r the binding of
the carbamates: methyl, propyl, t-h exy l, hexyl and benzyl is shown 
(Fig IV , 2 -6 ). For a ll the carbamate studies, except hexyl, a s tra ight 
line  p lot was obtained, but fo r hexyl carbamate the p lot was more d i f f ic u l t  
to in te rp re t. Graphical presentation of the data (Fig. IV , 5) implied 
curvature possibly indicative of more than one class of binding s ite . On 
evaluation of th is data by non-linear regression computer analysis, however, 
i t  could not be c learly  resolved into more than one lin e . This difference  
probably resulted from the unequal d istrib u tio n  of the experimental data, 
that is the lack of experimental data v:,at high r values (moles carbamate 
bound/mole albumin). The presence of more than one class of binding s ite  
could, therefore, not be v e rif ie d . In view of th is , the computer resolved, 
single regression line  was used fo r the determination of binding.parameters.
However, i f  the Scatchard p lot is tru ly  non-linear i t  could be 
attribu tab le  to e ith er the presence of more than one d is tin c t class of 
binding s ite  or to negative cooperativity effects (Conway and Koshland,
1968; Lai ken and Nemethy, 1970a). This negative cooperativity could be due 
to e ith er protein conformational changes which may occur on binding, or the 
binding of the in i t ia l  carbamate molecules in te rfe r in g , possibly by s te ric  
repulsion phenomena, with the binding of subsequent molecules.
In Table IV , 2, are presented the mean values obtained fo r the apparent 
association constant (k ) , number of binding sites (n ), nk (the in tercept 
value, on the Scatchard plot at r = o, termed here the apparent binding 
constant) and the regression correlation coeffic ien ts . I t  can be seen that 
fo r the s tra ight chain alkyl carbamates an increase in the term nk 
accompanied an increase in chain length fo r the series. On closer analysis 
the data revealed important differences in the number of binding sites (n ), 
and the apparent association constant (k ) , between methyl and ethyl
compared with the higher homologues propyl, bu ty l, pentyl and hexyl. For 
the homologues propyl to hexyl, an increase in k and a corresponding decrease 
in n, accompanied incremental changes in chain length. However for methyl 
and ethyl carbamate, the n values were found to be considerably lower than 
fo r the longer chain length homologues, while the k values corresponded 
closely to propyl and butyl carbamate respectively. Such differences could 
not be explained by experimental e rro r. For the branched chain te r t ia ry  
carbamates (Table IV , 2) a progressive increase in nk and k values 
accompanied an increase in chain length.
A p lo t of log. k (association constant) against log. P (p a rtitio n  
coeffic ien t) fo r propyl n -bu tyl, n-pentyl and n-hexyl indicated a good 
correlation fo r these homologues. Benzyl and t-buty l carbamates also 
correlated well with th is lin e , but methyl, e th y l, i-b u ty l, t-penty l and 
t-hexyl carbamates did not (Fig. IV , 7 ). The anomalous position of methyl 
and ethyl carbamates is well demonstrated, both showed much higher 
association constants than was expected from th e ir  p a rtitio n  coe ffic ien ts .
A plot of the apparent binding constant (nk) against p a rtitio n  c o e ffic ie n t, 
however, produced a good correlation (Fig. IV , 8 ) , even when methyl and 
ethyl carbamates were included. While a p lo t of association constant (k) 
against p a rtitio n  co effic ien t did not indicate such a relationship  (c f.
Figs. IV , 7 and 8 ). The importance of the term n is c learly  demonstrated.
The poor correlation of the association constant with l ip o p h ilic ity , and 
the variation in the number of binding sites would suggest that the nature 
of the carbamate-albumin in teraction is non-specific. For the re lationship  
between nk and p artitio n  co e ffic ien t, the te r t ia ry  carbamates showed a small 
divergence from the regression lin e , whereas i-b u ty l carbamate was-well 
correlated. Whether th is divergence fo r the te r t ia ry  carbamates was 
s ig n ifican t could not be v e rifie d . The role of s te ric  factors in the 
carbamate-albumin in teraction although perhaps indicated, could not be
shown conclusively, but in support o f this p o ss ib ility  Arvidsson et al_. (1971), 
have demonstrated reduced association constant values fo r branched-chain 
members of a series of long chain carboxylic acids.
I t  is important to note that whichever binding parameter was selected 
( i .e .  percentage bound, k and nk) benzyl carbamate correlated well with that 
expected from its  p a rtitio n  co e ffic ien t. The contribution of the aromatic ring  
would therefore appear to be largely one of an enhanced lip o p h ilic ity . The 
above good correlations of binding parameters with lip o p h ilic  character would 
strongly suggest that the carbamate-BSA in teraction is hydrophobic in  nature.
In order to substantiate th is , binding experiments at 10° C were performed fo r  
several carbamates; e th y l, pentyl, butyl and hexyl. An increase in the 
binding parameters (percentage bound, k, nk, and n) was observed at the lower 
temperature (Table IV ,3 ). A sim ilar increased value for the binding parameters 
(n and nk) has been reported for a series of p-hydroxybenzoic acid esters 
(P a te l, e t al_., 1968). A s lig h tly  increased curvature o f the Scatchard plots 
fo r both pentyl and hexyl was observed, however, the significance of th is  
cannot be deduced.
The thermodynamic parameters, free energy AG; enthalpy AH; and entropy 
AS,;were calculated (Daniel and A lberty, 1966) (Table IV ,4 ) . The free energy 
(AG) and enthalpy (AH) changes accompanying the binding were negative in a ll  
cases, indicating a favourable spontaneous exothermic in terac tio n . The 
positive entropy (AS) changes associated with the binding are compatible with 
an in teraction involving hydrophobic bonding. Such changes have been ascribed 
to the disruption of the 1ice-berg1 structure of water, around the hydrocarbon 
groups in aqueous solution (Frank and Evans, 1945; Kauzmann, 1959; Schachman, 
1963; Molyneux and Frank, 1969). A1ternatively the binding could involve 
in teraction of the carbamate with p artia l c lathrate  cages surrounding the 
apolar residues on the albumin surface (K lotz, 1958). This would not seem un­
lik e ly  however, for binding by the clathrate  mechanism would probably require  
a substantial negative enthalpy, whereas the enthalpy values found fo r the
carbamate binding, although negative, were re la tiv e ly  small.
As a resu lt of the carbamate-albumin in teraction increased rotational 
freedom of the carbamate and/or albumin, conformational changes in the 
albumin and/or carbamate, and increased translational freedom in the albumin 
might occur. Such affects would be consistent with the increased entropy 
(Aranow and Witten, 1960; Steinberg and Scheraga, 1963; O 'R e illy , 1969).
Hydrogen bonding has been stressed as a major factor determining the 
values of the physical properties of the insectic idal carbamates (Hadaway, e t a l . 
1970). However, i t  is  probably not a major determinant fo r the carbamate- 
albumin in teraction , fo r i f  th is were the case the lower carbamates would be 
expected to bind disproportionately well in the series studied. I f  the binding 
of the a lip h atic  group to BSA is prim arily  determined by lip id  s o lu b ility  then 
more lip o p h ilic  compounds with s im ilar molecular dimensions should show an 
enhanced binding. Replacement of the amino group in carbamates, by a methyl 
group as in acetates would be expected to increase lip id  s o lu b ility  without 
s ig n ific a n tly  a lte rin g  molecular dimensions. Sim ilar chain length acetates 
should therefore resu lt in an increased binding compared with the corresponding 
carbamates because of th e ir  higher lip id  s o lu b ility . A comparison of the 
binding of butyl and pentyl acetates with butyl and pentyl carbamates, showed 
this to be the case (Table IV ,5 ), although the percentage bound values for the 
acetates were not as high as would have been predicted from th e ir  p a rtit io n  
coeffic ien ts . These results further im plicate the importance of lip o p h ilic  
character in albumin binding. The p o ss ib ility  of a contributary ro le of 
molecular dimensional parameters in hydrophobic bonding must await fu rther  
investigation.
The apparent association constants found fo r the carbamates are of 
sim ilar magnitude ( i . e .  x lO3^ -1) to those reported for other short chain 
neutral compounds (Steinhardt and Reynolds, 1969).
The hydrophobic binding regions responsible fo r carbamate in teractions may 
involve apolar groups or cluster of groups on the surface or in  crevices of the 
protein (Steinhardt and Reynolds, 1969; Tanford, 1972). Hydrophobic 
interactions may also occur in the in te r io r  of the protein . Possible amino 
acids involved at these binding sites could be:- alanine, leucine, 
phenylalanine, tryptophan, isoleucine, methionine, proline and cysteine.
The low n values (number of binding s ites) for methyl and ethyl carbamate 
do not obey the relationship apparent fo r the higher s tra igh t chain homologues. 
I t  is possible that the very low percentage binding fo r methyl and ethyl might 
be a factor influencing th e ir  anomalously low n values. Binding studies using 
considerably higher albumin concentrations might c la r ify  th is . However, other 
hypotheses can also be proposed:- i t  might be that the binding s ites fo r methyl 
and ethyl are located in d iffe re n t regions of the protein from the binding 
sites for the higher homologues. Their h ydrop h ilic -lip oph ilic  balance could, 
for example, favour in teraction with binding sites on the protein surface, in  
contact with the aqueous phase. Whereas the higher homologues might penetrate 
into the protein in te r io r , or surface crevices. A lte rn a tiv e ly , small 
hydrophobic regions which lim it  binding of chain lengths in excess o f ethyl 
carbamate, could e x is t, according to Tanford (1972) th is  is , however, 
un like ly . Competitive studies should resolve whether methyl and ethyl and the
higher analogues share common binding s ites .
The observed decrease in the number of binding sites from propyl to 
hexyl carbamate may imply a common binding region of the protein fo r these 
homologues. An increase in the hydrocarbon chain length has been previously 
postulated, on theoretical grounds, to accompany a decrease in the number of 
binding sites fo r a lip h a tic  compounds on albumin, (Steinhardt and Reynolds, 
1969). I t  has been suggested that not a ll the carbon atoms in the hydrocarbon 
chain of a compound needs to be involved in its  protein binding, and even
contiguous methylene groups may not necessarily in terac t (Laiken and Nemethy,
1970a9b9:1971; Tanford, 1972). However, i t  remains to be demonstrated whether 
a ll or only part of the carbamate-hydrocarbon chain is involved in th e ir  
in teraction with BSA. I t  is possible that the binding interactions id en tifie d  
by the n values may not represent specific  classes of binding s ite ,  
a lte rn a tiv e ly  they may re fle c t binding areas constituting several types of 
s ite s , (Laiken and Nemethy, 1970a,b; 1971).
The relationship between the number of binding sites (n) fo r the 
carbamates propyl and hexyl, and chain length d iffe rs  in some respects from 
that reported for s im ilar chain length alkyl carboxylic acids (Teresi and Luck, 
1952, Table IV , 6 ) . The number of binding sites for these short chain 
carboxylic acids showed in s ig n ifican t variation  with chain length. Although 
th is  contrasts with the relationship found fo r the carbamates, some 
s im ila r it ie s  in n values for the two series are apparent. The reason for the 
d iffe re n t relationship between the number of binding sites and chain length, fo r  
the two series is unclear. However, i t  is of in teres t to note that fo r long 
chain anions e .g . dodecyl1 sulphate, the n value increased with increase of 
chain length (Ray et _al_., 1966; Steinhardt and Reynolds^ 1969 ) . I t  would also 
appear that the presence of an ionizable carboxyl group had l i t t l e  e ffe c t on 
e ith er the association constant (k) or the free energy (AG) of in te rac tio n . 
(Table IV , 6 ) . The binding of these short chain carboxylic acids would 
therefore appear to be largely governed by the lip o p h ilic  character of the 
side chain. I t  remains to be determined whether these short chain carboxylic 
acids and carbamates bind to the same s ite (s ) on albumin.
The Effect of Carbamate Binding on Albumin Difference Spectra and
Fluorescence
Wetlaufer and Lovrien, (1964) have suggested that a protein in teracting  
with a hydrocarbon should show evidence of structural change (optical 
ro ta tio n , uv difference spectra e tc .) i f  the binding takes place in the 
in te r io r  of the protein , but not i f  only the surface is involved. iVkova, e t a l . 
(1971) have shown that while the binding of iso-butanol to the in te r io r  of 
BSA produced marked conformational changes as determined by fluorescence, 
binding to the surface of the protein did not.
The p o ss ib ility  that observed differences in n values for methyl and 
ethyl and the higher homologues, might represent differences in  the location of 
the binding s ite  (e .g . surface or in te r io r  of the protein) was studied.
Possible induced conformational changes were studied by the techniques of uv 
difference spectrophotometry and fluorim etry.
No alterations in the uv> difference spectra of the albumin was apparent 
when i t  was t itra te d  with any of the carbamates, despite using a wider range 
of carbamate/albumin molar ra tio  than that used in the u lt r a f i l t r a t io n  study 
(3.5 -  35 molecules carbamate/albumin). The lack of observable perturbations 
of the albumin uv difference spectra on addition of the carbamates would 
imply that e ither conformational changes within the protein did not occur, or 
that they were so s lig h t as not to be detected by th is  technique. I t  may be 
relevant that in most studies where perturbations have been demonstrated with 
th is technique, high concentrations of long chain highly bound anionic 
compounds (r(moles bound/mole albumin)>5) have been necessary. Few studies 
with neutral compounds appear to have been performed (Ray, e t al_., 1966). 
Although Polet and Steinhardt (1968) have shown that octanol a t high r  values 
produced sim ilar effects on the phenylalanine and h istid ine  residues to those 
produced by the long chain anions.
No quenching of albumin fluorescence was observed with any of the carbamate 
homologues. However for homologues higher than butyl a 4nm s h ift  to a lower 
emission maximum (blue s h ift )  was observed (Fig. IV , 9 ). Blue spectral 
sh ifts  in the emission wavelength have also been reported for the binding of 
other compounds to BSA (Lenz, 1969; Lenz and Steinhardt, 1969; Halfman and 
Nishida, 1971, Steinhardt e£ al_. 9 19711). Spector and John (1968), showed 
that the binding of some carboxylic acids to BSA-also produced blue sh ifts  of 
the fluorescence emission.; They found that for the homologous series up to 
caproic acid no blue s h ift  could be detected, although the la te r  compound did 
produce s lig h t quenching. For higher analogues, however, blue sh ifts  of 
approximately 4nm were obtained. These higher analogues also showed increased 
fluorescence quenching. A fter caproic acid fu rther increase in  chain length 
did not produce increased quenching. I t  is important to note that Spector and 
John (1968), used an excitation wavelength of 280 nm in th e ir  study. At th is  
wavelength the emission spectra w ill contain a s ig n ifican t contribution from 
the amino acid tyrosine, as well as the major contribution from the amino acid 
tryptophan. In our carbamate studies, an excitation wavelength of 290nm, the 
maximum excitation wavelength fo r the protein , was used. A small contribution  
from tyrosine may occur; under these conditions.
Halfman and Nishida (1971) who investigated the binding o f dodecyl 
sulphate to BSA, suggested that the fluorescence a lterations in BSA proceeded 
in two stages. The binding of the f i r s t  four equivalents resulted in  tryptophan 
quenching, w h ils t subsequent additions produced blue sh ifts  in the tryptophan 
emission and increased fluorescence in ten s ity . They suggested th a t quenching 
was probably due to the influence of binding on the state of ion ization  of 
e-amino groups in the immediate v ic in ity  of a tryptophan. Whilst the blue s h if t  
and enhanced fluorescence in tensity  was caused by an increase in  the hydrophobic 
environment of the tryptophan residue on binding. L i t t le  influence on tyrosine 
occurred. Steinhardt e t a jk , (1971) obtained s im ilar findings and showed th a t
the degree of blue s h ift  fo r these compounds increased with r  (moles bound/ 
mole albumin). They also showed that the binding of hexyl sulphate to HSA 
and octyl sulphate to BSA produced neglig ib le effects on tryptophan and 
tyrosine fluorescence in ten s ity , although blue sh ifts  in emission wavelength 
did occur. The degree of blue wavelength sh ifts  fo r these small chain anions 
was less than for the long chain. Few studies have been performed on the 
effects of neutral compounds on albumin fluorescence (Ivkova, e t al_., 1970).
The spectral sh ifts  obtained for the carbamates could possibly occur by 
sim ilar mechanisms to those produced by long chain alkyl anions and/or fa t ty  
acids. However anomalies such as lack o f fluorescence quenching and 
enhancement effects have to be explained. For i f  the blue s h if t ,  apparent fo r 
the carbamates higher than butyl, is due to e ith er s im ilar environmental or 
conformational changes around the tryptophan or tyrosine residues, then 
effects on fluorescence in tensity  would have been expected.
Carbamate-Albumin Interaction: a possible model to account fo r the 
fluorescence observations
Steinhardt et. a K , (1971), have suggested a model fo r the observed 
spectral sh ifts  in  both uv difference and fluorescence spectra with long 
chain alkyl anions. Modification; of th is  theory would account fo r most of the 
effects produced by the carbamates.
I t  is suggested that the blue s h ift  is a resu lt o f the carbamates 
(pentyl and hexyl) binding to a hydrophobic region with one s ite  s u ff ic ie n tly  
near to an exposed tryptophan for the hydrocarbon ta i l  to cover the tryptophan. 
I f  th is  is the case then for the carbamate structure R-0-C0-NH2 an R chain
p
length of five  methylene groups (approx. 5.28A) is required to cover the
tryptophan. That benzyl carbamate does not produce the blue s h if t  would tend
o
to support th is  (approx. 4.30 A, Table IV , 7 ). An a lte rn a tive  explanation
might be that the lower homologues bind to d iffe re n t hydrophobic regions on 
the protein , from pentyl and hexyl carbamate. While the lower homologues 
may bind to surface sites on the protein , the binding of pentyl and hexyl 
carbamate possibly en ta ils  in teraction with sites embedded in  the protein  
structure. Surface binding would not be expected to e ffec t tryptophan 
fluorescence (Ivkova, et aj_., 1971). This may explain the anomalously low n 
values (number of binding s ites ) for methyl and ethyl carbamate,but i t  would 
not appear to account for the correlation between the n and k values for 
propyl, butyl and benzyl, and those of pentyl and hexyl.
To account fo r the lack of fluorescence enhancement on binding, the model 
for the hydrocarbon ta i l  covering tryptophan requires incorporation of the 
concepts of p artia l s ite  occupancy and d iffusion from s ite  to s ite . With 
diffusion times less than the life tim e  of the excited states (3-6 nano secs .). 
Only a few sites nearest the one which perturbs tryptophan need to be nearer 
than about 10$ away from i t ,  i f  the activation energy required is  that o f a 
diffusion-contro lled  process (Weber, 1970). I t  has been suggested 
(Steinhardt, et al_., 1971) even for compounds with high association constants, 
diffusion from occupied to unoccupied sites may occur in times substantia lly  
lower than the 10 8 sec. required fo r fluorescence.
The lack of quenching of the tryptophan fluorescence in binding of the 
carbamates, would imply that e ith er in s ig n ifican t or undetectable protein  
conformational changes were produced on binding. I t  should be noted th a t in  
order fo r conformational quenching effects to occur changes in the spatia l 
relationships of v ic inal sulphydryl. e-amino, a-ammonium groups or disulphide 
links to the excited state of tryptophan would be required (Cowgill, 1967; 
Shinitzky and Fridkin , 1969; Longworth, 1970).
The model would therefore give a t least a p a rtia l explanation to
observations fo r carbamate/albumin in teractions. The results suggest that a 
difference in degree of penetration of the protein structure may occur in the 
series. Such difference could possibly be resolved by competitive studies and 
the use of more sophisticated techniques (e .g . CD, NMR).
Summary
Our study of the carbamate/albumin in teraction has demonstrated the value 
of these re la tiv e ly  simple compounds as models fo r studying hydrophobic 
bonding. The use of the homologous series o f carbamates has permitted 
determination of the contribution to the free energy of association, from both 
a lip h atic  and aromatic groups, as well as the e ffe c t of branching of the 
a lip h a tic  side chain on the free energy of association. From these reuslts  
the AG values of the a lip h a tic  or aromatic groups can be calculated. Such 
values have been found to be in reasonable agreement with the values derived from 
models on the aqueous s o lu b ility  of the hydrocarbons (one >H2C...CH2 < in te r ­
action liberates approx. 0.62 Kcals/mole, Nemethy and Scherga (1963) reported 
0.7 Kcals/mole). Such values should be applicable to drug-protein interactions  
involving mixed forces, fo r theoretical assessments o f the contribution from 
hydrophobic forces to free energy o f in teraction . Application o f th is  to a 
comparison of the carbamates binding data with that published fo r the 
carboxylic acids (Teresi and Luck, 1952), demonstrated th a t the presence o f an 
ionizable group in these short chain carboxylic acids appeared to have l i t t l e  
e ffe c t. A s ig n ifican t contribution to the free energy of association would 
appear therefore to be from hydrophobic bonding. This study provides some 
information on the mechanism of hydrophobic in teractions, and reveals that fo r  a 
homologous series of short chain compounds, the number of binding sites (n) and 
association constant (k) fo r in teraction with BSA, may not obey the expected 
trend fo r a ll members. Divergence from such a trend is possibly a function  
of the compounds hydrophobic-hydrophilic balance. For such systems as the
carbamate-albumin, the term s ite  as defined by m ultiple equ ilib rian  theory 
may be inappropriate. Rather the concept o f the s ite  as a binding area 
which serves as a point of attachment fo r a single functional group or segment 
of the ligand, is to be preferred (Laiken and Nemethy, 1970a). Although 
in teresting differences in the e ffec t on albumin fluorescence are apparent 
fo r the series, i t  is un likely that any of the carbamates studied produced 
s ig n ifica n t conformational changes in the albumin molecule.
CHAPTER FIVE
I N V E S T I G A T I O N  OF  T H E  P L A S M A  
P R O T E I N  B I N D I N G  OF  W A R F A R I N  
U S I N G  A F L U O R E S C E N T  P R O B E  T E C H N I Q U E
Introduction.
The previous chapters have demonstrated the s u ita b ility  of 
the classical techniques: equilibrium d ia lys is , u lt r a f i l t r a t io n  and 
frontal analysis gel f i l t r a t io n  in studying protein binding 
and revealed the nature of the information that can be obtained, 
from these techniques, about small-molecule protein in teractions.
I t  is apparent from these studies that the information obtainable is  
largely of a quantitative nature and other techniques must be used 
i f  a q u a lita tiv e  insight into the binding process is required. 
However, techniques are available which can provide both quantita tive  
and q u a lita tive  information on drug-protein interactions (e .g . 
c ircu lar dichroism, nuclear magnetic resonance and the fluorescent 
probe techniques).
The use of fluorescent probes stems from the early  work of 
Weber and Laurence (1954) who demonstrated that several a n ilin o ­
naphthalene sulphonates and an iline  acridines, which were v ir tu a lly  
non-fluorescent in aqueous solution, exhibited marked enhancement of 
fluorescence in non-aqueous solvents or when bound to prote in . I t  
was la te r  shown that these fluorescent probes bind to hydrophobic 
sites on the protein molecule, through non-covalent bonds. These 
compounds have found considerable use as probes of the p o la rity  of 
binding s ites,as well as indicators of protein conformational changes 
occurring a t the binding s ite  (McClure and Edelman, 1966; Daniel 
and Weber, 1966; Weber and Daniel, 1966; S tryer, 1968; Radda, 1971; 
Brand and Gohlke, 1972). The most commonly used probe has been 
l-anilino-8-naphthalene sulphonate (ANS), although recently the
fluorescent probe potential of b io lo g ica lly  important tetracyclines  
(Popov et 1971; 1972), kynurenine (Churchich, 1972) and b iliru b in  
(Krasner, 1973) has been demonstrated. There is , however, an obvious 
need fo r s tru c tu ra lly  d iffe re n t fluorescent probes of biological 
significance. Chignell (1970a, b ), has reported that the binding 
of the anticoagulant drug warfarin to serum albumin resulted in a 
marked increase in the fluorescence y ie ld  of the drug, accompanied 
by a hypsochromic (blue) s h if t  in its  emission maximum. However 
the potential of warfarin as a fluorescent probe does not appear to 
have been further u tilis e d .
The binding of warfarin to human serum albumin has been 
widely studied (O 'R e illy  and Kowitz, 1967; Solomon and Schrogie, 1967; 
Solomon et al_., 1968; O 'R e illy , 1969; O 'R eilly  et_ al_., 1969; Perrin  
and Nelson, 1972) however, the in teraction of warfarin with albumin 
from d iffe re n t species has not (Meyer and Guttman, 1970b; O 'R e illy  
and Motley, 1971). In view of the established procedure fo r testing  
drugs in vivo in rodents, but examining th e ir  protein binding 
characteristics with bovine albumin preparations before c lin ic a lly  
evaluating th e ir  efficacy in man, the need fo r more detailed information 
the interspecies differences in the binding of drugs is apparent. In 
addition characterisation of the warfarin binding s ite  on albumin 
should provide valuable information on the binding sites of drugs 
known to compete with warfarin fo r albumin binding s ite s .
This study has therefore investigated the potential of warfarin  
as a fluorescent probe and used this property to gain an insight into  
possible interspecies differences in the nature of the warfarin-albumin  
in teraction . In order to fu rther characterise these sites a study of the 
binding of warfarin to chemically modified albumin has been commenced.
The potential of the fluorescent probe technique in studying drug 
competition has also been investigated.
Experimental Approach
For a ll fluorescence studies, albumin at concentrations of 0 .5 , 
1.0 or 2.0 x 10“%  in 0.1 M phosphate bu ffer, pH 7.4 was used.
(N.B. Albumin concentrations in excess of 3 x 10"% exh ib it 
concentration 'quenching' effects and therefore concentrations of 
2 x 10“%  were not exceeded.) Warfarin solutions (1 or 5 x 10"%) 
were routinely prepared in phosphate buffer (0.1 M, pH 7 .4 ).
Compounds used in the competition studies were prepared in e ither  
phosphate buffer or, where appropriate, ethanol. Fluorescence 
t itra tio n s  were performed as described in Chapter Two, a t 28 + 2°C.
Results
Table V, 1.
Fluorescence Data5 of Warfarin in D iffe ren t Solvents 
and Human Plasma Albumin.
Solvent Solvent 
D ie lec tric  
constant 
(Debye units)
Relative
Fluorescence
Quantum
Yield
Emmission 
Wavelength 
Max11, (nm)
Phosphate
buffer
(0.1 m4
pH 7.4)
78.5 13.9 0.015 386
Ethanol 24.3 31.7 0.034 383
n-Butanol 17.1 37.0 0.04 383
n-Hexane 1.9 2.0 0.002 354
Human 
Plasma 
Albumin 
(1x l0"5 M)
100 0.09 374
a Warfarin concentration was 25 x 10"6 M in a l l  cases and solutions were 
excited a t 320 nm.
b D ie lec tric  constant values from Handbook of Chemistry and Physics; 
46th Edition , 1965-1966. The Chemical Rubber Co., U.S.A.
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Fig. V, 1 Fluorescence Titration Curves of Human Plasma Albumin
and Phosphate Buffer with Warfarin
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Fig. V, 2. Quenching of Tryptophan Fluorescence in Human Plasma Albumin
and Phosphate Buffer (‘inner filter1 effect) by Warfarin
■ HPA (1 x 10"5M)
□ 1 x 10_5m tryptophan in 0.1M 
phosphate b u ffe r, pH 7 .4 , ( 'in n e r  
f i l t e r 1 e ffec t)
Fluorescence was monitored at 
Aex = 290 nm
30
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Warfarin Concn. (x 10"^M)
Fig.V , 3. Spectra of Warfarin and Human Plasma Albumin (HPA)
Fluorescence 
of HPA -  Warfarin 
Complex
HPA
Fluorescence0.6 Absorption 
Spectrum of 
Warfarin \ .
0.5
0.4
-  20
0.3
0.2
-  10Warfarin
Fluorescence
0.1
phosphate 
. bu ffer)
380 420260 300 340
Wavelength (nm)
The concentrations were: HPA, 2 x 10”5 M; warfarin in HPA, 2 x 10”5 M
and alone in 0.1 M phosphate bu ffe r, 29 x 10”6 M; HPA solution was excited  
a t 290 nm, while those solutions containing warfarin were excited a t 320 nm. 
A ll solutions were in 0.1 M phosphate b u ffer, pH 7 .4 .
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Fig V, 4. T itra tio n  of Tryptophan Solutions with Warfarin
Fluorescence monitored a t X = 320 nm 
and Aem = 386 nm
0 Phosphate buffer orvly (0.1M, pH 7.4)
a 1 x 10"5m tryptophan (in  phosphate buffer)
□ 2 x 10”5m tryptophan (in  phosphate buffer)
1 4 x 10"5m tryptophan (in  phosphate buffer)
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Table V, 2. Percentage Bound Values fo r the Binding of Warfarin
to D iffe ren t Albumins as Determined by the Fluorescent 
Probe Technigue
Warfarin 
Concn. 
x 10"6 M
% Bounda
HPA
(C rysta lline)
BSA
(C rysta lline)
BSA 
(Fraction V)
RSA 
(Fraction V)
0.50 — 71.1 + 2.0 - 97.8 + 3.25
1.00 90.4 + 4.7 74.5 + 4.65 - 91.1 + 1.0
1.50 88.2 + 1.85 70.4 + 4.2 - 91.2 + 2.8
2.00 84.5 + 2.55 68.2 + 3.75 97.4 + 2.95 78.55+ 0.6
2.50 7 4 . 2 + 3 . 4 66.2 + 3.9 - 74.15+ 1.0
3.00 75.9 + 3.3 63.7 + 0.75 90.4 + 2.3 70 .0 5 + 1 .4
3.98 69.9 + 2.5 60.85+ 2.45 85.8 + 2 . 3 6 4 . 0 + 0 . 3
4.98 65.1 + 2.6 56.2 + 3.0 82.7 + 3.8 55.5 + 0.7
5.96 61.8 + 0.5 54.2 + 2 . 6 79.1 + 2.2 53.0 + 1.4
6.95 58.9 + 0.2 51.4 + 2.2 77.4 + 1.7 -
7.94 56.0 + 0.6 50.9 + 2.45 74.3 + 2.2 46.3 + 1.3
8.92 53.7 + 0.7 4 7 . 7 + 0 . 9 69.4 + 1.3 -
9.90 50.2 + 0.4 46.0 + 1.1 67.15+ 0.9 41.5 + 1.3
12.35 45.3 + 1.1 44.9 + 0.45 62.1 + 1.3 37.2 + 1.1
14.78 43.2 + 0.5 42.9 + 0.45 59.8 + 0.9 34.1 + 0.9
17.20 41.2 + 0.5 40.3 + 0.1 56.7 + 0.6 32.1 + 0.7
19.61 39 .35+0 .6 38.7 + 0.05 54.4 + 1.1 33.7 + 1.7
24.39 37.3 + 0.7 36.2 + 0.35 49.4 + 0 . 7 26.4 + 0.8
29.13 3 5 . 7 + 0 . 3 33.7 + 0.15 46.5 + 0.7 -
33.82 3 4 . 8 + 0 . 6 32.2 + 0.45 44.0 + 0.5 -
r
a Mean + S.E.M. of two determinations, albumin concns. 25 x 10 M, 
0.1 M phosphate bu ffe r, pH 7 .4 , 28°C.
Scatchard Plots of Fluorescence Probe Binding Data fo r  
the In teraction of Warfarin with Several Species of Albumin.
•  BSA (C rysta lline) 
A RSA (Fraction V) 
o HPA (C rysta lline) 
a BSA (Fraction V)
Table V, 3 Binding Data for the Interaction of Warfarin with Different
Species of Albumin - Comparison of the results obtained in  
th is study with lite ra tu re  values.
Albumin
kl
x lO^M-l nl
k2
x lO^M"' n2 Reference a
HPA (C rysta lline) 6.46 0.9 4.20 8.1
This Study
b
BSA (C rysta lline 1.06 1.05 4.63 7.9
BSA (Fraction V) 3.60 1.6 11.75 7.4
RSA (Fraction V) 8.07 0.85 3.30 8.2
HPA (C rysta lline) 0.23 2.6 - -
O 'R eilly  and Motley
(1971)
BSA (C rysta lline) 0.05 2.9 - - Jun e t al_. (1972)
BSA (Fraction V) 6.24 1.0 2.61 6.0 Meyer and Guttman (1970b)
a Differences in experimental technique and s lig h t differences in 
experimental conditions are apparent between studies.
b Mean values, determined from a minimum of 20 data points.
Table V, 4.
Comparison of the Amino Acid Composition of
Albumins5
Amino
Acid
HSA BSA RSA
(Residues/mole of protein)
Glycine 12 16 17
Alanine 62 46 58
Valine 41-42 36-37 33
Leucine 60 62 53
Isoleucine 8 14 13
Serine 19 26 23
Threonine 24-25 34 31
Tyrosine 17-18 20 22
Aspartic 15 54 49
G1utami c 78-79 77-78 77
H istid ine 16 17 14
Arginine 24 22-23 23
Lysine 62 62 50
Phenylalanine 30 27 23
Tryptophan 1 2 1
H alf-cystine 37 . 36 31
Methionine 6 4 6
Proline 26 30 29
Ammonia 34-35 32-33 38
a Data from Kirschenbaum (1972).
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F ig. V, 8 Fluorescence T itra tio ns  of Acetic Anhydride Treated
and Control Human Plasma and Bovine-Serum.'.■Albumins 
with Warfarin.
a) C rysta lline  HPA (2 x 10 5 M)
emex
▲ Control
a  Acetic Anhydride Treated
10 15 20 25 300 5
Warfarin concn. x 10"®M
b) C rysta lline  BSA (2 x 10” 5 M)
= 320 nm = 374nm ex em
a Control
TO ~ a  Acetic Anhydride Treated
0 302510 15 205
Warfarin concn. x 10"^M
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Fig. V, 9
Fluorescence T itra tio n  Curve of Control and Pi ethylpyrocarbonate
Treated HPA with Warfarin.
X = 320 nm X
Ca
•  Control
□ 10 fold molar excess )
■ 100 fold molar excess ^
= 374 nmem
50 Di ethylpyrocarbonate 
treated
HPA concn. 2 x 10“ 5
40
30
20
10
1 0 15 20 305 25
Warfarin Cone11, x 10"6 M
Table V, 5.
In tr in s ic  Fluorescence of Albumin Derivatives
Derivatives of Albumin Emission3
Maxn.
(nm)
Tryptophanb
Quantum
Yield
HPA (C rysta lline)
Native 340 0.11
Acetic Anhydride 332 0.11
Diethylpyrocarbonate:c
10 fo ld  excess 333 0.11
100 fo ld  excess 334 0.09
BSA (C rysta lline)
Native 340 0.21
Acetic Anhydride 332 0.15
a Excitation wavelength was 290 nm.
b Quantum yields of native albumins from Longworth (1971).
c '10 fo ld  excess' denotes 10 fo ld  excess of diethyl pyrocarbonate per
mole of albumin.
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Table V, 7.
Effect of Various Compounds on the Fluorescence of 
Warfarin when Bound to Albumin.
Competitor Type ofa Displacement
Concn. Range 
of u 
Competitor 
(x 10~6 M)
Concn. Range 
of
Warfarin 
(x 10“6 M)
Phenylbutazone Competitive 0.5 -  40 2.5 -  25
Sulphormethoxine H 1.5 - 100 2.5 -  25
ANS ii 0.5 -  50 0.5 -  50
C lo fib rate0 ii 1 -  80 0.5 -  20
Biphenyl ) 
20 M " ) 
40 M " )
Non-competitive 50 2.5 -  25
Diazepam None 1 - 100 2.5 -  10
Chlordiazepoxide H 1 - 100 2.5 -  10
Iprindole n 1 - 30 2.5 -  10
Pentobarbitone n 1 -  80 2.5 -  12.5
Carbamates (methyl 
->• n-decyl) n 5 - 5 0 2.5 -  12.5
a Sim ilar effects were observed with both human plasma and bovine serum
albumin (1 x 10”5 M in 0.1 M phosphate b u ffe r, pH 7. 4) .
b Drug/warfarin ratios included lik e ly  therapeutic ra tio s .
c Competition appeared to be non-competitive a t low concentrations
(up to 6 x 10~6 M).
Discussion
A study of the fluorescence of warfarin in d iffe re n t solvents 
(Table V, 1) showed that warfarin exhibited a marked increase in 
fluorescence in tensity  or quantum y ie ld , and also a hypsochromic 
(blue) s h ift  in emission maximum on decrease of solvent p o la rity .
One anomaly of th is trend was the observed fluorescence in hexane, 
which although producing a 32 nm hypsochromic s h if t  with respect to 
bu ffer, showed a lower fluorescence in ten sity  than would have been 
expected from hexane's d ie le c tr ic  constant. Deviations between solvent 
d ie le c tr ic  constant and fluorescent in ten sity  have also been observed 
fo r other fluorescent probes (McClure and Edelman, 1966; Edelman and 
McClure, 1968; Thomson, 1969; Kotaki et al_., 1971). One possible 
explanation could be due to differences in solvent viscosity which are 
known to produce changes in quantum y ie ld  (McClure and Edelman, 1966;
Turner and Brand, 1968).
The data presented in Table V, 1 fo r warfarin would tend to suggest 
that the solvent p o la rity  was one of the major determinants a ffecting  its  
fluorescence. This suggested that the electronic tran s itio n  between 
ground state and the lowest, excited s ing le t state was of ^ ft* type 
(Kotaki et al_., 1971) and that warfarin can therefore function as a 
fluorescent probe for hydrophobic environments. The hypsochromic s h if t  
produced in the emission wavelength in the presence of human plasma 
albumin would support this view (Table V, 1 and Fig. V, 1 ). The 
observed fluorescence of warfarin in albumin suggested that the d ie le c tr ic  
nature of the environment of the binding sites was lower than th a t of water 
and that the intramolecular m obility of the drug was reduced (Kotaki e t a l . ,  
1971).
The binding of warfarin to plasma human albumin (HPA) increased 
the warfarin fluorescence and also produced a concomitant quenching of
the native fluorescence of albumin (Fig. V, 2 ). The fluorescence 
of albumin when excited at 290 nm, ch ie fly  re flects  the fluorescence 
from the amino acid tryptophan, although a small contribution from 
tyrosine may occur. The quenching of tryptophan fluorescence on 
sequential addition of warfarin to HPA was accompanied by bathochromic 
(red) s h if t  in the tryptophan emission. The degree of bathochromic 
s h if t  of the emission wavelength increased with warfarin concentration., 
from 340 nm before warfarin addition to 364 nm at 8 x 10"^M and f in a l ly  
to almost the emission maximum of the bound warfarin (Aem = 374 nm) on 
fu rther addition. This deactivation of a lig h t excited tryptophan 
molecule (T*) could occur by the following four processes:- fluorescence 
emission ( T * — ► T+ hv where h = Planck's constant, v = frequency of 
emitted l ig h t ) ,  radiationless deactivation (T * —► T ), co llis io n a l 
quenching (T* + I (quencher)-* T + I * )  and s ta tic  quenching
(T* + I —► [Y - i ]  ) 9 Honikel and Madsen, 1973).
The absorption band of warfarin was shown to overlap the 
emission band of HPA (F ig . V, 3 ). The quenching of tryptophan 
fluorescence promoted by addition of warfarin could therefore, a t least 
p artly , be explained in terms of radiationless energy transfer from the 
tryptophyl residues of HPA to the w arfarin . Fbrster (1951) has suggested 
that fo r this energy transfer mechanism to be operative an extensive 
overlap between the emission band of the donor and the absorption band
of the acceptor is required, this is c learly  met in warfarin binding
to HPA. Several authors have used th is concept to determine the c r it ic a l  
transfer distance of energy between the donor and acceptor (Chen and 
Kernohan, 1967; Chignell, 1970a; Wallach et al ,^ 1970; Churchich,, 1972).
Tryptophan quenching could also occur by 'inner f i l t e r '  
effec ts , such effects would be p a rtic u la rly  noticeable in strongly  
absorbing solutions and resu lt from the absorption of the excitation  
and/or fluorescence by the quencher. This was investigated by t itra t io n s
of tryptophan solutions comparable to that in the albumin preparations 
used (1 ,2  x !0“5ms and also 4 xl0"5jv|, in phosphate b u ffe r, pH 7. 4) .
I t  was apparent that warfarin was able to quench tryptophan fluorescence 
by 'inner f i l t e r 1 e ffec ts , but comparison of the quenching of 
tryptophan in aqueous solutions with that of HPA (F ig . V, 2) suggested 
that 'inner f i l t e r '  effects could only p a r t ia lly  account fo r the 
quenching in HPA solutions. This could not be accurately quantitated as 
tryptophan's quantum y ie ld  is known to increase in non-polar environments 
( i . e .  0.12 in aqueous solution and 0.18 in bovine serum albumin , Chen, 1967; 
Flanagan and Ainsworth, 1968; Chignell, 1970a). Despite the e ffe c t of 
warfarin on the fluorescence of tryptophan, no e ffe c t of tryptophan on 
the fluorescence of warfarin could be detected (F ig . V, 4) which further 
established the s u ita b ility  of warfarin as a fluorescent probe.Attallah  
and Lata (1968) have suggested that association constants can be derived 
from such tryptophan quench curves, however, in view of the assumptions 
made and d if f ic u lty  of accurate correction of the 'inner f i l t e r '  e ffec ts , 
the determined association constant values by this method are l ik e ly  
to be only approximate.
The fluorescence t it ra t io n  curves obtained with warfarin fo r the 
t it ra t io n  o f : -  human (c ry s ta llin e ); bovine (c ry s ta llin e , frac tion  V, 
defatted fraction V), and ra t (frac tio n  V) albumins, are given in 
Fig. V, 5 which indicates in teresting species differences. The 
fluorescence enhancement of warfarin was s ig n ific a n tly  greater on 
binding to human (c ry s ta llin e ) and ra t (frac tio n  V) albumins, than with 
bovine albumins (e ith er c ry s ta llin e , fraction  V or defatted frac tio n  V).
Binding of warfarin to RSA exhibited the largest enhancement of 
fluorescence. The fluorescence increase in c rys ta llin e  bovine serum 
albumin was greater than that with fraction  V, and the removal of
endogenously bound fa tty  acid had an in s ig n ifican t e ffe c t. Such differences
between the c rys ta llin e  and fraction V preparations may re fle c t  
the presence of the small amount of globulins in the fraction  V preparation. 
(N.B. Albumin solutions were of equal to ta l protein concentration, 
however the albumin concentration of fraction  V preparations w ill be 
reduced by approximately 3% as compared with c rys ta llin e  preparations.)
This finding may well support the view (O 'R e illy  and Kowitz, 1967) that 
warfarin does not s ig n ific a n tly  bind to the serum globulins. Comparison 
of the warfarin fluorescence t it ra t io n  in human serum with that fo r  
human plasma albumin (HPA) showed in s ig n ifican t d ifference, a s im ilar 
finding was observed fo r ra t serum and ra t serum albumin (RSA). L i t t le  
difference could be detected in the binding to albumin, 
of the R(+) and S( - )  isomers of w arfarin , th is find ing , which is in  
agreement with O 'R e illy  and Motley (1971), is important in view of the 
known differences in the plasma h a lf- liv e s  and pharmacological e ffects  of 
the isomers, and the known species differences between ra t and man 
(Eble e t a]_., 1966; Breckenridge and Orme, 1972; Hewick, 1972; Hewick 
and McEwen, 1973). The observed interspecies differences in the t it r a t io n  
curves for warfarin may be ind icative  of differences in the p o la rity  of 
the binding sites and/or differences in the degree of binding.
Analysis of binding data revealed that fo r s im ilar concentrations 
of w arfarin , differences in the percentage bound to the d iffe re n t  
albumins were apparent (Table V, 2 ), which were reflected  in the nature 
of the Scatchard plots (Fig. V, 6 ). For a ll  species o f albumin, marked 
curvature of the plots was apparent suggesting the presence of more 
than one d is tin c t class of binding s ite . (N.B. In terp re ta tion  may 
be complicated by other factors such as negative cooperativ ity , see 
Chapter Four). One primary s ite  (n-j) and approximately eight secondary
i
sites (r^) were calculated fo r each species. (N.B. BSA (frac tio n  V) 
indicated n-j value of 1 .6 , s lig h tly  higher than that found fo r the 
other albumins.) (Table V, 3 ). The association constant (k-j ) fo r  
the high a f f in i ty ,  primary binding s ite  of c ry s ta llin e , HPA and RSA 
(fractio n  V) was s ig n ific a n tly  higher than for c rys ta llin e  bovine 
serum albumin (BSA), while l i t t l e  difference was detectable in the 
association constant (k^) fo r the lower a f f in ity  secondary s ite s .
Also, rather surprisingly, the BSA (frac tio n  V) exhibited a higher 
k-| value than did BSA c rys ta llin e , although i t  was lower than both 
HPA and RSA. The association constant (k2 ) fo r the lower a f f in i ty  
secondary warfarin binding s ite  on BSA (fractio n  V) was higher than fo r  
the other albumins. Comparison of these determined n and k values 
for the binding of warfarin with published data is complicated by the 
inconsistent nature of the lite ra tu re  values (Table V, 3 ). Our 
results would appear to exhib it reasonable agreement with those 
reported by Meyer and Guttman (1970b),,although s lig h t differences are 
apparent in the values fo r the secondary s ite s . These authors also 
reported in s ig n ifican t differences between the binding o f warfarin to 
HSA (fractio n  V) and BSA (fractio n  V). I t  is not known i f  our results  
would be consistent with the finding of O 'R e illy  and Motley (1971), that 
warfarin was more highly bound to HPA (frac tio n  V) than to c ry s ta llin e  
HPA. However, determination of the binding of warfarin to HPA (frac tio n  V) 
by the fluorescent probe technique, should resolve th is . The considerable 
differences in the reported values of the binding parameters n and k fo r  
warfarin may indicate that they have been calculated over a d if fe re n t, and 
fo r some studies, an in su ffic ie n t range of r values (moles warfarin bound/ 
mole albumin). Also i t  should be added that the use of d iffe re n t  
techniques and small differences in experimental conditions may also 
contribute to the differences in n and k.
The differences in a f f in i ty  of warfarin binding to d iffe re n t  
albumin preparations was disturbing in view of the considerable 
differences between manufacturers specifications fo r both c rys ta llin e  
and fraction V preparations. The need for standardised methods of 
iso lation  of the albumins is apparent i f  va lid  comparisons are to be 
made. This would support the need to purchase albumins from one 
manufacturer. At present, however, no single manufacturer produces 
a s u ffic ie n tly  large range of both c rys ta llin e  and frac tion  V 
albumins from d iffe re n t species. These observed species differences  
in binding and fluorescence t it ra t io n  could resu lt from differences  
in the amino composition of the albumins (Table V, 4 ).
The measurement of the decreased albumin fluorescence 
(tryptophan quenching) upon t it ra t io n  with warfarin revealed fu rther  
in teresting species differences. In general a much higher degree of 
tryptophan quenching was found fo r bovine albumin than fo r  the other 
species of albumin. (N.B. Sim ilar quenching was found fo r c rys ta llin e  
and fraction V, bovine serum albumins.) (Fig. V, 7 ). Rat serum albumin 
and HPA contrasted with the other albumins studied fo r  although addition  
of low concentrations of warfarin (up to 2 xlO"^M) produced s lig h t  
quenching of tryptophan fluorescence, a t higher concentrations 
considerable enhancement of tryptophan fluorescence was observed. These 
changes were accompanied by a bathochromic s h ift  (red) in the tryptophan 
emission maximum (Aem = 374nm) a t warfarin concentrations o f above 
(8 xlO“^M). No s im ilar enhancement of tryptophan fluorescence was 
observed for warfarin t it ra t io n  of BSA (c ry s ta llin e , fraction  V or 
defatted fraction V). Although HPA produced enhancement, much higher 
warfarin concentrations (20 xlO“^M) were required than fo r RSA. A s im ilar  
shaped curve to that obtained with RSA was achieved with HPA, but a t a 
ten-fo ld  lower albumin concentration (1 x!0"^M). Undoubtedly the shape
of these tryptophan quenching curves are affected by 'inner f i l t e r '  e ffects
These effects are l ik e ly  to be greater in BSA due to the presence
of two tryptophan residues/mole of BSA as opposed to one with both
HSA and RSA. The bathochromic s h if t  in the albumins to the warfarin
emission wavelength would also support the view that 'inner f i l t e r '
effects are involved, however the differences between RSA and HSA,
both of which contain one tryptophan/mole albumin and shew only small differences
in the enhancement of warfarin fluorescence (F ig . V, 5 ), would
suggest that these observations cannot be completely explained by
'inner f i l t e r '  e ffec ts . Such effects would also not explain the
increase in tryptophan fluorescence in RSA, upon t it ra t io n  with
w arfarin . The observed increase in the tryptophan fluorescence in
RSA and HSA would however be consistent with the tryptophan residues
being moved into a more hydrophobic environment. Hypsochromic s h if t
in tryptophan emission maximum would also have been expected to
accompany the fluorescent enhancement, however, 'inner f i l t e r '  e ffects
may have obscured such changes. Tryptophan quenching followed by
enhancement on subsequent additions of compounds to human and bovine
albumins has . been reported (Halfman and Nishida, 1971; Steinhardt
e t al_., 1971). Further studies on other species of albumins may well
provide insight into the relationship between degree of quenching
produced by warfarin binding and number of tryptophans/mole albumin.
Suitable species of albumin would be, fo r example:- monkey (2-tryptophan/ 
mole p ro te in ), dog(l tryptophan/mole p ro te in ), most species of albumin 
contain 1 tryptophan/mole protein, although chicken albumin is unusual 
in being devoid of tryptophan.
The observed binding data and tryptophan quenching studies may be 
consistent with the primary binding on human albumin being in the region 
of the lone tryptophan residue. Swaney and Klotz (1970) have recently  
sequenced the immediate v ic in ity  of the tryptophan as:
Lys -  Ala-Trp-Ala-Val-Ala-Arg
I f  i t  is the locus of warfarin binding then the apolar character 
of this binding region may account fo r the observed hydrophobic nature 
of the warfarin fluorescence enhancement. Such a s ite  would be 
compatible with the suggested involvement of hydrogen and hydrophobic 
bonds in the binding of warfarin to HPA (O 'R e illy , 1969; Chignell, 1970a; 
O 'R eilly  and Motley, 1971). However, fo r bovine serum albumin the 
amino acid sequence in the neighbourhood of the tryptophans is  thought 
to d if fe r  and only one of the tryptophans in BSA is considered to be 
embedded in the protein structure. The amino acid composition in the 
neighbourhood of the lone tryptophan in RSA is unknown.
A study of the e ffe c t of protein modification on warfarin binding 
was undertaken to provide fu rther information on the nature of warfarin  
binding s ite s . Warfarin fluorescence when bound to acetylated c ry s ta llin e  
BSA and HPA was shown to be s ig n ific a n tly  decreased (83 and 70%) when 
compared with native albumins (F ig . V, 8a and b ). S im ilarly  HPA treated  
with diethylpyrocarbonate (100-fold excess/mole albumin) produced a 64% 
reduction in warfarin fluorescence (F ig . V, 9 ) . Determination of the 
in tr in s ic  fluorescence spectrum of acetic anhydride and diethylpyrocarbonate 
treated albumins revealed hypsochromic sh ifts  in the emission maximum of 
a ll albumins, quantum yields were also affected, but to d iffe re n t degrees 
(Table V, 5 ). The hypsochromic s h if t  in the emission suggested a net 
change to a less polar environment, while the decreased quantum yie lds  may 
be caused by a quenching of tryptophan fluorescence by the new groups 
introduced into the proteins.
The amino groups modified by acetic anhydride treatment included 
49 lysines in HPA and 51 in BSA, plus 7 and 10 tyrosine hydroxyl groups 
respectively. An excess of 10 moles of diethylpyrocarbonate per mole of 
albumin resulted in 2 modified histidines and 15 modified lysines in HPA,
whereas an increase in the reagent/albumin ra tio  ( i . e .  100-fold excess 
diethylpyrocarbonate) gave derivatives with 8 modified h istid ines and 
26 modified lysines. Tyrosine, arginine and tryptophan residues remained 
in tac t in a ll diethylpyrocarbonate derivatives (Table V, 6 ). A 10-fo ld  
excess of diethylpyrocarbonate per mole of albumin produced a neglig ib le  
e ffe c t on the fluorescence of warfarin in HPA (Fig. V, 9) whereas higher 
degrees of modification did. This suggested that in excess of 2 h istidines  
and 15 lysines had to be modified before the binding of warfarin to HPA 
was affected. That lysine was involved in the binding of warfarin was 
supported by the decreased fluorescence of warfarin when bound to acetylated  
albumins, although the modified tyrosines may also be involved. Acetic  
anhydride has been shown to produce unfolding in the albumin molecule 
as a resu lt of the increased net negative charge (Habeeb e t al_., 1958;
Jonas and Weber, 1970; Jacobsen, 1972) thus disrupting the hydrophobic 
environment of the warfarin binding s ite . However the hypsochromic s h if t  
in warfarin fluorescence on addition to acetylated albumins indicated that 
this e ffe c t was by no means to ta l. The binding of several other anions; 
/long chain fa tty  acids, (Spector e t al_., 1969), 2s4-dichlorophenolate 
(Teresi, 1950); 1 -a n ilino-8-naphthalene sulphonate (Jonas and Weber, 1971); 
sa lic y la te  (Sturman and Smith, 1967); b iliru b in  (Jacobsen, 1973) ) have 
also been shown to be reduced in acetic anhydride modified albumins.
Teresi (1950 suggested the involvement of lysine in the binding of methyl 
orange, and 2,4-dichlorophenolate to BSA. As a resu lt o f th e ir  studies 
Jonas and Weber (1971) have suggested that arginine may be involved in 
the binding s ite  of ANS in BSA, s im ila rly  Jacobsen (1972) has indicated  
involvement of arginine in the binding of b iliru b in  to HSA. Unfortunately  
glyoxal (known to modify guanidino groups, Nakaya e t al_., 1967; Jonas and 
Weber, 1971), is strongly fluorescent and therefore could not be used in 
our fluorescent probe studies. However, the finding that w arfarin in te r ­
acts with ANS in a d irec t competitive manner fo r albumin binding sites
(th is  study and Jun e t al_., 1972) may suggest the involvement of arginine  
in the binding of w arfarin , the determination of the binding of radio- 
actively  labelled warfarin to glyoxal treated albumin should resolve th is . 
Also binding determinations of warfarin in tetranitromethane, n-acetylim i­
dazole and o-nitrophenylsulfenylchloride modified albumins should c l a r i f y . 
the possible ro le of tyrosine and tryptophan in the binding process.
These findings give a p artia l insight into possible warfarin binding 
sites on albumin and indicate the role of lys ine, h is tid in e  and tyrosine in 
the in teraction . The fluorescent probe observations also indicated the 
hydrophobic nature of the binding s ite s .
A considerable number of drugs have been reported to displace 
w arfarin ,but few systematic studies have been presented (Solomon and 
Schrogie, 1967). The s u ita b ility  of the fluorescent probe technique to 
study displacement is demonstrated by the competitive displacement found, 
fo r warfarin binding to HPA, by therapeutic concentrations of phenylbutazone 
(F ig . V, 10). Several ac id ic , neutral and basic drugs have been investigated  
fo r th e ir  displacement of warfarin from both human and bovine albumin 
binding sites (Table V, 7 ). The d irec t competitive nature of the displace­
ment found fo r the acidic compounds ANS, c lo fib ra te , sulphormethoxine 
would appear to be in agreement with the findings of other workers 
(Solomon and Schrogie, 1967; Solomon e t aj_, 1968; Sellers and Koch-Weser, 
1971; Jun et a K , 1972). I t  has also been demonstrated that long-chain 
fa tty  acids compete with ANS fo r binding sites on albumin (Santos and 
Spectoir 1972). The observation that the benzodiazepines, chlordiazepoxide 
and diazepam did not displace warfarin would appear to support the finding  
of Orme e t al_. (1972) that administration of chlordiazepoxide did not 
a ffe c t the steady-state plasma warfarin concentrations, the plasma h a l f - l i f e  
or anticoagulant control in patients. Few binding studies of the benzo­
diazepines to plasma proteins appear to have been performed fan .der Kleijn , 1969; 
M liller and W ollert, 1973), however in i t ia l  indications are th a t they may
be highly bound. The results presented here would suggest that they 
bind to sites on albumin, other than those which bind w arfarin . The 
t r ic y c lic  antidepressant drug, iprindole was also found to have an 
in s ig n ifican t e ffec t on the binding of warfarin to both human and bovine 
albumins. BorgS e t al_. (1969) have demonstrated the high percentage 
binding to human plasma of therapeutic concentrations of several a n ti-  
depressants (ami try p ty lin e , imipramine, nortryptyline and p ro try p ty lin e ).
They have also reported that a large number of drugs, including phenyl­
butazone and c lo fib ra te , fa ile d  to displace the antidepressants from th e ir  
plasma protein binding s ite s . In general, however, i t  would appear from 
the lim ited studies carried out that basic compounds are less well bound 
than are acidic drugs and the percentage bound re la tiv e ly  independent of 
drug concentration (BorgS e t al_., 1969; Franksson and AnggSrd, 1970;
Olsen, 1972; 1973).
We attempted to u t i l iz e  the fluorescent properties of two basic 
compounds, iprindole and benzidine, to gain an insight into the nature 
of th e ir  albumin binding s ite . Despite the fa c t that both these compounds 
indicated the necessary fluorescent properties to function as fluorescent 
probes, no enhancement of th e ir  fluorescence, or hypsochromic wavelength 
s h if t ,  could be detected on binding to albumin. This finding may indicate  
that th e ir  binding sites were located in re la tiv e ly  hydrophilic environments, 
and would therefore appear to contrast d is tin c tly  with the hydrophobic 
environment of the warfarin binding s ite . No displacement of w arfarin , 
from albumin binding s ite s , by any of the neutral carbamates studied was 
observed, even though they are lik e ly  to bind to a hydrophobic s ite . The 
insertion of an electron doncxbing hydroxyl group into the biphenyl 
structure ( i . e .  2- and 4-hydroxy) appeared to produce increased displacement 
of w arfarin , although such displacement was non-competitive.
C learly , in su ffic ie n t s tru c tu ra lly  d iffe re n t compounds have been invest- 
gated for th e ir  displacement potential to allow firm  conclusions to be drawn
about the physico-chemical requirements for displacement. However, these 
findings would appear to confirm that acidic compounds form a major 
group of drugs which compete with warfarin fo r albumin binding s ite s .
This study has demonstrated the potential of the fluorescent probe 
technique in studying drug in teractions, although one important 
consideration is that the competitor should be re la tiv e ly  non-fluorescent, 
otherwise lengthy 'blank' corrections are required. Such studies need 
not be lim ited to albumin solutions and the technique is read ily  
compatible with the use of serum samples.
SUMMARY
The application of the fluorescent probe technique in studying 
protein binding has been demonstrated. A novel fluorescent probe, w arfarin , 
has been used to investigate its  binding to several d iffe re n t species 
and preparations of albumin as well as drug competition studies. In te r ­
species differences were apparent fo r the binding of w arfarin , and may 
suggest that c rys ta llin e  bovine albumin is unsuitable fo r warfarin binding 
determination, i f  extrapolation to man is required. The marked differences  
in the binding of warfarin to c rys ta llin e  and fraction  V bovine albumin 
preparations fu rther demonstrated the 'p i t fa l ls ' that may jeapordise 
meaningful correlation of in v itro  binding data with in vivo studies.
Good agreement was found between HPA and human serum fo r the binding of 
w arfarin , however, agreement between the binding data obtained with 
serum/plasma and isolated albumin fractions may not always occur (W itiak  
and Whitehouse, 1969; Thorp, 1972). The use of chemically modified 
albumins has provided a p a rtia l insight into the nature of the warfarin  
binding s ite  in both human plasma albumin and bovine serum albumin. The 
results would suggest that lys ine, h is tid in e  and tyrosine residues may be 
involved, e ither d ire c tly  or in d ire c tly  in the warfarin-albumin in te rac tio n ,
although the possible involvement of other amino acids (e .g . arginine) 
cannot be ruled out. Possible differences in the p o la rity  of the human?r a t  
and bovine albumin binding sites fo r warfarin were also apparent. Whether 
the high a f f in i ty  warfarin binding s ite  on human plasma albumin is that 
surrounding the 'lone' tryptophan residue (Swaney and K lotz, 1970) cannot 
be unambiguously concluded. The fluorescent probe method has been shown 
to be valuable in studying drug in teractions, and may present a re la tiv e ly  
simple and rapid procedure fo r screening novel drugs fo r th e ir  displacement 
potential o f the c lin ic a lly  important drug w arfarin .
CHAPTER SIX
U S E  O F F L U O R E S C E N T  P R O B E S  T O  
T O I N V E S T I G A T E  H E P A T I C  M I C R O S O M A L  
'D R U Gf B I N D I N G  S I T E S
. Introduction
The value of non-covalently bound fluorescent molecules as extrins ic  
probes of membrane structure and function is now well established, (Radda, 1971) 
In view of th is i t  is surprising that few studies have appeared using such 
compounds to investigate microsomal-sites of drug in teractions,
(DiAugustine, e t al_r31970, Eling and DiAugustine, 1971, Hawkins and 
Freedman, 1973). These sites have been c lass ified  as types 1, I I ,  and R I, 
(Remmer, et al_- 9l966, Imai and Sato, 1966, Schenkman, 'e t a K 1967) according to 
the nature of the spectral change produced on addition o f a compound to a 
microsomal protein solution. Previous applications of the fluorescent probe 
technique to the study microsomal binding sites has been restric ted  to the 
use of ANS, a type I fluorescent probe. (DiAugustine, et al_.,1970, Eling and 
DiAugustine, 1971). However to derive satisfactory information from th is  
technique, several probes with d iffe re n t physio-chemical and molecular 
properties are needed. Thus, in order to fu l ly  characterise microsomal 
binding s ite s , suitable types I ,  I I  and RI fluorescent probes are a 
pre-requ is ite .
The type of difference spectral change on in teraction with microsomes, 
e lic ite d  by the common used fluorescent probes, with the exception of ANS, is  
unknown, (Brand and Gohlke, 1972). However, close structural resemblance o f 
the large majority of these probes to ANS would suggest they are un like ly  to 
be suitable fo r the investigation of types I I  and RI microsomal s ite s . The 
in teraction of warfarin with ra t hepatic microsomes has been variously  
reported to produce type I I  (DiAugustine, et al_fj!970) or type RI (Deckert 
and Remmer, 1972) spectral changes. The results from the preceding chapter, 
(Chapter Five) demonstrated that warfarin exhibited the necessary fluorescent 
properties to be a suitable probe for albumin binding sites and its  value for
probing microsomal binding sites was therefore investigated.
Cytochrome P-450 has not been obtained in a purified  form and therefore  
l i t t l e  is known about the chemical bonds of the haem moiety or of the 
coordination bonds of the f i f t h  and sixth ligands of the haem iron .
Attempts to determine the nature of the binding sites of cytochrome P-450 
have therefore been in d irec t and highly speculative (Mannering, 1971). Our 
present understanding of the nature of types I ,  I I ,  and RI binding sites is  
thus poor.
We have attempted in th is study to gain an insight into the nature of 
type I ,  I I  and RI microsomal in teractions, through the use of appropriate 
fluorescent probes and conventional difference spectral techniques. The 
possible use of the protein albumin as a model fo r these 'drug'-microsomal 
protein in teractions, to overcome the problems inherent with studies of 
cytochrome P-450, has been discussed.
Results
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T a b l e  V I ,  2 . R e l a t i o n s h i p  between t h e  S p e c t r a l  D i s s o c i a t i o n 
C o n s t a n t  (Kc ) and Type o f  S p e c t r a l  Change 
f o r  Rat  and Hamster  Microsomes
Compound Rat Hamster
Ks
x 1 0 " 5M
Type o f  
S p e c t r a l  
C hange
Ks_
x 10” 5M
Type o f  
S p e c t r a  1 
Change
ANS k . 0+0 .. 3 1 6 . 5 + 0 .5 1
WARFARI N 
R+
s -
Racemi c
45 .0+i f  ,1 
16. 0+ 1. 1+ 
2 3 . 0 + 1 . 8
RI
RI
RI
8 . 0+ 1.5 
11. 0+ 1.2 
8 . 8+ 1.0
1
RI
RI
BEN ZIDINE 6 . 0+0.8 1 1 5 . 3 + 0 .6 1 1
M ic rosoma l  P r o t e i n  C o n c e n t r a t i o n  -  2 mg/ml •. 
Mean + S.E.M.  o f  k  a n i m a l s .
Data for Spectral Interaction of R(+) + S(-) Isomers of Warfarin
With Control and Phenobarbitone Pretreated Rat Microsomes
Microsomal Protein Concn* = 2 mg/ml 
Mean of 4 animals
R(+) Warfarin - Type RI
Control
Microsomes
Fig. V, 3a
Phenobarbitone 
Pre-treatedAE.
10 150 55
ft + Warfar in  x "# r i
5 ( - )  Warfarin - Type RI
Fig. V I, 3b
Control
Microsomes
Phenobarbitone 
Pretreated
0 10 155 5
1
S (-) Warfarin x mM"1
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Fig. VI, 4.
Fluorescence Titration of Hamster Microsomes and
Phosphate Buffer with ANS.
Microsomal Protein 
Concn. 1 mg/ml
Fluorescence excited at 376 nm 
with both microsomes and 
phosphate buffer.
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Fig. VI, 5.
Fluorescence Titrations of Hamster Hepatic Microsomes
and Phosphate Buffer with (R+) Warfarin
Fluorescence excited a t 320 nm 
mean of 4 determinations
■ Microsomal Protein, Concn. = 2 mg/ml
20
□ Phosphate b u ffe r, 0.1 M10
105
R+ Warfarin Cone11, (x 10  ^M)
Fig. VI, 6.
T itra tio n  of Hamster Microsomes with R(+) and S (-) Warfarin
•  (R+) Warfarin 
o (S-) Warfarin 
= 320 nmex
Microsomal Protein  
Cone11. = 2 mg/ml
CO
+->
= 374 nmem
CO
Mean of 4 animals
Lu
105
Warfarin Cone11, (x 10  ^ M)
Fig. VI, 7. Lineweaver-Burk plot for the Competitive Inhibition
by ANS of the Binding of S (-) Warfarin to Hamster
Microsomes
Microsomal, Protein 2 mg/ml
em = 374 nm 
ANS = type I 
S (-) Warfarin = type RI
o
o S (-) Warfarin
Li_ S (-) Warfarin
(fluorim etric  
dissociation  
constant)
S (-) Warfarin
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Fig. VI, 8.
Lineweaver-Burk Plot of the E ffect of S (-) Warfarin (Type RI) 
on ANS-Hamster Microsome Fluorescence.
Microsomal Protein
2mg/ml
oo
•ANS + S(-}W arfarin  
(7 .4  x 10 5M) in  0.1M 
phosphate buffer pH 7.4
oANS in buffer
ANS fluorescence measured 
a t Aex=376 nm, Aem=464nm
6050403020lO0-lO
T O T  x mM
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Fig. VI, 9.
T itra tio n  of Control and Phenobarbitone Induced Hamster 
Microsomes with R (+) Warfarin
■ Phenobarbitone Induced 
Microsomes
□ Control Microsomes
Microsomal Protein  
Cone11. = 1 mg/ml
= 374 nmemex
mean of 4 animals
1050
R+ Warfarin Cone11, (x 10”  ^M)
Pi scussion
From the studies presented (Table V I, 1 ) , /\NS 
would appear to be a suitable type I fluorescent probe fo r hepatic 
microsomes, thus confirming the work of Eling and DiAugustine (1971). 
Investigation of warfar in  fluorescence in the presence of microsomes (Table 
V I, 1 ), revealed that i t  exhibited a s im ilar 12nm hypsochromic s h if t  in  
emission wavelength to that experienced in the presence of albumin(Chapter Five) 
although the enhancement of fluorescence was less. This finding validated  
its  use as a fluorescent probe fo r hepatic microsomes.
Difference spectral studies of the hepatic microsomal in teraction  of 
warfarin revealed some in teresting species differences. Whilst the racemate 
and S (-) isomer produced a RI spectral change with both ra t and hamster 
microsomes, the R(+) isomer d iffe re d , producing a type RI change with ra t ,  
but a typical type I change with hamster microsomes (F ig . V I, 1 ).
The racemic and S (-) w arfarins , therefore can be ju s t i f ia b ly  used as RI 
fluorescent probes fo r ra t and hamster microsomes, whereas the R(+) warfarin  
can be employed as an additional type I fluorescent probe fo r studies 
involving hamster microsomes.
The search for potential type I I  fluorescent probe raised some 
in triguing problems. The main c r ite r ia  required being a compound with 
suitable fluorescence in tensity  and wavelength changes in solvents of 
d iffe re n t p o la rity , and also one that would produce a type I I  spectral change 
on in teraction with microsomes.
Several compounds were studied which met one, but not both, selection  
c r ite r ia .  However, our attention was drawn to a paper describing the 
application of benzidine in the determination of small amounts of n i t r i t e  
(Oshima and Nagasawa, 1970), in which i t  was demonstrated that benzidine 
exhibited increased fluorescence in ethanol compared with aqueous solution. On
more detailed investigation of the fluorescence properties of benzidine 
in several solvents, i t  was found that an increase in benzidine fluorescence 
and hypsochromic s h ift  in emission wavelength (24 nm, aqueous to hexane,
Table V I, 1) occurred on decrease in the solvent p o la rity . Investigation of 
the in teraction of benzidine with both ra t and hamster microsomes, by 
difference spectra, revealed a characteris tic  type I I  spectral change. The 
decrease in the magnitude of the type I I  spectrum due to benzidine, on the 
addition of an iline  as a spectral modifier (Leibman, et aU  1969) to both 
reference and sample cuvettes, ve rified  benzidine as a type I I  compound. 
Addition of biphenyl (type I )  as a spectral modifier produced an increase in 
the magnitude of the type I I  spectral change with benzidine. Sim ilar 
findings have been reported fo r a n ilin e  by several authors (Schenkman, 1970; 
Orrenius eit al_.-, 1972) who interpreted them as being due to the presence of 
a type I component in the an iline  type I I  spectral change. However, th e ir  
suggestion has not been ve rified  experimentally and i t  is lik e ly  that*other 
factors may be involved.
The above investigations have shown that ANS, benzidine and the 
Warfarins can be used as suitable fluorescent probes fo r the three types of 
microsomal binding s ite . Difference spectral and fluorescent probe studies 
with these compounds were therefore performed, over the same concentration 
range, in both ra t and hamster microsomes.
A typical Lineweaver-Burk p lot for the difference spectral in teraction  
of R(+) Warfarin with ra t microsomes (F ig . V I, 2) showed that a single  
regression lin e  could be adequately f it te d  to the experimental data, although 
a possible divergence is apparent at low substrate concentrations. Such 
divergence may indicate the involvement of high and low a f f in i ty  binding 
sites (Walker, 1963; Burke, 1972). S im ilarly  good correlations were 
obtained for each probe. The spectral dissociation constant (K$) ,  fo r ANS 
was sim ilar for ra t and hamster microsomes (Table V I, 2) and was in good
agreement with the determined fluorescence dissociation constant (Kp) derived
-5 -5from the fluorescent probe studies (e .g . Kg = 6.5 x 10 , ^  = 8.5 x 10 M,
fo r hamster microsomes). The Kg values fo r benzidine were also s im ilar in
both species, however the s ituation with warfarin was more:complex. As well
as the apparent species difference in type of spectral binding, the Ks values
for a ll  three warfarins were found to be higher with ra t microsomes than for
hamster microsomes. This discrepancy was more noticeable fo r the R(+)
isomer, than the S ( - ) ,  while the racemate reflected the contribution from
both R(+) and S (-) isomers. (Table V I, 2 ). The K$ value fo r racemic
warfarin in ra t microsomes was in good agreement with that found by Deckert
and Remmer (1972). Phenobarbitone pretreatment of both hamster and ra t
hepatic microsomes induced no s ig n ifican t changes in e ith er Ks or the shape
of the difference spectrum for R(+) warfarin^(with control hamster microsomes
-5the Kg was 45.0 ± 4 .1  and for induced microsomes 38.0 ± 2.0 x 10 M). 
S im ilarly  no differences were observed for ANS binding. These results are 
in agreement with those of Kato, et al_. ,(1970) who reported no s ig n ific a n t  
hexobarbital type I K$ changes a fte r  phenobarbitone or 3-methylcholanthrene 
induction. However, fo r the S (-) w a rfa rin , i t  was not possible to calculate  
the Ks value because the magnitude of the spectral change was reduced with 
increase of S (-) w arfarin concentration (F ig . V I, 3b). The shape of the 
Lineweaver-Burk plot may suggest that only binding to the low a f f in i ty  
s ite  was affected, however, why the binding of the R(+) isomer (F ig . V I, 3a) 
was not s im ila rly  affected , has yet to be ascertained. However, th is  may 
re fle c t an important difference between the isomers and c le a rly  requires 
fu rther investigation, as does the nature of the high and low a f f in i ty  s ite s . 
I t  may be that the low a f f in i ty  s ite  is  purely hydrophobic in in te rac tio n , 
whereas the high a f f in ity  might re fle c t  an e lec tro s ta tic  in teraction  with 
cationic phospholipid groups, possibly s tabilised by hydrophobic forces.
The presence of more than one class of s ite , as evidenced by the biphasic 
nature of Lineweaver-Burk plots fo r spectral data, has been reported for
both type I and I I  compounds (Schenkman, 1970).
Recent work in our Department would support the role of hydrophobic 
interactions in type I microsomal binding. A linear correlation has been 
found between the log. Kg and log. p a rtitio n  co effic ien t for the binding of 
a lip h a tic  carbamates (butyl to decyl) to ra t microsomes, (B. Houston,
personal communication), and fo r aromatic ring systems containing alkyl side 
chains (K. A l-G alainy, personal communication). That such correlations are 
not restric ted  to type I compounds, has been shown with type I I  
n-alkylamines (Jefcoate, e t  al_. ,1969). Whether this la t te r  correlation is  a 
re fle c tio n  of the type I I  s ite , or simply indicates a type I component in  
the observed type I I  spectra (Orrenius, e t al_. ,1972) is  uncertain.
Binding of ANS to hepatic microsomes produced a 49nm hypsochromic s h if t  
in emission wavelength maximum of ANS, accompanied by an increase in  its  
fluorescence in ten s ity . A typical curve fo r the t it r a t io n  of microsomes with 
ANS is shown in Fig. V I, 4. Sim ilar fluorescence changes were obtained for  
both ra t and hamster microsomes, indicating that the ANS s ite  (type I )  is 
located in a hydrophobic region of cytochrome P-450. The binding of R(+) 
warfarin to microsomes was accompanied by a 12nm hypsochromic s h if t  in  
emission wavelength, and an increase in fluorescence in ten s ity  (F ig . V I, 5 ) , .  
which was sim ilar fo r both ra t and hamster microsomes. Although the increase 
in the observed fluorescence is  less than that obtained with serum albumin 
(Chapt.Five) i t  is nevertheless adequate to reveal the nature of type RI 
site's environment. I t  is important to note that the fluorescence of S (-)
(type RI) and R(+) (type I )  warfarins in hamster microsomes (F ig . V I, 6) 
gave identical fluorescence increases and produced s im ilar sh ifts  of emission 
maxima. Likewise the fluorescence of racemic S (-) and R(+) Warfarins were 
indistinguishable in ra t microsomes. These results would suggest that the 
type I and RI microsomal binding sites are located in s im ila rly  lip o p h ilic  
environments.
Competitive studies, between ANS and the warfarin isomers using the 
fluorescent probe technique, were performed in both ra t and hamster 
microsomes. ANS (type I )  and racemic or S (-) warfarin (type RI) as well as 
R(+) warfarin (type I ) ,  appeared to in terac t in a d irec t competitive manner. 
(Figs. VT, 7 and 8 ) . ANS and both Warfarin isomers appeared to be mutually 
e ffec tive  in displacing each other from th e ir microsomal binding s ite ,  
sim ilar findings were observed with albumin. DiAugustine, e t al_., (1970), 
suggested that racemic Warfarin competitively displaced ANS from high but not 
low, a f f in i ty  binding sites in ra t hepatic microsomes.
Following phenobarbitone pretreatment both ra t and hamster microsomes 
did not display any increase in the in tensity  of fluorescence expressed per 
mg. of microsomal protein , with e ith er ANS, racemic, S (-) or R(+) Warfarins, 
(F ig. Vt 9 ) . This suggests that the environment of the type I and type RI 
binding sites are not s ig n ific a n tly  altered by phenobarbitone pretreatment 
in e ither species. I t  is  d i f f ic u l t  to resolve the suggestions of 
Schenkman, et al_., (1969) and D ieh l, e t a]_ ., (1970), th a t the type RI binding 
s ite  is  due to the displacement of an endogenous type I compound, with the 
above finding that there are marked differences in the form of spectral 
binding for very closely structural related compounds namely the two warfarin  
isomers in hamster microsomes ( i . e .  R (+), type I ;  S ( - ) ,  type R I) .
Furthermore, using hamster microsomes no s ig n ifican t d ifference in the 
spectral dissociation constant (Ks) could be detected for these isomers 
(Table Vl, 2 ). An a f f in i ty  change would be expected i f  only the S (-) isomer 
were able to displace the endogenous type I compound. Neither would the 
findings support the view of Orrenius, e t al_., (1972), that the type RI 
spectrum might be a composite spectrum arising from the superimposition of a 
type I with a type I I  spectrum, since no change in the type of spectral 
binding, or fluorescent probe ch aracteris tics , were observed over a wide 
concentration range of warfarin used. Some detectable changes would appear
l ik e ly  i f  a type I contributor were present in the type RI spectral change. 
Although Orrenius, e t a K , (1972), could not demonstrate a type I component 
in the type RI spectra of ethanol, they were however, able to show i t  fo r the 
mono-oxygenase substrates, tryptophan and agroclavine. They suggested that 
the lack of a type I component in the type RI spectra might distinguish type 
RI non-substrates from type RI substrates, however th is would not explain the 
differences for the w arfarins, which are known substrates of the mono­
oxygenase system. Our results would appear to support the suggestion that 
the type I s ite  is in a hydrophobic environment, probably the phospholipid 
region of the microsomal membrane (Imai and Sato, 1967; DiAugustine e t a l . ,  
1970; Mannering, 1971). From the studies with the isomers of Warfarin and 
also the competitive studies with ANS, the type RI s ite  would appear to be 
either the same s ite  as the type I ,  or a s im ila rly  lip o p h ilic  s ite  in close 
proximity to i t .  Further work is required to establish whether th is  la t te r  
suggestion is compatible with the view of Schenkman, e t al_. ,(1972), that the 
type RI s ite  is a s ite  on the 'substrate-bound' form of cytochrome P-450 
other than the type I s ite . However, the noteworthy differences between the 
type o f spectral change encountered with the R(+) and S (-) Warfarins in ra t  
and hamster microsomal fractions , implies that very subtle changes in the 
stereochemical configuration may profoundly influence the nature of the 
spectral change accompanying cytochrome P-450 'drug' in teractions.
Benzidine, as reported e a r l ie r , was shown to change its  fluorescence 
wavelength and in ten sity  with variations in solvent p o la rity  (Table VT, 1 ). 
Although benzidine exhibited a low Kg value for both ra t and hamster 
microsomes (Table VT, 2 ), lower even than an ilin e  (the classical type I I  
substrate) i t  showed in s ig n ifican t fluorescent enhancement and no emission 
wavelength s h if t  when bound to hepatic microsomes (Table VT, 1 ). I t  thus 
exhibited fluorescence characteristics typical of a hydrophilic 
environment. Furthermore, these fluorescence observations would not appear
to support the presence o f a type I component in the type I I  spectral 
change of benzidine. T itra tio n  of e ith er serum (ra t  and hamster) or albumin 
solutions with benzidine, also fa ile d  to produce any s ig n ifican t a lte ra tio n  
in fluorescence characteris tics .
Our finding that the type I I  s ite  appears to be in a re la tiv e ly  
hydrophilic environment, w hilst the type I s ite  is in a hydrophobic region, 
is  nevertheless consistent with the view that the two sites may be located 
in close proximity (N etter, e t al_., 1969). I t  may be that the haem moiety 
projects from the hydrophobic environment of the phospholipid membrane, into  
a re la tiv e ly  polar environment. Coordination complex formation
between the nitrogen of a type I I  compound and the haem iron is lik e ly  to be 
favoured by a more hydrophilic surrounding (H ill  e t a l . ,  1970).
Recent electron paramagnetic resonance studies on purified  cytochrome P"450cam
from Pseudomonas putida (Peterson and G r if f in , 1973), have shown that the 
fe rr ic  ion of the haem group when bound to metyrapone (type I I )  was in a 
more hydrophilic environment than when bound to camphor (type I ) .
Our study has provided a p artia l insight into the nature of the hepatic 
microsomal binding s ite s , and demonstrated the potential of fluorescent 
probes in providing information on cytochrome P-450-drug in teractions.
However;*: the significance of the contribution of th is technique depends 
largely on the discovery or synthesis of fu rther appropriate probes. These 
incorporated with low temperature and fluorescence life tim e  studies, should 
contribute s ig n ific a n tly  to our understanding of drug-P-450 in teractions.
The possible use of albumin as a model fo r these drug-microsomal 
interactions has been investigated. The results would suggest th a t the 
albumin and microsomal binding sites fo r the probes, are characterised by 
s im ilarly  hydrophobic (fo r ANS and w arfarin) or hydrophilic (fo r benzidine) 
environments. Although, i t  should be pointed out that the extent to which
benzidine is  bound to albumin remains to be determined. I t  is therefore, 
not possible to fu l ly  evaluate whether the fluorescence characteristics in  
albumin were due to a hydrophilic binding s ite  or that the degree of 
binding was very low. Nevertheless, the finding that ANS and the 
warfarin isomers, in terac t in a d irec t competitive manner in both albumin 
and microsomes, may . suggest that the probes are bound by s im ilar forces 
(possibly hydrophobic and e lec tro s ta tic ) in both systems. However, more 
extensive studies are required before an assessment of albumin as a model 
for microsomal binding studies can be made.
CHAPTER SEVEN
F I N A L  D I S C U S S I O N
This las t chapter contains a b r ie f discussion on the implications 
of the experimental findings presented in th is thesis and suggestions 
fo r future investigations.
The comparative evaluation of the three widely used techniques of 
equilibrium d ia lys is , u lt ra f i l t r a t io n  and fronta l analysis, gel chromato­
graphy (Chapter Three) has shown that the binding data obtained by these 
three techniques, under the experimental conditions employed, is d ire c tly  
comparable over given variations in the percentage bound and the physico­
chemical properties of the drug. These techniques would therefore appear, 
on the basis of the data obtained, to be equally applicable to the study 
of the protein binding of other small molecules. C learly , however, certain  
experimental considerations may predispose towards the selection of one 
technique in preference to another. For example, i f  studies are to be made 
using plasma samples in which pH control by O2 /CO2 gas mixture rather than 
foreign buffer is required, u lt ra f i l t r a t io n  (e .g . using Toribara tubes) 
w ill probably be the most su itab le . However, both u l t r a f i l t r a t io n  and 
dialysis w ill not be suitable fo r drugs which bind to the d ia lysis  membrane. 
The finding of good agreement between the techniques is reassuring, and may 
imply that where difference in the lite ra tu re  fo r the binding data of a 
particu lar compound exists , then factors other than the experimental method 
are responsible.
Most drug-plasma protein in teraction investigations have been 
concerned with determination of binding in drug-protein systems a t 
equilibrium , however, such determinations may tend to obscure the k in e tic
nature of the in teraction , p articu la rly  as occurring in v ivo . The kinetics of 
binding are seldom investigated,however Froese, e t al_., (1962) studied the 
in teraction between an acidic, azo dye and bovine serum albumin, and showed 
that dissociation was extremely rapid (e .g . h a l f - l i f e  of 20 mi 11i-seconds).  
In teresting ly  both these workers and Robbins et al_., (1965), who examined 
the in teraction of thyroxine with albumin, showed that the dissociation  
process could be resolved into two h a lf- l iv e s . I f  the rate of association 
of dissociation of drug-plasma protein complexes is of a s im ilar order 
then i t  w ill scarcely lim it  transport of drugs into or out of the plasma.
The paucity of quantitative information on the kinetics of binding emphasises 
the need for fundamental studies on drug-protein in teractions. Such studies 
are lik e ly  to require techniques more fa m ilia r ly  associated with the study 
of enzyme-substrate in teractions, e .g . stopped flow spectrophotometry and 
fluorim etry, temperature and pressure jump studies, flash photolysis, and 
fluorescence life tim e  studies,which could also be used fo r investigating  
the kinetics of drug displacement
I t  is often ta c it ly  assumed that the protein bound drug is always in 
complete equilibrium with unbound drug and that the removal o f unbound 
drug from the plasma (e .g . by excretion, metabolism) w ill re su lt in the 
immediate release of bound drug u n til equilibrium is restored. However, 
th is may not always be the case. Extrapolation of in v itro  determined 
equilibrium binding results to in vivo conditions may be of l i t t l e  
practical relevance, p a rticu la rly  when binding a t only one drug concentration, 
often unrelated to the therapeutic le v e l* is  determined. Several non­
equilibrium dialysis methods have been introduced in recent years which 
do circumvent some of the problems apparent with the equilibrium  techniques,, 
but they are by no means ideal as they require large volumes and s t i l l  
employ a membrane. The replacement of the d ialysis membrane by a p artitio n in g  
system (e .g . organic solvents; hexane or octanol) could be v a lid ly
incorporated into a non-equilibrium system, and might be an improved 
model fo r the in vivo s itua tio n . Meyer and Guttman (1970 ) have reported 
good agreement between th e ir  non-equilibrium dialysis  technique and 
equilibrium  systems ( i . e .  equilibrium  d ialysis  and u l t r a f i l t r a t io n ) .  I t  is  
perhaps iron ic  that even though the criticism s of equilibrium  techniques 
are well established, these and other authors s t i l l  ju s t i fy  the v a lid ity  
of a new method by the s im ila r ity  of the data produced to that obtained 
with established equilibrium  methods.
The finding in th is study of a good agreement between the binding 
of sa licy la te  to ra t serum by in v itro  u lt r a f i l t r a t io n , and in vivo d ia ly s is , 
may suggest that these in v itro  techniques are able to re fle c t  the in vivo 
binding. However, only a small serum sa licy la te  concentration range was 
obtained in vivo, under the dosage regime employed, thus i t  cannot be 
unambiguously concluded whether such an agreement would s t i l l  pertain at 
higher serum levels . I t  remains to be established whether th is technique 
would be suitable for drugs of re la tiv e ly  short h a l f - l i f e  where the serum 
concentration is rapidly changing. The successful application of th is  
in vivo approach w ill necessitate more precise information regarding the 
re la tiv e  rates of change of the drug in the serum, peritoneal f lu id  and 
dialysis sac contents. I t  may have considerable potential in both pharmaco­
k inetic  and pharmacodynamic studies especially i f  e ith er regular sampling, 
or continual recircu lation  of the d ialysis  sac contents, possibly employing 
flow-through monitoring devices, can be obtained. The suggestion (Keen, 1971) 
that the concentration in the d ialysis  sac does not represent tissue f lu id ,  
because the e ffec tive  diameter of the dialysis membrane pores is very much 
less than that of cap illa ry  pores, must however be considered, and experiments 
employing membranes with larger pore size should be performed. Adaptation and 
development of a technique recently described (Aziz and Dennhardt, 1973) of 
the continuous in vivo u lt ra f i l t ra t io n  of c ircu lating  blood may also have 
considerable potential in binding studies. The in vivo d ia lys is  technique
may however be of considerable value, as demonstrated in our study with 
tryptophan, fo r investigating competitive binding effects of drugs with 
endogenous and other exogenous compounds and th e ir  concomitant c lin ic a l 
im plications. The displacement of endogenous nutrients by drugs and other 
exogenous compounds is an area which merits fa r  more atten tion .
When considering drug-plasma protein in teractions, i t  is often ta c it ly  
assumed that the equilibrium is completely revers ib le, and the p o ss ib ility  
of some irrevers ib le  binding is invariably ignored. Iro n ic a lly  the zonal gel 
chromatography technique, discarded in this study as unsuitable fo r reversible  
binding, could be of value fo r the measurement of irrevers ib le  binding. 
Exhaustive d ialysis  could be an a lte rn a tive  to th is  method. The presence of a 
small portion of the drug concentration irrevers ib ly  bound may p o te n tia lly  
have several e ffec ts , fo r example, i t  may possess antigenic properties and 
this is presumably the case fo r morphine which binds irre ve rs ib ly  to y-g lobuli 
(Ryan et a]_., 1971). S im ilarly  the in vivo acetylation of human albumin by 
acetyl s a lic y lic  acid is suggested to produce antibodies against acetyl sal ic y li  
acid and acetylated albumin, as well as a lte r  albumin's binding capacity fo r  
acetrizoate (Farr, 1971).
I t  has become re la tiv e ly  common to express in v itro  binding data in 
terms of the number of binding sites (n) on the protein and the association 
constant (k) fo r the in teraction . While th is is obviously more informative 
than expression of the binding data as simply fraction  or percentage bound, 
i t  is nevertheless not free from p i t fa l ls .  I t  is generally accepted that 
the graphical p lo t of choice fo r obtaining such information is that due to 
Scatchard (1949), however, while this method of data expression is id ea lly  
suited when the data can be f i t te d  into a single lin ear p lo t, when curvature 
of this p lot occurs then in terpretation  can be precarious. For accurate 
estimation of the binding parameters from the Scatchard p lo t i t  is essential 
that binding be determined over a wide drug concentration range. I t  is
p artic u la rly  important when examining drug-protein interactions of high 
a f f in ity  and involving a small number of binding s ite s , that a number of 
determinations be made a t low r  values (moles drug bound/mole albumin) e .g . <1. 
Even when this is accomplished i t  is frequently d i f f ic u l t  to obtain s u ffic ie n t  
data points in the asymptotic slope corresponding to the primary binding s ite  
(high a f f in i t y ) .  S im ilarly  fo r the secondary s ite  (low a f f in i ty )  a t re la tiv e ly  
high r  values. Whilst curved Scatchard plots can be analysed 'by eye ', or by 
' t r ia l  and erro r' solution of quadratic equations, the methods are tedious 
and in the case of the former, lia b le  to considerable erro r; solution by computer 
analysis is preferable. The v a lid ity  of some of the quoted n and k values in 
the lite ra tu re  is highly questionable. S im ilarly  controversy s t i l l  exists as 
to whether n values should be expressed as integer or non-integer values.
Possibly a lte rn ative  graphical plots could be devised without the ambiguities 
apparent with the Scatchard p lo t (e .g . lo g -p lo ts ). However, i f  the Scatchard 
plot continues to be widely used then some attempt a t standardisation of data 
evaluation must be made. Perhaps a ll quoted values fo r n and k should be 
q u alified  by the relevant r  values over which the determinations were made, 
other variables such as temperatures and pH must of course be quoted. 
A lte rn a tive ly , the use of thermodynamic parameters, enthalpy and entropy 
may eradicate some of the problems associated with data evaluation.
The value of the establishment of binding parameters in assessing the 
contribution of a p articu lar physico-chemical parameter of the drug to the 
binding was demonstrated in this study fo r the binding of a homologous series 
of a lip h a tic  carbamates to bovine serum albumin. This study also fa c il i ta te d  
an assessment of the importance of hydrophobic bonding in small mol ecu!e- 
protein in teractions. The carbamates were selected a fte r  careful consideration 
of the requirements necessary fo r a study of hydrophobic bonding. Both the 
percentage bound and binding constant (nk) fo r the carbamate-BSA in te ra c tio n ,
were found to be lin e a rly  correlated with the lip o p h ilic  character 
of carbamates. The presence of an aromatic ring (benzyl carbamate) did not 
detract from this relationship and possible s te ric  e ffec ts , due to branching 
of the a lip h a tic  side chain, could not be conclusively demonstrated. This 
lin e a r ity  represents the fundamental relationship between the p articu lar  
binding parameter and lip id  s o lu b ility  and departure from lin e a r ity  thus 
must resu lt from the superimposition of other variables. The slopes of 
these lines should be s im ilar fo r other series of compounds whose binding is 
largely  hydrophobic in nature, providing that s im ilar experimental conditions 
preva il. However, the relationship between association constant (k) and 
lip id  s o lu b ility  was not so well correlated. The finding that the number 
of binding sites on albumin fo r the carbamates varied with chain length 
emphasised the need to consider both the parameters (n and k) when 
investigating suspected correlations between binding and physico-chemical 
parameters. Where considerable variation in n is apparent fo r a homologous 
series the parameter nk is to be preferred.
The calculated free energy change for a s in g le  HC2 . . .  C H ^
\
in teraction showed reasonable agreement with that reported in the lite ra tu re  
from studies on the aqueous s o lu b ility  of hydrocarbons and would suggest that 
hydrophobic bonding is analogous to a p artitio n in g  e ffe c t. Nagwekar and 
Kostenbauder (1970), have suggested that estimation of the thermodynamic 
contribution of hydrophobic groups to form a drug-protein complex, may 
sometimes be obscured by the simultaneous contribution of protein molecules 
due to th e ir  'conformational a d a p ta b ility 1. I f  th is is true then the estimated 
free energy (AG) values for hydrophobic bonding from the carbamate binding data 
may be of l i t t l e  quantitative s ignificance, however, no evidence of conform­
ational changes in the protein in our studies could be detected by uv. 
difference or fluorescence spectrophotometry. The calculated free  energy change 
may be used as an approximate indication of the contribution of hydrophobic 
bonding in , fo r example, the in teraction of long chain compounds. Determination
of the free energy of interaction for other functional groups (e .g . aromatic 
rings) may allow a theoretical assessment of the a f f in i ty  of binding of a novel 
compound from a consideration of its  chemical structure. The fe a s ib i l i ty  of 
such extrapolation awaits further systematic data collection.
At the re la t iv e ly  high carbamate-albumin ratios employed i t  is possible 
that other classes of binding s ite  may have been missed. While no evidence 
for this was apparent for the lower homologues, some evidence of curvature was 
apparent for hexyl carbamate. Binding studies a t lower carbamate concentrations 
using radioactivelylabelled carbamate should elucidate th is . Although the 
association constants for the binding ofcarbamate to BSA were low ( i . e .  10^ -  
10^ M ^ ) , for long chain alkyl molecules the a f f in i ty  of binding could be 
considerable. Comparison of the binding data of the carbamates with published 
values for the equivalent chain length carboxylic acids suggested that the 
presence of an ionizable group had l i t t l e  e f fe c t ,  however, this should 
be confirmed by determination of the fa t ty  acid binding under the experimental 
conditions employed in our study. Sim ilarly  i t  would be of value to know 
whether carbamates bind to the same s ite  as fa t ty  acids and displacement 
studies should reveal th is . Ind irect evidence that they may bind to d if fe re n t  
sites is suggested by the in a b i l i ty  of the carbamates to displace warfarin,  
whereas fa tty  acids are known to displace this drug. While hydrophobic bonding 
may be a major contributor to the binding of many drugs, i t  may not solely  
contribute to the binding a f f in i t y .  Thus fo r  warfarin hydrogen, hydrophobic 
and e lectrosta tic  bonds may be involved in its  interaction with albumin.
Instead of investigating the binding of a drug or series of s tru c tu ra lly  
related compounds d ire c t ly ,  displacement could be employed. This approach has 
been demonstrated in the present work where the use of the fluorescent probe 
properties of warfarin has been made. The complete characterisation of the 
warfarin binding s ite  on albumin would obviously considerably enhance the 
information available from such studies. The extent of displacement can of 
course be used to derive values for the association constant of the displacing
agent. S im ilarly , provided the displacer drug does not quench the in tr in s ic  
fluorescence of the protein, an association constant can be calculated i f  i t  
competitively displaces another compound which does quench the fluorescence of 
the protein. Displacement studies can also be studied by non-spectroscopic 
techniques, especially i f  rad ioactively-labelled compounds can be employed.
Such studies could be particu larly  valuable for potential displacing agents for  
which no simple means of assessment are available . I t  should be remembered, 
however, that quantitative information derived from such displacement studies 
only concerns those sites a t which competition occurs, and no d irect information 
is obtained regarding other s ites . This fluorescence probe technique is 
particu larly  suitable fo r such studies in view of the speed with which 
studies can be performed, although the possible in tr in s ic  fluorescence of 
the displacing agent must be accounted fo r  in order to avoid erroneous 
conclusions. Such a technique may provide a valuable and rapid means of 
screening novel drugs, or combinations, for  th e ir  displacement potential of 
warfarin. Other b io log ica lly  important compounds namely; tetracyclines,  
b il iru b in  and kynurenine have also been reported to be potential fluorescent 
probes and these compounds could considerably extend the potential of this  
approach.
Attempts to characterise the warfarin binding s ite  on albumin by 
modification of the protein structure have suggested that lysine, h is tid ine  
and tyrosine may be involved in the binding of warfarin. Further studies 
on 'modified' albumins are needed to fu l ly  elucidate the nature of the s ites .
The primary, high a f f in i t y ,  warfarin binding s ite  in human albumin may be 
compatible with the amino acid sequence in the neighbourhood of the Tone 
tryptophan in human serum albumin, with hydrogen, hydrophobic and e lec trosta tic  
bonding possibly partic ipating in complex formation. Bonding may possibly 
occur with the lysine residue, although i f  this is the binding s ite  fo r warfarin  
then interaction with the arginine may also occur. Determination of the 
binding of warfarin to glyoxal modified albumins could elucidate whether 
arginine is involved in this binding process. The warfarin binding s ite  can
also bind other anions as witnessed by its  competitive displacement o f ,  for  
example, phenylbutazone and c lo f ib ra te . In our study, no competitive 
displacement of warfarin could be detected by any of the neutral or basic 
compunds investigated.
I t  has been suggested that studies of drug-albumin interactions might 
serve as useful models for more fundamental understanding of drug-protein 
interactions. We selected cytochrome P-450 as a suitable reference tissue 
protein to investigate this hypothesis because of the ease with which its  
substrate interactions could be id en tif ie d . Our results suggest that a 
s im ila r ity  in the nature of the environments of the binding sites on albumin 
and microsomal cytochrome P-450 does e x is t ,  and may imply that drug-albumin 
interactions would be suitable models for a more detailed characterisation of 
the hepatic microsomal interactions. Further characterisation of the 
s im ila r it ies  between albumin and microsomal systems should involve evaluation 
of numbers of binding sites and a f f in i t ie s  of in teraction, and more extensive 
displacement studies using e ither the fluorescent probe technique or 
conventional non-spectroscopic methods should be carried out. The potential 
of albumin-drug interactions for providing fundamental information on other 
protein-drug interactions including enzyme-substrate in teraction, cannot be 
va lid ly  assessed at the present time. Information of the absolute configurati 
of a drug would be invaluable in typifying binding sites on a protein and 
enable models of binding sites to be constructed, this could lead to the 
design of better drug molecules. I t  is apparent that understanding the protei 
drug interaction on a molecular level is essential to our understanding of 
drug action, as well as understanding the transport function of the plasma 
proteins for nutrients. Characterisation of the physico-chemical parameters 
influencing the binding of a drug to plasma and tissue proteins are essential 
to our prediction of the protein binding of a novel drug. For drugs in which 
the degree of binding is l ik e ly  to be of importance ( i . e .  highly bound drugs) 
binding to several species including human albumin and human serum should be 
determined.
I t  may well prove possible in the near future, using either a practical 
or theoretical assessment of the binding of a drug to plasma proteins to 
predict, by the use of computer models, the e ffec t of a> drug's protein 
binding on i ts  pharmacological action and duration.
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S t i l l  round the corner there may wait 
A new road or a secret gate,
And though we pass them by today, 
Tomorrow we may come this way.
J.R.R. To!kien.
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